RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Abstract

The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described. 20 24 20 13 49 29 F eb 2 02 4 2 0 2 4 2 0 1 3 4 9 2 9 F e b 2 0 2 4 l e v e l s a r e a l s o d e s c r i b e d .

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of Australian Application No. 2017315952, filed 25 August 2017, is related to PCT / US2017 / 048757, and claims priority from U.S. Provisional Application No. 62 / 380,216, filed 26 August 2016, all of which are incorporated herein by reference in their entirety. DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

[0002] The present application contains a Sequence Listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The computer readable format copy of the Sequence Listing, which was created on August 25, 2017, is named A-2094-WO-PCT ST25 and is 1.49 megabytes in size. FIELD OF THE INVENTION

[0003] The present invention relates to compositions and methods for modulating liver expression of asialoglycoprotein receptor 1 (ASGR1). In particular, the present invention relates to nucleic acid-based therapeutics for reducing ASGR1 expression via RNA interference and methods of using such nucleic acid-based therapeutics to treat or prevent cardiovascular disease. BACKGROUND OF THE INVENTION

[0004] Despite the many advancements and new therapeutics that have emerged over the last several years, cardiovascular disease remains the leading cause of death worldwide. One out of every three adults in America has some form of cardiovascular disease, including coronary artery disease, myocardial infarction, angina, heart failure, and stroke (Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation, Vol.l33:e38-e360, 2016). In 2013, over 17.3 million people globally and 1.4 million people in the United States died from some form of cardiovascular disease, accounting for 31% of all global deaths and 54% of all deaths in the U.S. that year (Heart disease and stroke statistics-2016 update). Cardiovascular disease currently claims more lives each year than the next two leading causes of death, cancer and chronic lower respiratory disease, combined (Heart disease and stroke 2024201349   29 Feb 2024 statistics-2016 update). Thus, there remains a need for additional therapeutic agents for the treatment of cardiovascular disease.

[0005] The asialoglycoprotein receptor is a calcium-dependent receptor expressed on the surface of hepatocytes that contributes to the removal and degradation of desialylated glycoproteins from the serum by binding to ligands with terminal galactose and N-acetylgalactosamine residues (Weigel, Bioessays, Vol. 16:519-524, 1994; Stockert, Physiol. Rev., Vol. 75: 591-609, 1995). The hetero-oligomeric asialoglycoprotein receptor is comprised of two different proteins, a 48 kDa asialoglycoprotein receptor 1 (ASGR1) major subunit and a 40 kDa asialoglycoprotein receptor 2 (ASGR2) minor subunit (see, e.g., Stockert, 1995). The asialogylcoprotein receptor has been implicated in the clearance of low density lipoproteins and chylomicron remnants, suggesting a role for the receptor in lipoprotein metabolism (Windier et al., Biochem J., Vol. 276(Pt 1):79-87, 1991; Ishibashi etal., J Biol Chern., Vol. 271:22422-22427, 1996). Recently, human carriers of loss of function variant alleles of the ASGR1 subunit of the asialoglycoprotein receptor were reported to have lower serum levels of non-high-density lipoprotein (HDL) cholesterol and a lower risk of coronary artery disease and myocardial infarction as compared to non-carriers (Nioi et al., New England Journal of Medicine, Vol. 374(22):2131-2141, 2016). Accordingly, therapeutics targeting ASGR1 function represent a novel approach to reducing non-HDL cholesterol levels and treating cardiovascular disease, particularly coronary artery disease. SUMMARY OF THE INVENTION

[0006] The present invention is based, in part, on the design and generation of RNAi constructs that target the ASGR1 gene and reduce expression of ASGR1 in liver cells. The sequencespecific inhibition of ASGR1 expression is useful for treating or preventing conditions associated with ASGR1 expression, such as cardiovascular disease. Accordingly, in one embodiment, the present invention provides an RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a region having a sequence that is complementary to an ASGR1 mRNA sequence. In certain embodiments, the antisense strand comprises a region having at least 15 contiguous nucleotides from an antisense sequence listed in Table 1, Table 6, or Table 8.

[0007] In some embodiments, the sense strand of the RNAi constructs described herein comprises a sequence that is sufficiently complementary to the sequence of the antisense strand 2024201349   29 Feb 2024 to form a duplex region of about 15 to about 30 base pairs in length. In these and other embodiments, the sense and antisense strands each are about 15 to about 30 nucleotides in length. In some embodiments, the RNAi constructs comprise at least one blunt end. In other embodiments, the RNAi constructs comprise at least one nucleotide overhang. Such nucleotide overhangs may comprise 1 to 6 unpaired nucleotides and can be located at the 3' end of the sense strand, the 3' end of the antisense strand, or the 3' end of both the sense and antisense strand. In certain embodiments, the RNAi constructs comprise an overhang of two unpaired nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand. In other embodiments, the RNAi constructs comprise an overhang of two unpaired nucleotides at the 3' end of the antisense strand and a blunt end of the 3' end of the sense strand / 5' end of the antisense strand.

[0008] The RNAi constructs of the invention may comprise one or more modified nucleotides, including nucleotides having modifications to the ribose ring, nucleobase, or phosphodiester backbone. In some embodiments, the RNAi constructs comprise one or more 2'-modified nucleotides. Such 2'-modified nucleotides can include 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-O-allyl modified nucleotides, bicyclic nucleic acids (BNA), or combinations thereof. In one particular embodiment, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or combinations thereof. In some embodiments, all of the nucleotides in the sense and antisense strand of the RNAi construct are modified nucleotides.

[0009] In some embodiments, the RNAi constructs comprise at least one backbone modification, such as a modified internucleotide or internucleoside linkage. In certain embodiments, the RNAi constructs described herein comprise at least one phosphorothioate internucleotide linkage. In particular embodiments, the phosphorothioate intemucleotide linkages may be positioned at the 3' or 5' ends of the sense and / or antisense strands.

[0010] In some embodiments, the antisense strand and / or the sense strand of the RNAi constructs of the invention may comprise or consist of a sequence from the antisense and sense sequences listed in Tables 1, 6, or 8. In certain embodiments, the RNAi construct may be any one of the duplex compounds listed in any one of Tables 1 to 10. In one embodiment, the RNAi construct is D-1098, D-l 176, D-1200, D-1206, D-1235, D-1246, D-1373, D-1389, D-1813, D-1815, D-1983, D-2000, D-2045, D-2142, D-2143, D-1438, D-1494, D-2357, D-2359, D-2361, D-2365, D-2461, D-3036, D-3037, D-3051, D-3053, D-3057, D-3779, D-3780, D-3782, D-3788, 2024201349   29 Feb 2024 D-3791, D-3795, D-3799, or D-3800. In another embodiment, the RNAi construct is D-1200, D-1206, D-1235, D-1815, D-2143, D-2359, D-2361, D-2365, D-2142, D-1176, D-3779, D-3782, D-3788, D-3799, or D-3800. In another embodiment, the RNAi construct is D-2359. In another embodiment, the RNAi construct is D-1815. In yet another embodiment, the RNAi construct is D-1235. In still another embodiment, the RNAi construct is D-2143. In another embodiment, the RNAi construct is D-2361. In some embodiments, the RNAi construct is D-3782. In other embodiments, the RNAi construct is D-3799.

[0011] The RNAi constructs may further comprise a ligand to facilitate delivery or uptake of the RNAi constructs to specific tissues or cells, such as liver cells. In certain embodiments, the ligand targets delivery of the RNAi constructs to hepatocytes. In these and other embodiments, the ligand may comprise galactose, galactosamine, or N-acetyl-galactosamine (GalNAc). In certain embodiments, the ligand comprises a multivalent galactose or multivalent GalNAc moiety, such as a trivalent or tetravalent galactose or GalNAc moiety. The ligand may be covalently attached to the 5' or 3' end of the sense strand of the RNAi construct, optionally through a linker. In some embodiments, the RNAi constructs comprise a ligand and linker having a structure according to any of Formulas I to XXIX described herein. In certain embodiments, the RNAi constructs comprise a ligand and linker having a structure according to Formula VII, Formula VIII, Formula XVI, Formula XXVI, or Formula XXIX. In one embodiment, the RNAi constructs comprise a ligand and linker having a structure according to Formula XVI, wherein n =1 and k =3.

[0012] In certain embodiments, the ligand may comprise an antibody or antigen-binding fragment thereof that specifically binds to ASGR1. The 5' or 3' end of the sense strand of the RNAi construct may be covalently linked to the antibody or antigen-binding fragment through the side chain of an amino acid residue in the light chain or heavy chain of the antibody or antigen-binding fragment. In some embodiments, the sense strand of the RNAi construct is covalently attached, optionally through a linker, to the side chain of a cysteine residue present in the heavy chain or light chain of the antibody or antigen-binding fragment thereof. In one embodiment, the anti-ASGRl antibody-RNA molecule conjugate comprises at least one copy of the interfering RNA molecule (e.g. siRNA or shRNA). In another embodiment, the anti-ASGRl antibody-RNA molecule conjugate comprises two copies of the interfering RNA molecule (e.g. siRNA or shRNA). 2024201349   29 Feb 2024

[0013] The present invention also provides pharmaceutical compositions comprising any of the RNAi constructs described herein and a pharmaceutically acceptable carrier, excipient, or diluent. Such pharmaceutical compositions are particularly useful for reducing expression of ASGR1 in the cells (e.g. liver cells) of a patient in need thereof. Patients who may be administered a pharmaceutical composition of the invention can include patients with a history of myocardial infarction, patients diagnosed with or at risk for coronary artery disease or other form of cardiovascular disease, and patients with elevated levels of non-HDL cholesterol. Accordingly, the present invention includes methods of treating or preventing cardiovascular disease in a patient in need thereof by administering an RNAi construct or pharmaceutical composition described herein. In certain embodiments, the present invention provides methods for reducing non-HDL cholesterol in a patient in need thereof by administering an RNAi construct or pharmaceutical composition described herein.

[0014] The use of ASGR1-targeting RNAi constructs in any of the methods described herein or for preparation of medicaments for administration according to the methods described herein is specifically contemplated. For instance, the present invention includes an ASGR1-targeting RNAi construct for use in a method for treating or preventing cardiovascular disease, including coronary artery disease or myocardial infarction, in a patient in need thereof. The present invention also includes an ASGR1-targeting RNAi construct for use in a method for reducing non-HDL cholesterol in a patient in need thereof. In some embodiments, the present invention provides an ASGR1-targeting RNAi construct for use in a method for reducing the risk of myocardial infarction in a patient in need thereof.

[0015] The present invention also encompasses the use of an ASGR1-targeting RNAi construct in the preparation of a medicament for treating or preventing cardiovascular disease, including coronary artery disease or myocardial infarction, in a patient in need thereof. In certain embodiments, the present invention provides the use of an ASGR1-targeting RNAi construct in the preparation of a medicament for reducing non-HDL cholesterol in a patient in need thereof. In certain other embodiments, the present invention provides the use of an ASGR1-targeting RNAi construct in the preparation of a medicament for reducing the risk of myocardial infarction in a patient in need thereof. 2024201349   29 Feb 2024 BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1A shows the nucleotide sequence of transcript variant 1 of human ASGR1 (NCBI Reference Sequence No. NM_001671.4; SEQ ID NO: 1). The transcript sequence is depicted as the complementary DNA (cDNA) sequence with thymine bases replacing uracil bases.

[0017] Figure IB shows the nucleotide sequence of transcript variant 2 of human ASGR1 (NCBI Reference Sequence No. NM_001197216.2; SEQ ID NO: 2). The transcript sequence is depicted as the cDNA sequence with thymine bases replacing uracil bases.

[0018] Figure 2 shows the nucleotide sequence of transcript variant 1 of mouse Asgrl (NCBI Reference Sequence No. NM_009714.2; SEQ ID NO: 3011). The transcript sequence is depicted as the complementary DNA (cDNA) sequence with thymine bases replacing uracil bases.

[0019] Figure 3 shows the nucleotide sequence of a transcript of rat Asgrl (SEQ ID NO: 3012). The transcript sequence is depicted as the complementary DNA (cDNA) sequence with thymine bases replacing uracil bases.

[0020] Figure 4 shows the nucleotide sequence of a transcript of macaque (Macaca fascicularis) ASGR1 (NCBI Reference Sequence No. XM_005582698.1; SEQ ID NO: 3013). The transcript sequence is depicted as the complementary DNA (cDNA) sequence with thymine bases replacing uracil bases.

[0021] Figure 5 depicts the synthetic scheme for a tetravalent GalNAc moiety that can be incorporated into any of the RNAi constructs of the invention.

[0022] Figure 6A is a bar graph of human ASGR1 expression levels in livers of ASGR1 knockout mice injected with an AAV encoding human ASGR1 and treated with 5 mg / kg subcutaneous injections of the indicated GalNAc-ASGRl siRNA conjugates. Human ASGR1 expression was measured by qPCR and is reported as expression levels relative to the AAV only control animals, which were ASGR1 knockout animals injected with the AAV encoding human ASGR1, but were otherwise untreated. Expression levels are shown at day 8 (d8) and day 15 (dl5) after GalNAc-siRNA conjugate administration. Wild-type (WT) mice and ASGR1 knockout (KO) animals were included as controls.

[0023] Figure 6B is a bar graph of serum levels of alkaline phosphatase (ALP) from the animals described in Figure 6A. Serum was obtained at day 8 (d8) and day 15 (dl5) following administration of the indicated GalNAc-siRNA conjugates. 2024201349   29 Feb 2024

[0024] Figure 7A is a schematic illustrating the reaction to add a bromoacetyl linker to the 3' end of the sense strand of a siRNA duplex.

[0025] Figure 7B is a schematic depicting the conjugation reaction to attach a siRNA duplex to an anti-ASGRl antibody.

[0026] Figure 8 is a bar graph showing a dose-dependent knockdown of ASGR1 mRNA in human primary hepatocytes observed with the 3549 (RNA-Ab ratio of 1) and 3550 (RNA-Ab ratio of 2) anti-ASGRl mAb-siRNA conjugates. The unconjugated anti-ASGRl cys mAb (PL53515) was used as a control.

[0027] Figure 9A is a bar graph showing the ASGR1 mRNA level in livers from wild-type mice in all dosing groups measured at the indicated time points (days 2, 4, 8, and 15). The same siRNA conjugated to a GalNAc moiety (compound 1418) was used as a positive control. The amount of siRNA in 5 mpk of 1418 is equivalent to that in 30 mpk of the 3550 compound, which has 2 siRNAs / mAb.

[0028] Figure 9B is a line graph depicting ASGR1 protein expression in livers from wild-type mice in all dosing groups measured at the indicated time points (days 2, 4, 8, and 15). The same siRNA conjugated to a GalNAc moiety (compound 1418) was used as a positive control. The amount of siRNA in 5 mpk of 1418 is equivalent to that in 30 mpk of the 3550 compound, which has 2 siRNAs / mAb.

[0029] Figure 10 is a bar graph showing serum alkaline phosphatase (ALP) from wild-type mice in all dosing groups measured at the indicated time points (days 2, 4, 8, and 15). The same siRNA conjugated to a GalNAc moiety (compound 1418) was used as a positive control. The amount of siRNA in 5 mpk of 1418 is equivalent to that in 30 mpk of the 3550 compound, which has 2 siRNAs / mAb. DETAILED DESCRIPTION

[0030] The present invention is directed to compositions and methods for regulating the expression of the asialoglycoprotein receptor in a cell or mammal. In some embodiments, compositions of the invention comprise RNAi constructs that target an ASGR1 mRNA and reduce ASGR1 expression in a cell or mammal. Such RNAi constructs are useful for treating or preventing various forms of cardiovascular disease, such as, for example, by reducing non-HDL 2024201349   29 Feb 2024 cholesterol serum levels and reducing the risk of developing coronary artery disease or myocardial infarction.

[0031] As used herein, the term “RNAi construct” refers to an agent comprising a RNA molecule that is capable of downregulating expression of a target gene (e.g. ASGR1) via a RNA interference mechanism when introduced into a cell. RNA interference is the process by which a nucleic acid molecule induces the cleavage and degradation of a target RNA molecule (e.g. messenger RNA or mRNA molecule) in a sequence-specific manner, e.g. through a RNA-induced silencing complex (RISC) pathway. In some embodiments, the RNAi construct comprises a double-stranded RNA molecule comprising two antiparallel strands of contiguous nucleotides that are sufficiently complementary to each other to hybridize to form a duplex region. “Hybridize” or “hybridization” refers to the pairing of complementary polynucleotides, typically via hydrogen bonding (e.g. Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary bases in the two polynucleotides. The strand comprising a region having a sequence that is substantially complementary to a target sequence (e.g. target mRNA) is referred to as the “antisense strand.” The “sense strand” refers to the strand that includes a region that is substantially complementary to a region of the antisense strand. In some embodiments, the sense strand may comprise a region that has a sequence that is substantially identical to the target sequence.

[0032] A double-stranded RNA molecule may include chemical modifications to ribonucleotides, including modifications to the ribose sugar, base, or backbone components of the ribonucleotides, such as those described herein or known in the art. Any such modifications, as used in a double-stranded RNA molecule (e.g. siRNA, shRNA, or the like), are encompassed by the term “double-stranded RNA” for the purposes of this disclosure.

[0033] As used herein, a first sequence is “complementary” to a second sequence if a polynucleotide comprising the first sequence can hybridize to a polynucleotide comprising the second sequence to form a duplex region under certain conditions, such as physiological conditions. Other such conditions can include moderate or stringent hybridization conditions, which are known to those of skill in the art. A first sequence is considered to be fully complementary (100% complementary) to a second sequence if a polynucleotide comprising the first sequence base pairs with a polynucleotide comprising the second sequence over the entire length of one or both nucleotide sequences without any mismatches. A sequence is “substantially 2024201349   29 Feb 2024 complementary” to a target sequence if the sequence is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% complementary to a target sequence. Percent complementarity can be calculated by dividing the number of bases in a first sequence that are complementary to bases at corresponding positions in a second or target sequence by the total length of the first sequence. A sequence may also be said to be substantially complementary to another sequence if there are no more than 5, 4, 3, or 2 mismatches over a 30 base pair duplex region when the two sequences are hybridized. Generally, if any nucleotide overhangs, as defined herein, are present, the sequence of such overhangs is not considered in determining the degree of complementarity between two sequences. By way of example, a sense strand of 21 nucleotides in length and an antisense strand of 21 nucleotides in length that hybridize to form a 19 base pair duplex region with a 2 nucleotide overhang at the 3' end of each strand would be considered to be fully complementary as the term is used herein.

[0034] In some embodiments, a region of the antisense strand comprises a sequence that is fully complementary to a region of the target RNA sequence (e.g. ASGR1 mRNA). In such embodiments, the sense strand may comprise a sequence that is fully complementary to the sequence of the antisense strand. In other such embodiments, the sense strand may comprise a sequence that is substantially complementary to the sequence of the antisense strand, e.g. having 1, 2, 3, 4, or 5 mismatches in the duplex region formed by the sense and antisense strands. In certain embodiments, it is preferred that any mismatches occur within the terminal regions (e.g. within 6, 5, 4, 3, or 2 nucleotides of the 5' and / or 3' ends of the strands). In one embodiment, any mismatches in the duplex region formed from the sense and antisense strands occur within 6, 5, 4, 3, or 2 nucleotides of the 5' end of the antisense strand.

[0035] In certain embodiments, the sense strand and antisense strand of the double-stranded RNA may be two separate molecules that hybridize to form a duplex region, but are otherwise unconnected. Such double-stranded RNA molecules formed from two separate strands are referred to as “small interfering RNAs” or “short interfering RNAs” (siRNAs). Thus, in some embodiments, the RNAi constructs of the invention comprise a siRNA.

[0036] In other embodiments, the sense strand and the antisense strand that hybridize to form a duplex region may be part of a single RNA molecule, i.e. the sense and antisense strands are part of a self-complementary region of a single RNA molecule. In such cases, a single RNA molecule comprises a duplex region (also referred to as a stem region) and a loop region. The 3' 2024201349   29 Feb 2024 end of the sense strand is connected to the 5' end of the antisense strand by a contiguous sequence of unpaired nucleotides, which will form the loop region. The loop region is typically of a sufficient length to allow the RNA molecule to fold back on itself such that the antisense strand can base pair with the sense strand to form the duplex or stem region. The loop region can comprise from about 3 to about 25, from about 5 to about 15, or from about 8 to about 12 unpaired nucleotides. Such RNA molecules with at least partially self-complementary regions are referred to as “short hairpin RNAs” (shRNAs). In certain embodiments, the RNAi constructs of the invention comprise a shRNA. The length of a single, at least partially self-complementary RNA molecule can be from about 35 nucleotides to about 100 nucleotides, from about 45 nucleotides to about 85 nucleotides, or from about 50 to about 60 nucleotides and comprise a duplex region and loop region each having the lengths recited herein.

[0037] In some embodiments, the RNAi constructs of the invention comprise a sense strand and an antisense strand, wherein the antisense strand comprises a region having a sequence that is substantially or fully complementary to an ASGR1 messenger RNA (mRNA) sequence. As used herein, an “ASGR1 mRNA sequence” refers to any messenger RNA sequence, including splice variants, encoding an ASGR1 protein, including ASGR1 protein variants or isoforms from any species (e.g. mouse, rat, non-human primate, human). ASGR1 protein (also known as HL-1, ASGPR Hl, ASGPR1, and CLEC4H1), as used herein, refers to the major subunit of the asialoglycoprotein receptor. In humans, ASGR1 is found on chromosome 17p 13.2 and is expressed as two different isoforms, a long isoform (Hl a or isoform A) of about 291 amino acids and a short soluble isoform (Hlb or isoform B) of about 252 amino acids.

[0038] An ASGR1 mRNA sequence also includes the transcript sequence expressed as its complementary DNA (cDNA) sequence. A cDNA sequence refers to the sequence of an mRNA transcript expressed as DNA bases (e.g. guanine, adenine, thymine, and cytosine) rather than RNA bases (e.g. guanine, adenine, uracil, and cytosine). Thus, the antisense strand of the RNAi constructs of the invention may comprise a region having a sequence that is substantially or fully complementary to a target ASGR1 mRNA sequence or ASGR1 cDNA sequence. An ASGR1 mRNA or cDNA sequence can include, but is not limited to, any ASGR1 mRNA or cDNA sequence selected from the NCBI Reference sequences NM 001671.4 (human; Figure 1A, SEQ ID NO: 1), NM_001197216.2 (human; Figure IB, SEQ ID NO: 2), NM_009714.2 (mouse; Figure 2, SEQ ID NO: 3011), and XM 005582698.1 (cynomolgus monkey; Figure 4, SEQ ID 2024201349   29 Feb 2024 NO: 3013) or the rat sequence in Figure 3 (SEQ ID NO: 3012). In one embodiment, the ASGR1 mRNA sequence is human transcript variant 1 listed in the NCBI database as Reference Sequence NM 001671.4 (see Figure 1A; SEQ ID NO: 1). In another embodiment, the ASGR1 mRNA sequence is human transcript variant 2 listed in the NCBI database as Reference Sequence NM_001197216.2 (see Figure IB; SEQ ID NO: 2).

[0039] A region of the antisense strand can be substantially complementary or fully complementary to at least 15 consecutive nucleotides of the ASGR1 mRNA sequence. In some embodiments, the target region of the ASGR1 mRNA sequence to which the antisense strand comprises a region of complementarity can range from about 15 to about 30 consecutive nucleotides, from about 16 to about 28 consecutive nucleotides, from about 18 to about 26 consecutive nucleotides, from about 17 to about 24 consecutive nucleotides, from about 19 to about 25 consecutive nucleotides, from about 19 to about 23 consecutive nucleotides, or from about 19 to about 21 consecutive nucleotides. In certain embodiments, the region of the antisense strand comprising a sequence that is substantially or fully complementary to an ASGR1 mRNA sequence may, in some embodiments, comprise at least 15 contiguous nucleotides from an antisense sequence listed in Table 1, Table 6, or Table 8. In other embodiments, the antisense sequence comprises at least 16, at least 17, at least 18, or at least 19 contiguous nucleotides from an antisense sequence listed in Table 1, Table 6, or Table 8. For instance, in some embedments, the region of the antisense strand comprising a sequence that is substantially or fully complementary to an ASGR1 mRNA sequence comprises at least 15 contiguous nucleotides from a sequence selected from SEQ ID NO: 1606, SEQ ID NO: 1684, SEQ ID NO: 1708, SEQ ID NO: 1714, SEQ ID NO: 1743, SEQ ID NO: 1754, SEQ ID NO: 1881, SEQ ID NO: 1897, SEQ ID NO: 2321, SEQ ID NO: 2323, SEQ ID NO: 2491, SEQ ID NO: 2508, SEQ ID NO: 2553, SEQ ID NO: 2650, SEQ ID NO: 2651, SEQ ID NO: 1946, SEQ ID NO: 2002, SEQ ID NO: 2865, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 2873, SEQ ID NO: 2969, SEQ ID NO: 3701, SEQ ID NO: 3702, SEQ ID NO: 3716, SEQ ID NO: 3718, SEQ ID NO: 3722, SEQ ID NO: 4618, SEQ ID NO: 4619, SEQ ID NO: 4621, SEQ ID NO: 4627, SEQ ID NO: 4630, SEQ ID NO: 4634, SEQ ID NO: 4638, or SEQ ID NO: 4639.

[0040] The sense strand of the RNAi construct typically comprises a sequence that is sufficiently complementary to the sequence of the antisense strand such that the two strands hybridize under physiological conditions to form a duplex region. A “duplex region” refers to the region in two 2024201349   29 Feb 2024 complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or other hydrogen bonding interaction, to create a duplex between the two polynucleotides. The duplex region of the RNAi construct should be of sufficient length to allow the RNAi construct to enter the RNA interference pathway, e.g. by engaging the Dicer enzyme and / or the RISC complex. For instance, in some embodiments, the duplex region is about 15 to about 30 base pairs in length. Other lengths for the duplex region within this range are also suitable, such as about 15 to about 28 base pairs, about 15 to about 26 base pairs, about 15 to about 24 base pairs, about 15 to about 22 base pairs, about 17 to about 28 base pairs, about 17 to about 26 base pairs, about 17 to about 24 base pairs, about 17 to about 23 base pairs, about 17 to about 21 base pairs, about 19 to about 25 base pairs, about 19 to about 23 base pairs, or about 19 to about 21 base pairs. In one embodiment, the duplex region is about 17 to about 24 base pairs in length. In another embodiment, the duplex region is about 19 to about 21 base pairs in length.

[0041] For embodiments in which the sense strand and antisense strand are two separate molecules (e.g. RNAi construct comprises a siRNA), the sense strand and antisense strand need not be the same length as the length of the duplex region. For instance, one or both strands may be longer than the duplex region and have one or more unpaired nucleotides or mismatches flanking the duplex region. Thus, in some embodiments, the RNAi construct comprises at least one nucleotide overhang. As used herein, a “nucleotide overhang” refers to the unpaired nucleotide or nucleotides that extend beyond the duplex region at the terminal ends of the strands. Nucleotide overhangs are typically created when the 3' end of one strand extends beyond the 5' end of the other strand or when the 5' end of one strand extends beyond the 3' end of the other strand. The length of a nucleotide overhang is generally between 1 and 6 nucleotides, 1 and 5 nucleotides, 1 and 4 nucleotides, 1 and 3 nucleotides, 2 and 6 nucleotides, 2 and 5 nucleotides, or 2 and 4 nucleotides. In some embodiments, the nucleotide overhang comprises 1, 2, 3, 4, 5, or 6 nucleotides. In one particular embodiment, the nucleotide overhang comprises 1 to 4 nucleotides. In certain embodiments, the nucleotide overhang comprises 2 nucleotides. The nucleotides in the overhang can be ribonucleotides, deoxyribonucleotides, or modified nucleotides as described herein. In some embodiments, the overhang comprises a 5'-uridine-uridine-3' (5'-UU-3') dinucleotide. In such embodiments, the UU dinucleotide may comprise 2024201349   29 Feb 2024 ribonucleotides or modified nucleotides, e.g. 2'-modified nucleotides. In other embodiments, the overhang comprises a 5'-deoxythymidine-deoxythymidine-3' (5'-dTdT-3') dinucleotide.

[0042] The nucleotide overhang can be at the 5' end or 3' end of one or both strands. For example, in one embodiment, the RNAi construct comprises a nucleotide overhang at the 5' end and the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises a nucleotide overhang at the 5' end and the 3' end of the sense strand. In some embodiments, the RNAi construct comprises a nucleotide overhang at the 5' end of the sense strand and the 5' end of the antisense strand. In other embodiments, the RNAi construct comprises a nucleotide overhang at the 3' end of the sense strand and the 3' end of the antisense strand.

[0043] The RNAi constructs may comprise a single nucleotide overhang at one end of the double-stranded RNA molecule and a blunt end at the other. A “blunt end” means that the sense strand and antisense strand are fully base-paired at the end of the molecule and there are no unpaired nucleotides that extend beyond the duplex region. In some embodiments, the RNAi construct comprises a nucleotide overhang at the 3' end of the sense strand and a blunt end at the 5' end of the sense strand and 3' end of the antisense strand. In other embodiments, the RNAi construct comprises a nucleotide overhang at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand and the 3' end of the sense strand. In certain embodiments, the RNAi construct comprises a blunt end at both ends of the double-stranded RNA molecule. In such embodiments, the sense strand and antisense strand have the same length and the duplex region is the same length as the sense and antisense strands (i.e. the molecule is double-stranded over its entire length).

[0044] The sense strand and antisense strand can each independently be about 15 to about 30 nucleotides in length, about 18 to about 28 nucleotides in length, about 19 to about 27 nucleotides in length, about 19 to about 25 nucleotides in length, about 19 to about 23 nucleotides in length, about 21 to about 25 nucleotides in length, or about 21 to about 23 nucleotides in length. In certain embodiments, the sense strand and antisense strand are each about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25 nucleotides in length. In some embodiments, the sense strand and antisense strand have the same length but form a duplex region that is shorter than the strands such that the RNAi construct has two nucleotide overhangs. For instance, in one embodiment, the RNAi construct comprises (i) a sense strand and an antisense strand that are each 21 nucleotides in length, (ii) a duplex region 2024201349   29 Feb 2024 that is 19 base pairs in length, and (iii) nucleotide overhangs of 2 unpaired nucleotides at both the 3' end of the sense strand and the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises (i) a sense strand and an antisense strand that are each 23 nucleotides in length, (ii) a duplex region that is 21 base pairs in length, and (iii) nucleotide overhangs of 2 unpaired nucleotides at both the 3' end of the sense strand and the 3' end of the antisense strand. In other embodiments, the sense strand and antisense strand have the same length and form a duplex region over their entire length such that there are no nucleotide overhangs on either end of the double-stranded molecule. In one such embodiment, the RNAi construct is blunt ended and comprises (i) a sense strand and an antisense strand, each of which is 21 nucleotides in length, and (ii) a duplex region that is 21 base pairs in length. In another such embodiment, the RNAi construct is blunt ended and comprises (i) a sense strand and an antisense strand, each of which is 23 nucleotides in length, and (ii) a duplex region that is 23 base pairs in length.

[0045] In other embodiments, the sense strand or the antisense strand is longer than the other strand and the two strands form a duplex region having a length equal to that of the shorter strand such that the RNAi construct comprises at least one nucleotide overhang. For example, in one embodiment, the RNAi construct comprises (i) a sense strand that is 19 nucleotides in length, (ii) an antisense strand that is 21 nucleotides in length, (iii) a duplex region of 19 base pairs in length, and (iv) a single nucleotide overhang of 2 unpaired nucleotides at the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises (i) a sense strand that is 21 nucleotides in length, (ii) an antisense strand that is 23 nucleotides in length, (iii) a duplex region of 21 base pairs in length, and (iv) a single nucleotide overhang of 2 unpaired nucleotides at the 3' end of the antisense strand.

[0046] The antisense strand of the RNAi constructs of the invention can comprise the sequence of any one of the antisense sequences listed in Table 1, Table 6, or Table 8, the sequence of nucleotides 1-19 of any of these antisense sequences, or the sequence of nucleotides 2-19 of any of these antisense sequences. Each of the antisense sequences listed in Tables 1, 6, and 8 comprises a sequence of at least 19 consecutive nucleotides (first 19 nucleotides counting from the 5' end) that is complementary to an ASGR1 mRNA sequence plus a two nucleotide overhang sequence. Thus, in some embodiments, the antisense strand comprises a sequence of nucleotides 1-19 of any one of SEQ ID NOs: 1508-3010, 3665-4315, or 4513-4687. In other embodiments, the antisense strand comprises a sequence of nucleotides 2-19 of any one of SEQ ID NOs: 1508- 2024201349   29 Feb 2024 3010, 3665-4315, or 4513-4687. In still other embodiments, the antisense strand comprises a sequence selected from SEQ IDNOs: 1508-3010, 3665-4315, or 4513-4687. In certain embodiments, the antisense strand comprises, or consists of, a sequence selected from SEQ ID NO: 1606, SEQ ID NO: 1684, SEQ ID NO: 1708, SEQ ID NO: 1714, SEQ ID NO: 1743, SEQ ID NO: 1754, SEQ ID NO: 1881, SEQ ID NO: 1897, SEQ ID NO: 2321, SEQ ID NO: 2323, SEQ ID NO: 2491, SEQ ID NO: 2508, SEQ ID NO: 2553, SEQ ID NO: 2650, SEQ ID NO: 2651, SEQ ID NO: 1946, SEQ ID NO: 2002, SEQ ID NO: 2865, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 2873, SEQ ID NO: 2969, SEQ ID NO: 3701, SEQ ID NO: 3702, SEQ ID NO: 3716, SEQ ID NO: 3718, SEQ ID NO: 3722, SEQ ID NO: 4618, SEQ ID NO: 4619, SEQ ID NO: 4621, SEQ ID NO: 4627, SEQ ID NO: 4630, SEQ ID NO: 4634, SEQ ID NO: 4638, or SEQ ID NO: 4639. In some embodiments, the antisense strand comprises, or consists of, a sequence selected from SEQ ID NO: 1684, SEQ ID NO: 1708, SEQ ID NO: 1714, SEQ ID NO: 1743, SEQ ID NO: 2323, SEQ ID NO: 2650, SEQ ID NO: 2651, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 2873, SEQ ID NO: 4618, SEQ ID NO: 4621, SEQ ID NO: 4627, SEQ ID NO: 4638, or SEQ ID NO: 4639. In other embodiments, the antisense strand comprises, or consists of, a sequence selected from SEQ ID NO: 1743, SEQ ID NO: 2323, SEQ ID NO: 2651, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 4621, or SEQ ID NO: 4638.

[0047] In these and other embodiments, the sense strand of the RNAi constructs of the invention can comprise the sequence of any one of the sense sequences listed in Table 1, Table 6, or Table 8, the sequence of nucleotides 1-19 of any of these sense sequences, or the sequence of nucleotides 2-19 of any of these sense sequences. Each of the sense sequences listed in Tables 1, 6, and 8 comprises a sequence of at least 19 consecutive nucleotides (first 19 nucleotides counting from the 5' end) that is identical to an ASGR1 mRNA sequence and complementary to the corresponding antisense sequence, plus a two nucleotide overhang sequence. Thus, in some embodiments, the sense strand comprises a sequence of nucleotides 1-19 of any one of SEQ ID NOs: 5-1507, 3014-3664, or 4319-4512. In other embodiments, the sense strand comprises a sequence of nucleotides 2-19 of any one of SEQ ID NOs: 5-1507, 3014-3664, or 4319-4512. In still other embodiments, the sense strand comprises a sequence selected from SEQ ID NOs: 51507, 3014-3664, or 4319-4512. In certain embodiments, the sense strand comprises, or consists of, a sequence selected from SEQ ID NO: 103, SEQ ID NO: 181, SEQ ID NO: 205, SEQ ID NO: 211, SEQ ID NO: 240, SEQ ID NO: 251, SEQ ID NO: 378, SEQ ID NO: 394, SEQ ID NO: 2024201349   29 Feb 2024 818, SEQ ID NO: 820, SEQ ID NO: 988, SEQ ID NO: 1005, SEQ ID NO: 1050, SEQ ID NO: 1147, SEQ ID NO: 1148, SEQ ID NO: 443, SEQ ID NO: 499, SEQ ID NO: 1362, SEQ ID NO 1364, SEQ ID NO: 1366, SEQ ID NO: 1370, SEQ ID NO: 1466, SEQ ID NO: 3050, SEQ ID NO: 3051, SEQ ID NO: 3065, SEQ ID NO: 3067, SEQ ID NO: 3071, SEQ ID NO: 4443, SEQ ID NO: 4444, SEQ ID NO: 4446, SEQ ID NO: 4452, SEQ ID NO: 4455, SEQ ID NO: 4459, SEQ ID NO: 4463, or SEQ ID NO: 4464. In certain other embodiments, the sense strand comprises, or consists of, a sequence selected from SEQ ID NO: 181, SEQ ID NO: 205, SEQ ID NO: 211, SEQ ID NO: 240, SEQ ID NO: 820, SEQ ID NO: 1147, SEQ ID NO: 1148, SEQ ID NO: 1364, SEQ ID NO: 1366, SEQ ID NO: 1370, SEQ ID NO: 4443, SEQ ID NO: 4446, SEQ ID NO: 4452, SEQ ID NO: 4463, or SEQ ID NO: 4464. In some embodiments, the sense strand comprises, or consists of, a sequence selected from SEQ ID NO: 240, SEQ ID NO: 820, SEQ ID NO: 1148, SEQ ID NO: 1364, SEQ ID NO: 1366, SEQ ID NO: 4446 or SEQ ID NO: 4463.

[0048] In certain embodiments of the invention, the RNAi constructs comprise (i) a sense strand comprising a sequence selected from SEQ ID NOs: 5-1507, 3014-3664, or 4319-4512, nucleotides 1-19 of any one of SEQ ID NOs: 5-1507, 3014-3664, or 4319-4512, or nucleotides 2-19 of any one of SEQ ID NOs: 5-1507, 3014-3664, or 4319-4512, and (ii) an antisense strand comprising a sequence selected from SEQ ID NOs: 1508-3010, 3665-4315, or 4513-4687, nucleotides 1-19 of any one of SEQ ID NOs: 1508-3010, 3665-4315, or 4513-4687, or nucleotides 2-19 of any one of SEQ ID NOs: 1508-3010, 3665-4315, or 4513-4687. In some embodiments, the RNAi constructs comprise (i) a sense strand comprising, or consisting of, a sequence selected from SEQ ID NO: 103, SEQ ID NO: 181, SEQ ID NO: 205, SEQ ID NO: 211, SEQ ID NO: 240, SEQ ID NO: 251, SEQ ID NO: 378, SEQ ID NO: 394, SEQ ID NO: 818, SEQ ID NO: 820, SEQ ID NO: 988, SEQ ID NO: 1005, SEQ ID NO: 1050, SEQ ID NO: 1147, SEQ ID NO: 1148, SEQ ID NO: 443, SEQ ID NO: 499, SEQ ID NO: 1362, SEQ ID NO 1364, SEQ ID NO: 1366, SEQ ID NO: 1370, SEQ ID NO: 1466, SEQ ID NO: 3050, SEQ ID NO: 3051, SEQ ID NO: 3065, SEQ ID NO: 3067, SEQ ID NO: 3071, SEQ ID NO: 4443, SEQ ID NO: 4444, SEQ ID NO: 4446, SEQ ID NO: 4452, SEQ ID NO: 4455, SEQ ID NO: 4459, SEQ ID NO: 4463, or SEQ ID NO: 4464 and (ii) an antisense strand comprising, or consisting of, a sequence selected from SEQ ID NO: 1606, SEQ ID NO: 1684, SEQ ID NO: 1708, SEQ ID NO: 1714, SEQ ID NO: 1743, SEQ ID NO: 1754, SEQ ID NO: 1881, SEQ ID NO: 1897, SEQ ID NO: 2321, SEQ ID NO: 2323, SEQ ID NO: 2491, SEQ ID NO: 2508, SEQ ID NO: 2553, SEQ 2024201349   29 Feb 2024 ID NO: 2650, SEQ ID NO: 2651, SEQ ID NO: 1946, SEQ ID NO: 2002, SEQ ID NO: 2865, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 2873, SEQ ID NO: 2969, SEQ ID NO: 3701, SEQ ID NO: 3702, SEQ ID NO: 3716, SEQ ID NO: 3718, SEQ ID NO: 3722, SEQ ID NO: 4618, SEQ ID NO: 4619, SEQ ID NO: 4621, SEQ ID NO: 4627, SEQ ID NO: 4630, SEQ ID NO: 4634, SEQ ID NO: 4638, or SEQ ID NO: 4639. In other embodiments, the RNAi constructs comprise (i) a sense strand comprising, or consisting of, a sequence selected from SEQ ID NO: 181, SEQ ID NO: 205, SEQ ID NO: 211, SEQ ID NO: 240, SEQ ID NO: 820, SEQ ID NO: 1147, SEQ ID NO: 1148, SEQ ID NO: 1364, SEQ ID NO: 1366, SEQ ID NO: 1370, SEQ ID NO: 4443, SEQ ID NO: 4446, SEQ ID NO: 4452, SEQ ID NO: 4463, or SEQ ID NO: 4464, and (ii) an antisense strand comprising, or consisting of, a sequence selected from SEQ ID NO: 1684, SEQ ID NO: 1708, SEQ ID NO: 1714, SEQ ID NO: 1743, SEQ ID NO: 2323, SEQ ID NO: 2650, SEQ ID NO: 2651, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 2873, SEQ ID NO: 4618, SEQ ID NO: 4621, SEQ ID NO: 4627, SEQ ID NO: 4638, or SEQ ID NO: 4639. In still other embodiments, the RNAi constructs comprise (i) a sense strand comprising, or consisting of, a sequence selected from SEQ ID NO: 240, SEQ ID NO: 820, SEQ ID NO: 1148, SEQ ID NO: 1364, SEQ ID NO: 1366, SEQ ID NO: 4446 or SEQ ID NO: 4463, and (ii) an antisense strand comprising, or consisting of, a sequence selected from SEQ ID NO: 1743, SEQ ID NO: 2323, SEQ ID NO: 2651, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 4621, or SEQ ID NO: 4638.

[0049] In certain embodiments, the RNAi constructs comprise: (a) a sense strand comprising the sequence of SEQ ID NO: 181 and an antisense strand comprising the sequence of SEQ ID NO: 1684; (b) a sense strand comprising the sequence of SEQ ID NO: 205 and an antisense strand comprising the sequence of SEQ ID NO: 1708; (c) a sense strand comprising the sequence of SEQ ID NO: 211 and an antisense strand comprising the sequence of SEQ ID NO: 1714; (d) a sense strand comprising the sequence of SEQ ID NO: 240 and an antisense strand comprising the sequence of SEQ ID NO: 1743; (e) a sense strand comprising the sequence of SEQ ID NO: 820 and an antisense strand comprising the sequence of SEQ ID NO: 2323; (f) a sense strand comprising the sequence of SEQ ID NO: 1147 and an antisense strand comprising the sequence of SEQ ID NO: 2650; (g) a sense strand comprising the sequence of SEQ ID NO: 1148 and an antisense strand comprising the sequence of SEQ ID NO: 2651; (h) a sense strand comprising the sequence of SEQ ID NO: 1364 and an antisense strand comprising the sequence of SEQ ID NO: 2024201349   29 Feb 2024 2867; (i) a sense strand comprising the sequence of SEQ ID NO: 1366 and an antisense strand comprising the sequence of SEQ ID NO: 2869; or (j) a sense strand comprising the sequence of SEQ ID NO: 1370 and an antisense strand comprising the sequence of SEQ ID NO: 2873.

[0050] The RNAi construct of the invention can be any of the duplex compounds listed in Tables 1 to 10 (including the nucleotide sequences and / or chemical modifications of the compounds). In some embodiments, the RNAi construct is any of the duplex compounds listed in Table 1. In other embodiments, the RNAi construct is any of the duplex compounds listed in Table 6 (including the nucleotide sequences and / or chemical modifications of the compounds). In still other embodiments, the RNAi construct is any of the duplex compounds listed in Table 8 (including the nucleotide sequences and / or chemical modifications of the compounds). In certain embodiments, the RNAi construct is D-1098, D-l 176, D-1200, D-1206, D-1235, D-1246, D-1373, D-1389, D-1813, D-1815, D-1983, D-2000, D-2045, D-2142, D-2143, D-1438, D-1494, D-2357, D-2359, D-2361, D-2365, D-2461, D-3036, D-3037, D-3051, D-3053, D-3057, D-3779, D-3780, D-3782, D-3788, D-3791, D-3795, D-3799, or D-3800. In some embodiments, the RNAi construct is D-1200, D-1206, D-1235, D-1815, D-2143, D-2359, D-2361, D-2365, D-2142, D-l 176, D-3779, D-3782, D-3788, D-3799, or D-3800. In one particular embodiment, the RNAi construct is D-1235. In another particular embodiment, the RNAi construct is D-2143. In another embodiment, the RNAi construct is D-2361. In another embodiment, the RNAi construct is D-1815. In another embodiment, the RNAi construct is D-2359. In still another embodiment, the RNAi construct is D-3782. In yet another embodiment, the RNAi construct is D-3799.

[0051] In certain embodiments, the antisense strands of the RNAi constructs of the invention may target certain regions of the ASGR1 mRNA sequence. For instance, in some embodiments, the antisense strand of an RNAi construct of the invention comprises a sequence that is substantially complementary or fully complementary to nucleotides 692 to 721 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1, nucleotides 692 to 716 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1, or nucleotides 692 to 710 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1. In such embodiments, the RNAi construct may comprise a sense strand that is substantially complementary or fully complementary to the antisense strand targeting this region. Thus, in these embodiments, the sense strand may 2024201349   29 Feb 2024 comprise a sequence identical to nucleotides 692 to 721, nucleotides 692 to 716, or nucleotides 692 to 710 of SEQ ID NO: 1.

[0052] In other embodiments, the antisense strand of an RNAi construct of the invention comprises a sequence that is substantially complementary or fully complementary to nucleotides 396 to 425 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1, nucleotides 396 to 420 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1, or nucleotides 396 to 414 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1. In such embodiments, the RNAi construct may comprise a sense strand that is substantially complementary or fully complementary to the antisense strand targeting this region. Thus, in these embodiments, the sense strand may comprise a sequence identical to nucleotides 396 to 425, nucleotides 396 to 420, or nucleotides 396 to 414 of SEQ ID NO: 1.

[0053] In still other embodiments, the antisense strand of an RNAi construct of the invention comprises a sequence that is substantially complementary or fully complementary to nucleotides 886 to 915 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1, nucleotides 886 to 910 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1, or nucleotides 886 to 904 of the human ASGR1 mRNA transcript set forth in SEQ ID NO: 1. In such embodiments, the RNAi construct may comprise a sense strand that is substantially complementary or fully complementary to the antisense strand targeting this region. Thus, in these embodiments, the sense strand may comprise a sequence identical to nucleotides 886 to 915, nucleotides 886 to 910, or nucleotides 886 to 904 of SEQ ID NO: 1.

[0054] The RNAi constructs of the invention may comprise one or more modified nucleotides. A “modified nucleotide” refers to a nucleotide that has one or more chemical modifications to the nucleoside, nucleobase, pentose ring, or phosphate group. As used herein, modified nucleotides do not encompass ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate, and cytidine monophosphate, and deoxyribonucleotides containing deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and deoxycytidine monophosphate. However, the RNAi constructs may comprise combinations of modified nucleotides, ribonucleotides, and deoxyribonucleotides. Incorporation of modified nucleotides into one or both strands of double-stranded RNA molecules can improve the in vivo stability of the RNA molecules, e.g., by reducing the molecules’ susceptibility to nucleases and other degradation 2024201349   29 Feb 2024 processes. The potency of RNAi constructs for reducing expression of the target gene can also be enhanced by incorporation of modified nucleotides.

[0055] In certain embodiments, the modified nucleotides have a modification of the ribose sugar. These sugar modifications can include modifications at the 2' and / or 5' position of the pentose ring as well as bicyclic sugar modifications. A 2'-modified nucleotide refers to a nucleotide having a pentose ring with a substituent at the 2' position other than H or OH. Such 2'-modifications include, but are not limited to, 2'-O-alkyl (e.g. O-Ci-Cio or O-Ci-Cio substituted alkyl), 2'-O-allyl (O-CH2CH=CH2), 2'-C-allyl, 2'-fluoro, 2'-O-methyl (OCH3), 2'-O-methoxyethyl (O-(CH2)2OCH3), 2'-OCF3, 2'-O(CH2)2SCH3, 2'-O-aminoalkyl, 2'-amino (e.g. NH2), 2'-O-ethylamine, and 2'-azido. Modifications at the 5' position of the pentose ring include, but are not limited to, 5'-methyl (R or S); 5'-vinyl, and 5'-methoxy.

[0056] A “bicyclic sugar modification” refers to a modification of the pentose ring where a bridge connects two atoms of the ring to form a second ring resulting in a bicyclic sugar structure. In some embodiments the bicyclic sugar modification comprises a bridge between the 4' and 2' carbons of the pentose ring. Nucleotides comprising a sugar moiety with a bicyclic sugar modification are referred to herein as bicyclic nucleic acids or BNAs. Exemplary bicyclic sugar modifications include, but are not limited to, a-L-Methyleneoxy (4'-CH2—O-2') bicyclic nucleic acid (BNA); P-D-Methyleneoxy (4'-CH2—O-2') BNA (also referred to as a locked nucleic acid or LNA); Ethyleneoxy (4'-(CH2)2—O-2') BNA; Aminooxy (4'-CH2—O—N(R)- 2') BNA; Oxyamino (4'-CH2—N(R) —0-2') BNA; Methyl(methyleneoxy) (4'-CH(CH3) —0-2') BNA (also referred to as constrained ethyl or cEt); methylene-thio (4'-CH2—S-2') BNA; methylene-amino (4'-CH2-N(R)- 2') BNA; methyl carbocyclic (4'-CH2—CH(CH3)- 2') BNA; propylene carbocyclic (4'-(CH2)3-2') BNA; and Methoxy(ethyleneoxy) (4'-CH(CH2OMe)-O-2') BNA (also referred to as constrained MOE or cMOE). These and other sugar-modified nucleotides that can be incorporated into the RNAi constructs of the invention are described in U.S. Patent No. 9,181,551, U.S. Patent Publication No. 2016 / 0122761, and Deleavey and Damha, Chemistry and Biology, Vol. 19: 937-954, 2012, all of which are hereby incorporated by reference in their entireties.

[0057] In some embodiments, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-O-allyl modified nucleotides, bicyclic nucleic acids (BNAs), or combinations thereof. In certain 2024201349   29 Feb 2024 embodiments, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, or combinations thereof. In one particular embodiment, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides or combinations thereof.

[0058] Both the sense and antisense strands of the RNAi constructs can comprise one or multiple modified nucleotides. For instance, in some embodiments, the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modified nucleotides. In certain embodiments, all nucleotides in the sense strand are modified nucleotides. In some embodiments, the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modified nucleotides. In other embodiments, all nucleotides in the antisense strand are modified nucleotides. In certain other embodiments, all nucleotides in the sense strand and all nucleotides in the antisense strand are modified nucleotides. In these and other embodiments, the modified nucleotides can be 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or combinations thereof.

[0059] In some embodiments, all pyrimidine nucleotides preceding an adenosine nucleotide in the sense strand, antisense strand, or both strands are modified nucleotides. For example, where the sequence 5'-CA-3' or 5'-UA-3' appears in either strand, the cytidine and uridine nucleotides are modified nucleotides, preferably 2'-O-methyl modified nucleotides. In certain embodiments, all pyrimidine nucleotides in the sense strand are modified nucleotides (e.g. 2'-O-methyl modified nucleotides), and the 5' nucleotide in all occurrences of the sequence 5'-CA-3' or 5'-UA-3' in the antisense strand are modified nucleotides (e.g. 2'-O-methyl modified nucleotides). In other embodiments, all nucleotides in the duplex region are modified nucleotides. In such embodiments, the modified nucleotides are preferably 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides or combinations thereof.

[0060] In embodiments in which the RNAi construct comprises a nucleotide overhang, the nucleotides in the overhang can be ribonucleotides, deoxyribonucleotides, or modified nucleotides. In one embodiment, the nucleotides in the overhang are deoxyribonucleotides, e.g. deoxythymidine. In another embodiment, the nucleotides in the overhang are modified nucleotides. For instance, in some embodiments, the nucleotides in the overhang are 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-methoxyethyl modified nucleotides, or combinations thereof. 2024201349   29 Feb 2024

[0061] The RNAi constructs of the invention may also comprise one or more modified internucleotide linkages. As used herein, the term “modified internucleotide linkage” refers to an intemucleotide linkage other than the natural 3' to 5' phosphodiester linkage. In some embodiments, the modified internucleotide linkage is a phosphorous-containing internucleotide linkage, such as a phosphotriester, aminoalkylphosphotriester, an alkylphosphonate (e.g. methylphosphonate, 3' -alkylene phosphonate), a phosphinate, a phosphoramidate (e.g. 3'-amino phosphoramidate and aminoalkylphosphoramidate), a phosphorothioate (P=S), a chiral phosphorothioate, a phosphorodithioate, a thionophosphoramidate, a thionoalkylphosphonate, a thionoalkylphosphotriester, and a boranophosphate. In one embodiment, a modified internucleotide linkage is a 2' to 5' phosphodiester linkage. In other embodiments, the modified internucleotide linkage is a non-phosphorous-containing internucleotide linkage and thus can be referred to as a modified internucleoside linkage. Such non-phosphorous-containing linkages include, but are not limited to, morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane linkages (—O—Si(H)2—O—); sulfide, sulfoxide and sulfone linkages; formacetyl and thioformacetyl linkages; alkene containing backbones; sulfamate backbones; methylenemethylimino (—CH2—N(CHs) —O—CH2—) and methylenehydrazino linkages; sulfonate and sulfonamide linkages; amide linkages; and others having mixed N, O, S and CH2 component parts. In one embodiment, the modified intemucleoside linkage is a peptide-based linkage (e.g. aminoethylglycine) to create a peptide nucleic acid or PNA, such as those described in U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262. Other suitable modified internucleotide and internucleoside linkages that may be employed in the RNAi constructs of the invention are described in U.S. Patent No. 6,693,187, U.S. Patent No. 9,181,551, U.S. Patent Publication No. 2016 / 0122761, and Deleavey and Damha, Chemistry and Biology, Vol. 19: 937954, 2012, all of which are hereby incorporated by reference in their entireties.

[0062] In certain embodiments, the RNAi constructs comprise one or more phosphorothioate internucleotide linkages. The phosphorothioate internucleotide linkages may be present in the sense strand, antisense strand, or both strands of the RNAi constructs. For instance, in some embodiments, the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide linkages. In other embodiments, the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide linkages. In still other embodiments, both strands comprise 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide linkages. The RNAi 2024201349   29 Feb 2024 constructs can comprise one or more phosphorothioate intemucleotide linkages at the 3'-end, the 5'-end, or both the 3'- and 5'-ends of the sense strand, the antisense strand, or both strands. For instance, in certain embodiments, the RNAi construct comprises about 1 to about 6 or more (e.g., about 1, 2, 3, 4, 5, 6 or more) consecutive phosphorothioate internucleotide linkages at the 3'-end of the sense strand, the antisense strand, or both strands. In other embodiments, the RNAi construct comprises about 1 to about 6 or more (e.g., about 1, 2, 3, 4, 5, 6 or more) consecutive phosphorothioate intemucleotide linkages at the 5'-end of the sense strand, the antisense strand, or both strands. In one embodiment, the RNAi construct comprises a single phosphorothioate intemucleotide linkage at the 3' end of the sense strand and a single phosphorothioate intemucleotide linkage at the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises two consecutive phosphorothioate intemucleotide linkages at the 3' end of the antisense strand (i.e. a phosphorothioate intemucleotide linkage at the first and second intemucleotide linkages at the 3' end of the antisense strand). In another embodiment, the RNAi construct comprises two consecutive phosphorothioate intemucleotide linkages at both the 3' and 5' ends of the antisense strand. In yet another embodiment, the RNAi construct comprises two consecutive phosphorothioate intemucleotide linkages at both the 3' and 5' ends of the antisense strand and two consecutive phosphorothioate intemucleotide linkages at the 5' end of the sense strand. In still another embodiment, the RNAi construct comprises two consecutive phosphorothioate intemucleotide linkages at both the 3' and 5' ends of the antisense strand and two consecutive phosphorothioate intemucleotide linkages at both the 3' and 5' ends of the sense strand (i.e. a phosphorothioate intemucleotide linkage at the first and second intemucleotide linkages at both the 5' and 3' ends of the antisense strand and a phosphorothioate intemucleotide linkage at the first and second intemucleotide linkages at both the 5' and 3' ends of the sense strand). In any of the embodiments in which one or both strands comprises one or more phosphorothioate intemucleotide linkages, the remaining intemucleotide linkages within the strands can be the natural 3' to 5' phosphodiester linkages. For instance, in some embodiments, each intemucleotide linkage of the sense and antisense strands is selected from phosphodiester and phosphorothioate, wherein at least one intemucleotide linkage is a phosphorothioate.

[0063] In embodiments in which the RNAi construct comprises a nucleotide overhang, two or more of the unpaired nucleotides in the overhang can be connected by a phosphorothioate intemucleotide linkage. In certain embodiments, all the unpaired nucleotides in a nucleotide 2024201349   29 Feb 2024 overhang at the 3' end of the antisense strand and / or the sense strand are connected by phosphorothioate intemucleotide linkages. In other embodiments, all the unpaired nucleotides in a nucleotide overhang at the 5' end of the antisense strand and / or the sense strand are connected by phosphorothioate internucleotide linkages. In still other embodiments, all the unpaired nucleotides in any nucleotide overhang are connected by phosphorothioate internucleotide linkages.

[0064] In certain embodiments, the modified nucleotides incorporated into one or both of the strands of the RNAi constructs of the invention have a modification of the nucleobase (also referred to herein as “base”). A “modified nucleobase” or “modified base” refers to a base other than the naturally occurring purine bases adenine (A) and guanine (G) and pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases can be synthetic or naturally occurring modifications and include, but are not limited to, universal bases, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine (X), hypoxanthine (I), 2-aminoadenine, 6-methyladenine, 6-methylguanine, and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine.

[0065] In some embodiments, the modified base is a universal base. A “universal base” refers to a base analog that indiscriminately forms base pairs with all of the natural bases in RNA and DNA without altering the double helical structure of the resulting duplex region. Universal bases are known to those of skill in the art and include, but are not limited to, inosine, C-phenyl, C-naphthyl and other aromatic derivatives, azole carboxamides, and nitroazole derivatives, such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole.

[0066] Other suitable modified bases that can be incorporated into the RNAi constructs of the invention include those described in Herdewijn, Antisense Nucleic Acid Drug Dev., Vol. 10: 297-310, 2000 and Peacock et al., J. Org. Chern., Vol. 76: 7295-7300, 2011, both of which are hereby incorporated by reference in their entireties. The skilled person is well aware that 2024201349   29 Feb 2024 guanine, cytosine, adenine, thymine, and uracil may be replaced by other nucleobases, such as the modified nucleobases described above, without substantially altering the base pairing properties of a polynucleotide comprising a nucleotide bearing such replacement nucleobase.

[0067] In some embodiments, the sense and antisense strands of the RNAi constructs may comprise one or more abasic nulceotides. An “abasic nucleotide” or “abasic nucleoside” is a nucleotide or nucleoside that lacks a nucleobase at the 1' position of the ribose sugar. In certain embodiments, the abasic nucleotides are incorporated into the terminal ends of the sense and / or antisense strands of the RNAi constructs. In one embodiment, the sense strand comprises an abasic nucleotide as the terminal nucleotide at its 3' end, its 5' end, or both its 3' and 5' ends. In another embodiment, the antisense strand comprises an abasic nucleotide as the terminal nucleotide at its 3' end, its 5' end, or both its 3' and 5' ends. In such embodiments in which the abasic nucleotide is a terminal nucleotide, it may be linked to the adjacent nucleotide through a 3'-3' internucleotide linkage (i.e. an inverted nucleotide) rather than the natural 3'-5' internucleotide linkage.

[0068] In some embodiments of the RNAi constructs of the invention, the 5' end of the sense strand, antisense strand, or both the antisense and sense strands comprises a phosphate moiety. As used herein, the term “phosphate moiety” refers to a terminal phosphate group that includes unmodified phosphates (—O—P=O)(OH)OH) as well as modified phosphates. Modified phosphates include phosphates in which one or more of the O and OH groups is replaced with H, O, S, N(R) or alkyl where R is H, an amino protecting group or unsubstituted or substituted alkyl. Exemplary phosphate moi eties include, but are not limited to, 5'-monophosphate; 5'-diphosphate; 5'-triphosphate; 5'-guanosine cap (7-methylated or non-methylated); 5'-adenosine cap or any other modified or unmodified nucleotide cap structure; 5'-monothiophosphate (phosphorothioate); 5'-monodithiophosphate (phosphorodithioate); 5'-alpha-thiotriphosphate; 5'-gamma-thiotriphosphate, 5'-phosphoramidates; 5'-vinylphosphates; 5'-alkylphosphonates (e.g., alkyl = methyl, ethyl, isopropyl, propyl, etc.); and 5'-alkyletherphosphonates (e.g., alkylether = methoxymethyl, ethoxymethyl, etc.).

[0069] The modified nucleotides that can be incorporated into the RNAi constructs of the invention may have more than one chemical modification described herein. For instance, the modified nucleotide may have a modification to the ribose sugar as well as a modification to the nucleobase. By way of example, a modified nucleotide may comprise a 2' sugar modification 2024201349   29 Feb 2024 (e.g. 2'-fluoro or 2'-methyl) and comprise a modified base (e.g. 5-methyl cytosine or pseudouracil). In other embodiments, the modified nucleotide may comprise a sugar modification in combination with a modification to the 5' phosphate that would create a modified internucleotide or intemucleoside linkage when the modified nucleotide was incorporated into a polynucleotide. For instance, in some embodiments, the modified nucleotide may comprise a sugar modification, such as a 2'-fluoro modification, a 2'-O-methyl modification, or a bicyclic sugar modification, as well as a 5' phosphorothioate group. Accordingly, in some embodiments, one or both strands of the RNAi constructs of the invention comprise a combination of 2' modified nucleotides or BNAs and phosphorothioate internucleotide linkages. In certain embodiments, both the sense and antisense strands of the RNAi constructs of the invention comprise a combination of 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, and phosphorothioate internucleotide linkages. Exemplary RNAi constructs comprising modified nucleotides and internucleotide linkages are shown in Tables 6 and 8.

[0070] Preferably, the RNAi constructs of the invention reduce or inhibit the expression of ASGR1 in cells, particularly liver cells. Accordingly, in one embodiment, the present invention provides a method of reducing ASGR1 expression in a cell by contacting the cell with any RNAi construct described herein. The cell may be in vitro or in vivo. ASGR1 expression can be assessed by measuring the amount or level of ASGR1 mRNA, ASGR1 protein, or another biomarker linked to ASGR1 expression, such as serum levels of alkaline phosphatase. The reduction of ASGR1 expression in cells or animals treated with an RNAi construct of the invention can be determined relative to the ASGR1 expression in cells or animals not treated with the RNAi construct or treated with a control RNAi construct. For instance, in some embodiments, reduction of ASGR1 expression is assessed by (a) measuring the amount or level of ASGR1 mRNA in liver cells treated with a RNAi construct of the invention, (b) measuring the amount or level of ASGR1 mRNA in liver cells treated with a control RNAi construct (e.g. RNAi agent directed to a RNA molecule not expressed in liver cells or a RNAi construct having a nonsense or scrambled sequence) or no construct, and (c) comparing the measured ASGR1 mRNA levels from treated cells in (a) to the measured ASGR1 mRNA levels from control cells in (b). The ASGR1 mRNA levels in the treated cells and controls cells can be normalized to RNA levels for a control gene (e.g. 18S ribosomal RNA or housekeeping gene) prior to comparison. ASGR1 mRNA levels can be measured by a variety of methods, including Northern 2024201349   29 Feb 2024 blot analysis, nuclease protection assays, fluorescence in situ hybridization (FISH), reversetranscriptase (RT)-PCR, real-time RT-PCR, quantitative PCR, droplet digital PCR, and the like.

[0071] In other embodiments, reduction of ASGR1 expression is assessed by (a) measuring the amount or level of ASGR1 protein in liver cells treated with a RNAi construct of the invention, (b) measuring the amount or level of ASGR1 protein in liver cells treated with a control RNAi construct (e.g. RNAi agent directed to a RNA molecule not expressed in liver cells or a RNAi construct having a nonsense or scrambled sequence) or no construct, and (c) comparing the measured ASGR1 protein levels from treated cells in (a) to the measured ASGR1 protein levels from control cells in (b). Methods of measuring ASGR1 protein levels are known to those of skill in the art, and include Western Blots, immunoassays (e.g. ELISA), and flow cytometry. An exemplary immunoassay-based method for assessing ASGR1 protein expression is described in Examples 2 and 7. Example 3 describes an exemplary method for measuring ASGR1 mRNA using RNA FISH, and Example 8 describes an exemplary method for assessing ASGR1 mRNA using droplet digital PCR. Any method capable of measuring ASGR1 mRNA or protein can be used to assess the efficacy of the RNAi constructs of the invention.

[0072] In some embodiments, the methods to assess ASGR1 expression levels are performed in vitro in cells that natively express ASGR1 (e.g. liver cells) or cells that have been engineered to express ASGR1. In certain embodiments, the methods are performed in vitro in liver cells. Suitable liver cells include, but are not limited to, primary hepatocytes (e.g. human, non-human primate, or rodent hepatocytes), HepAD38 cells, HuH-6 cells, HuH-7 cells, HuH-5-2 cells, BNLCL2 cells, Hep3B cells, or HepG2 cells. In one embodiment, the liver cells are Hep3B cells. In another embodiment, the liver cells are human primary hepatopyctes.

[0073] In other embodiments, the methods to assess ASGR1 expression levels are performed in vivo. The RNAi constructs and any control RNAi constructs can be administered to an animal (e.g. rodent or non-human primate) and ASGR1 mRNA or protein levels assessed in liver tissue harvested from the animal following treatment. Alternatively or additionally, a biomarker or functional phenotype associated with ASGR1 expression can be assessed in the treated animals. For instance, elevated serum alkaline phosphatase levels correlate with reduced serum levels of non-HDL cholesterol in individuals with loss of function mutations in the ASGR1 gene (Nioi et al., New England Journal of Medicine, Vol. 374(22):2131-2141, 2016, which is hereby incorporated by reference in its entirety). Thus, serum levels of alkaline phosphatase or non- 2024201349   29 Feb 2024 HDL cholesterol can be measured in animals treated with RNAi constructs of the invention to assess the functional efficacy of reducing ASGR1 expression. Exemplary methods for these analyses are described in Examples 6, 9, and 10.

[0074] In certain embodiments, expression of ASGR1 is reduced in liver cells by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% by an RNAi construct of the invention. In some embodiments, expression of ASGR1 is reduced in liver cells by at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, or at least 85% by an RNAi construct of the invention. In other embodiments, the expression of ASGR1 is reduced in liver cells by about 90% or more, e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more by an RNAi construct of the invention. The percent reduction of ASGR1 expression can be measured by any of the methods described herein as well as others known in the art. For instance, in certain embodiments, the RNAi constructs of the invention inhibit at least 45% of ASGR1 expression at 5 nM in Hep3B cells in vitro. In related embodiments, the RNAi constructs of the invention inhibit at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75% of ASGR1 expression at 5 nM in Hep3B cells in vitro. In other embodiments, the RNAi constructs of the invention inhibit at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, or at least 98% of ASGR1 expression at 5 nM in Hep3B cells in vitro.

[0075] In some embodiments, an IC50 value is calculated to assess the potency of an RNAi construct of the invention for inhibiting ASGR1 expression in liver cells. An “IC50 value” is the dose / concentration required to achieve 50% inhibition of a biological or biochemical function. The IC50 value of any particular substance or antagonist can be determined by constructing a dose-response curve and examining the effect of different concentrations of the substance or antagonist on expression levels or functional activity in any assay. IC50 values can be calculated for a given antagonist or substance by determining the concentration needed to inhibit half of the maximum biological response or native expression levels. Thus, the IC50 value for any RNAi construct can be calculated by determining the concentration of the RNAi construct needed to inhibit half of the native ASGR1 expression level in liver cells (e.g. ASGR1 expression level in control liver cells) in any assay, such as the immunoassay, RNA FISH assay, qPCR or droplet digital PCR assays described in the Examples. The RNAi constructs of the invention may inhibit ASGR1 expression in liver cells (e.g. Hep3B cells) with an IC50 of less than about 10 nM, less 2024201349   29 Feb 2024 than about 5 nM, or less than about 1 nM. For example, the RNAi constructs inhibit ASGR1 expression in liver cells with an IC50 of about 0.5 nM to about 10 nM, about 0.8 nM to about 8 nM, about 1 nM to about 5 nM, about 0.8 nM to about 3 nM, about 0.001 nM to about 1 nM, about 0.001 nM to about 0.50 nM, about 0.001 nM to about 0.1 nM, about 0.001 nM to about 0.01 nM, about 0.01 nM to about 0.50 nM, about 0.02 nM to about 0.80 nM, about 0.01 nM to about 1.0 nM, about 0.1 nM to about 0.9 nM, or about 0.05 nM to about 0.5 nM. In certain embodiments, the RNAi construct inhibits ASGR1 expression in liver cells (e.g. Hep3B cells) with an IC50 of about 0.5 nM to about 5 nM. In other embodiments, the RNAi construct inhibits ASGR1 expression in liver cells (e.g. Hep3B cells) with an IC50 of about 0.01 nM to about 0.9 nM.

[0076] The RNAi constructs of the invention can readily be made using techniques known in the art, for example, using conventional nucleic acid solid phase synthesis. The polynucleotides of the RNAi constructs can be assembled on a suitable nucleic acid synthesizer utilizing standard nucleotide or nucleoside precursors (e.g. phosphoramidites). Automated nucleic acid synthesizers are sold commercially by several vendors, including DNA / RNA synthesizers from Applied Biosystems (Foster City, CA), MerMade synthesizers from BioAutomation (Irving, TX), and OligoPilot synthesizers from GE Healthcare Life Sciences (Pittsburgh, PA).

[0077] The 2' silyl protecting group can be used in conjunction with acid labile dimethoxytrityl (DMT) at the 5' position of ribonucleosides to synthesize oligonucleotides via phosphoramidite chemistry. Final deprotection conditions are known not to significantly degrade RNA products. All syntheses can be conducted in any automated or manual synthesizer on large, medium, or small scale. The syntheses may also be carried out in multiple well plates, columns, or glass slides.

[0078] The 2'-O-silyl group can be removed via exposure to fluoride ions, which can include any source of fluoride ion, e.g., those salts containing fluoride ion paired with inorganic counterions e.g., cesium fluoride and potassium fluoride or those salts containing fluoride ion paired with an organic counterion, e.g., a tetraalkylammonium fluoride. A crown ether catalyst can be utilized in combination with the inorganic fluoride in the deprotection reaction. Preferred fluoride ion source are tetrabutyl ammonium fluoride or aminohydrofluorides (e.g., combining aqueous HF with triethylamine in a dipolar aprotic solvent, e.g., dimethylformamide). 2024201349   29 Feb 2024

[0079] The choice of protecting groups for use on the phosphite triesters and phosphotriesters can alter the stability of the triesters towards fluoride. Methyl protection of the phosphotriester or phosphitetriester can stabilize the linkage against fluoride ions and improve process yields.

[0080] Since ribonucleosides have a reactive 2' hydroxyl substituent, it can be desirable to protect the reactive 2' position in RNA with a protecting group that is orthogonal to a 5'-O-dimethoxytrityl protecting group, e.g., one stable to treatment with acid. Silyl protecting groups meet this criterion and can be readily removed in a final fluoride deprotection step that can result in minimal RNA degradation.

[0081] Tetrazole catalysts can be used in the standard phosphoramidite coupling reaction. Preferred catalysts include, e.g., tetrazole, S-ethyl-tetrazole, benzylthiotetrazole, p-nitropheny Itetrazol e.

[0082] As can be appreciated by the skilled artisan, further methods of synthesizing the RNAi constructs described herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Other synthetic chemistry transformations, protecting groups (e.g., for hydroxyl, amino, etc. present on the bases) and protecting group methodologies (protection and deprotection) useful in synthesizing the RNAi constructs described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof. Custom synthesis of RNAi agents is also available from several commercial vendors, including Dharmacon, Inc. (Lafayette, CO), AxoLabs GmbH (Kulmbach, Germany), and Ambion, Inc. (Foster City, CA).

[0083] The RNAi constructs of the invention may comprise a ligand. As used herein, a “ligand” refers to any compound or molecule that is capable of interacting with another compound or molecule, directly or indirectly. The interaction of a ligand with another compound or molecule may elicit a biological response (e.g. initiate a signal transduction cascade, induce receptor-mediated endocytosis) or may just be a physical association. The ligand can modify one or more properties of the double-stranded RNA molecule to which is attached, such as the 2024201349   29 Feb 2024 pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and / or clearance properties of the RNA molecule.

[0084] The ligand may comprise a serum protein (e.g., human serum albumin, low-density lipoprotein, globulin), a cholesterol moiety, a vitamin (biotin, vitamin E, vitamin B12), a folate moiety, a steroid, a bile acid (e.g. cholic acid), a fatty acid (e.g., palmitic acid, myristic acid), a carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid), a glycoside, a phospholipid, or antibody or binding fragment thereof (e.g. antibody or binding fragment that targets the RNAi construct to a specific cell type, such as liver). Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyl oxy hexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, 03-(oleoyl)lithocholic acid, 03-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine), peptides (e.g., antennapedia peptide, Tat peptide, RGD peptides), alkylating agents, polymers, such as polyethylene glycol (PEG )(e.g., PEG-40K), polyamino acids, and polyamines (e.g. spermine, spermidine).

[0085] In certain embodiments, the ligands have endosomolytic properties. The endosomolytic ligands promote the lysis of the endosome and / or transport of the RNAi construct of the invention, or its components, from the endosome to the cytoplasm of the cell. The endosomolytic ligand may be a polycationic peptide or peptidomimetic, which shows pH-dependent membrane activity and fusogenicity. In one embodiment, the endosomolytic ligand assumes its active conformation at endosomal pH. The “active” conformation is that conformation in which the endosomolytic ligand promotes lysis of the endosome and / or transport of the RNAi construct of the invention, or its components, from the endosome to the cytoplasm of the cell. Exemplary endosomolytic ligands include the GALA peptide (Subbarao et al., Biochemistry, Vol. 26: 2964-2972, 1987), the EALA peptide (Vogel etal., J. Am. Chern. Soc., Vol. 118: 1581-1586, 1996), and their derivatives (Turk etal., Biochem. Biophys. Acta, Vol. 1559: 56-68, 2002). In one embodiment, the endosomolytic component may contain a chemical group (e.g., an amino acid) which will undergo a change in charge or protonation in response to a change in pH. The endosomolytic component may be linear or branched. 2024201349   29 Feb 2024

[0086] In some embodiments, the ligand comprises a lipid or other hydrophobic molecule. In one embodiment, the ligand comprises a cholesterol moiety or other steroid. Cholesterol-conjugated oligonucleotides have been reported to be more active than their unconjugated counterparts (Manoharan, Antisense Nucleic Acid Drug Development, Vol. 12: 103-228, 2002). Ligands comprising cholesterol moieties and other lipids for conjugation to nucleic acid molecules have also been described in U.S. Patent Nos. 7,851,615; 7,745,608; and 7,833,992 , all of which are hereby incorporated by reference in their entireties. In another embodiment, the ligand comprises a folate moiety. Polynucleotides conjugated to folate moieties can be taken up by cells via a receptor-mediated endocytosis pathway. Such folate-polynucleotide conjugates are described in U.S. Patent No. 8,188,247, which is hereby incorporated by reference in its entirety.

[0087] Given that ASGR1 is expressed on the surface of liver cells (e.g. hepatocytes) as a component of the asialoglycoprotein receptor (ASGR), in certain embodiments, it is desirable to specifically deliver the RNAi construct to those liver cells. Accordingly, in certain embodiments, the ligand targets delivery of the RNAi constructs specifically to liver cells (e.g. hepatocytes) using various approaches as described in more detail below. In certain embodiments, the RNAi constructs are targeted to liver cells with a ligand that binds to the surface-expressed ASGR, ASGR1 and / or ASGR2. In these embodiments, it is envisioned that this targeting approach can result in a self-regulating system that reduces the amount of RNAi construct delivered to the liver cells as expression of ASGR1 is reduced due to the effect of the previously delivered RNAi construct.

[0088] In some embodiments, RNAi constructs can be specifically targeted to the liver by employing ligands that bind to or interact with proteins expressed on the surface of liver cells. For example, in certain embodiments, the ligands may comprise antigen binding proteins (e.g. antibodies or binding fragments thereof (e.g. Fab, scFv)) that specifically bind to a receptor expressed on hepatocytes, such as the asialoglycoprotein receptor and the LDL receptor. In one particular embodiment, the ligand comprises an antibody or binding fragment thereof that specifically binds to ASGR1 and / or ASGR2. In another embodiment, the ligand comprises a Fab fragment of an antibody that specifically binds to ASGR1 and / or ASGR2. A “Fab fragment” is comprised of one immunoglobulin light chain (i.e. light chain variable region (VL) and constant region (CL)) and the CHI region and variable region (VH) of one immunoglobulin heavy chain. In another embodiment, the ligand comprises a single-chain variable antibody fragment (scFv 2024201349   29 Feb 2024 fragment) of an antibody that specifically binds to ASGR1 and / or ASGR2. An “scFv fragment” comprises the VH and VL regions of an antibody, wherein these regions are present in a single polypeptide chain, and optionally comprising a peptide linker between the VH and VL regions that enables the Fv to form the desired structure for antigen binding. Exemplary antibodies and binding fragments thereof that specifically bind to ASGR1 that can be used as ligands for targeting the RNAi constructs of the invention to the liver are described in U.S. Patent Application No. 62 / 234,546 and WIPO Publication No. WO 2017 / 058944, both of which are hereby incorporated by reference in their entireties. Other antibodies or binding fragments thereof that specifically bind to ASGR1, LDL receptor, or other liver surface-expressed proteins suitable for use as ligands in the RNAi constructs of the invention are commercially available.

[0089] In some embodiments, the ligand comprises a cys monoclonal antibody (mAb) or antigen-binding fragment thereof. A “cys mAb” is a monoclonal antibody or antigen-binding fragment thereof in which at least one amino acid in the light chain or heavy chain has been substituted with a cysteine amino acid or at least one cysteine amino acid has been inserted into the primary sequence of the light chain or heavy chain. The free thiol group in the side chain of the cysteine amino acid provides a conjugation site to which the sense strand of the RNAi constructs of the invention can be covalently linked. The cysteine substitutions / additions can be at the amino-terminus or carboxy-terminus of the light chain or heavy chain of the antibody or antigen-binding fragment. Alternatively or additionally, the cysteine substitutions / additions can be located at an internal site within the light chain or heavy chain so long as the cysteine substitution / addition does not affect the binding affinity of the antibody or antigen-binding fragment to its target antigen (e.g. ASGR1). Exemplary amino acids within the heavy and light chains of antibodies that may be substituted with cysteine residues are described in WIPO Publication Nos. WO 2006 / 034488 and WO 2007 / 022070, both of which are hereby incorporated by reference in their entireties. In certain embodiments, the ligand comprises a cys mAb or antigen-binding fragment thereof that specifically binds to human ASGR1. An exemplary anti-ASGRl cys mAb is described in Example 10. In one embodiment, the ligand comprises an anti-ASGRl antibody having a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO: 4696 and the light chain comprises the sequence of SEQ ID NO: 4697. Anti-ASGRl cys mAbs or antigen-binding fragments thereof may be covalently attached to the 5' end or 3' end of the sense strand of an RNAi construct of the 2024201349   29 Feb 2024 invention, optionally through any of the linkers described herein. In some embodiments, the anti-ASGR1 antibody-RNA molecule conjugate comprises one copy of the interfering RNA molecule (e.g. siRNA or shRNA)(i.e. an RNAi-to-antibody ratio of 1). In other embodiments, the anti-ASGR1 antibody-RNA molecule conjugate comprises two copies of the interfering RNA molecule (e.g. siRNA or shRNA)(i.e. an RNAi-to-antibody ratio of 2).

[0090] In certain embodiments, the ligand comprises a carbohydrate. A “carbohydrate” refers to a compound made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Carbohydrates include, but are not limited to, the sugars (e.g., monosaccharides, di saccharides, trisaccharides, tetrasaccharides, and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides, such as starches, glycogen, cellulose and polysaccharide gums. In some embodiments, the carbohydrate incorporated into the ligand is a monosaccharide selected from a pentose, hexose, or heptose and di- and tri-saccharides including such monosaccharide units. In other embodiments, the carbohydrate incorporated into the ligand is an amino sugar, such as galactosamine, glucosamine, N-acetylgalactosamine, and N-acetylglucosamine.

[0091] In some embodiments, the ligand comprises a hexose or hexosamine. The hexose may be selected from glucose, galactose, mannose, fucose, or fructose. The hexosamine may be selected from fructosamine, galactosamine, glucosamine, or mannosamine. In certain embodiments, the ligand comprises glucose, galactose, galactosamine, or glucosamine. In one embodiment, the ligand comprises glucose, glucosamine, or N-acetylglucosamine. In another embodiment, the ligand comprises galactose, galactosamine, or N-acetyl-galactosamine. In particular embodiments, the ligand comprises N-acetyl-galactosamine. Ligands comprising glucose, galactose, and N-acetyl-galactosamine (GalNAc) are particularly effective in targeting compounds to liver cells because such ligands bind to the ASGR expressed on the surface of hepatocytes. See, e.g., D’Souza and Devarajan, J. Control Release, Vol. 203: 126-139, 2015. Examples of GalNAc- or galactose-containing ligands that can be incorporated into the RNAi constructs of the invention are described in U.S. Patent Nos. 7,491,805; 8,106,022; and 8,877,917; U.S. Patent Publication No. 20030130186; and WIPO Publication No. WO 2013166155, all of which are hereby incorporated by reference in their entireties. 2024201349   29 Feb 2024

[0092] In certain embodiments, the ligand comprises a multivalent carbohydrate moiety. As used herein, a “multivalent carbohydrate moiety” refers to a moiety comprising two or more carbohydrate units capable of independently binding or interacting with other molecules. For example, a multivalent carbohydrate moiety comprises two or more binding domains comprised of carbohydrates that can bind to two or more different molecules or two or more different sites on the same molecule. The valency of the carbohydrate moiety denotes the number of individual binding domains within the carbohydrate moiety. For instance, the terms “monovalent,” “bivalent,” “trivalent,” and “tetravalent” with reference to the carbohydrate moiety refer to carbohydrate moieties with one, two, three, and four binding domains, respectively. The multivalent carbohydrate moiety may comprise a multivalent lactose moiety, a multivalent galactose moiety, a multivalent glucose moiety, a multivalent N-acetyl-galactosamine moiety, a multivalent N-acetyl-glucosamine moiety, a multivalent mannose moiety, or a multivalent fucose moiety. In some embodiments, the ligand comprises a multivalent galactose moiety. In other embodiments, the ligand comprises a multivalent N-acetyl-galactosamine moiety. In these and other embodiments, the multivalent carbohydrate moiety is bivalent, trivalent, or tetravalent. In such embodiments, the multivalent carbohydrate moiety can be bi-antennary or tri-antennary. In one particular embodiment, the multivalent N-acetyl-galactosamine moiety is trivalent or tetravalent. In another particular embodiment, the multivalent galactose moiety is trivalent or tetravalent. Exemplary trivalent and tetravalent GalNAc-containing ligands for incorporation into the RNAi constructs of the invention are described in detail below.

[0093] The ligand can be attached or conjugated to the RNA molecule of the RNAi construct directly or indirectly. For instance, in some embodiments, the ligand is covalently attached directly to the sense or antisense strand of the RNAi construct. In other embodiments, the ligand is covalently attached via a linker to the sense or antisense strand of the RNAi construct. The ligand can be attached to nucleobases, sugar moieties, or internucleotide linkages of polynucleotides (e.g. sense strand or antisense strand) of the RNAi constructs of the invention. Conjugation or attachment to purine nucleobases or derivatives thereof can occur at any position including, endocyclic and exocyclic atoms. In certain embodiments, the 2-, 6-, 7-, or 8-positions of a purine nucleobase are attached to a ligand. Conjugation or attachment to pyrimidine nucleobases or derivatives thereof can also occur at any position. In some embodiments, the 2-, 5-, and 6-positions of a pyrimidine nucleobase can be attached to a ligand. Conjugation or 2024201349   29 Feb 2024 attachment to sugar moieties of nucleotides can occur at any carbon atom. Example carbon atoms of a sugar moiety that can be attached to a ligand include the 2', 3', and 5' carbon atoms. The 1' position can also be attached to a ligand, such as in an abasic residue. Internucleotide linkages can also support ligand attachments. For phosphorus-containing linkages (e.g., phosphodiester, phosphorothioate, phosphorodithiotate, phosphoroamidate, and the like), the ligand can be attached directly to the phosphorus atom or to an O, N, or S atom bound to the phosphorus atom. For amine- or amide-containing internucleoside linkages (e.g., PNA), the ligand can be attached to the nitrogen atom of the amine or amide or to an adjacent carbon atom.

[0094] In certain embodiments, the ligand may be attached to the 3' or 5' end of either the sense or antisense strand. In certain embodiments, the ligand is covalently attached to the 5' end of the sense strand. In other embodiments, the ligand is covalently attached to the 3' end of the sense strand. For example, in some embodiments, the ligand is attached to the 3'-terminal nucleotide of the sense strand. In certain such embodiments, the ligand is attached at the 3'-position of the 3'-terminal nucleotide of the sense strand. In alternative embodiments, the ligand is attached near the 3' end of the sense strand, but before one or more terminal nucleotides (i.e. before 1, 2, 3, or 4 terminal nucleotides). In some embodiments, the ligand is attached at the 2'-position of the sugar of the 3'-terminal nucleotide of the sense strand.

[0095] In certain embodiments, the ligand is attached to the sense or antisense strand via a linker. A “linker” is an atom or group of atoms that covalently joins a ligand to a polynucleotide component of the RNAi construct. The linker may be from about 1 to about 30 atoms in length, from about 2 to about 28 atoms in length, from about 3 to about 26 atoms in length, from about 4 to about 24 atoms in length, from about 6 to about 20 atoms in length, from about 7 to about 20 atoms in length, from about 8 to about 20 atoms in length, from about 8 to about 18 atoms in length, from about 10 to about 18 atoms in length, and from about 12 to about 18 atoms in length. In some embodiments, the linker may comprise a bifunctional linking moiety, which generally comprises an alkyl moiety with two functional groups. One of the functional groups is selected to bind to the compound of interest (e.g. sense or antisense strand of the RNAi construct) and the other is selected to bind essentially any selected group, such as a ligand as described herein. In certain embodiments, the linker comprises a chain structure or an oligomer of repeating units, such as ethylene glycol or amino acid units. Examples of functional groups that are typically employed in a bifunctional linking moiety include, but are not limited to, 2024201349   29 Feb 2024 electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In some embodiments, bifunctional linking moieties include amino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double or triple bonds), and the like.

[0096] Linkers that may be used to attach a ligand to the sense or antisense strand in the RNAi constructs of the invention include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid, succinimidyl 4-(N-maleimidomethyl)cyclohexane-l-carboxylate, 6-aminohexanoic acid, substituted C1-C10 alkyl, substituted or unsubstituted C2-C10 alkenyl or substituted or unsubstituted C2-C10 alkynyl. Preferred substituent groups for such linkers include, but are not limited to, hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

[0097] In certain embodiments, the linkers are cleavable. A cleavable linker is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In some embodiments, the cleavable linker is cleaved at least 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or more, or at least 100 times faster in the target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).

[0098] Cleavable linkers are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linker by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linker by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

[0099] A cleavable linker may comprise a moiety that is susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable group that is cleaved at a preferred 2024201349   29 Feb 2024 pH, thereby releasing the RNA molecule from the ligand inside the cell, or into the desired compartment of the cell.

[0100] A linker can include a cleavable group that is cleavable by a particular enzyme. The type of cleavable group incorporated into a linker can depend on the cell to be targeted. For example, liver-targeting ligands can be linked to RNA molecules through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other types of cells rich in esterases include cells of the lung, renal cortex, and testis. Linkers that contain peptide bonds can be used when targeting cells rich in peptidases, such as liver cells and synoviocytes.

[0101] In general, the suitability of a candidate cleavable linker can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linker. It will also be desirable to also test the candidate cleavable linker for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It may be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In some embodiments, useful candidate linkers are cleaved at least 2, 4, 10, 20, 50, 70, or 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

[0102] In other embodiments, redox cleavable linkers are utilized. Redox cleavable linkers are cleaved upon reduction or oxidation. An example of reductively cleavable group is a disulfide linking group (-S-S-). To determine if a candidate cleavable linker is a suitable “reductively cleavable linker,” or for example is suitable for use with a particular RNAi construct and particular ligand, one can use one or more methods described herein. For example, a candidate linker can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent known in the art, which mimics the rate of cleavage that would be observed in a cell, e.g., a target cell. The candidate linkers can also be evaluated under conditions which are selected to mimic blood or serum conditions. In a specific embodiment, candidate linkers are cleaved by at most 10% in 2024201349   29 Feb 2024 the blood. In other embodiments, useful candidate linkers are degraded at least 2, 4, 10, 20, 50, 70, or 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions).

[0103] In yet other embodiments, phosphate-based cleavable linkers are cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that hydrolyzes phosphate groups in cells are enzymes, such as phosphatases in cells. Examples of phosphate-based cleavable groups are -O-P(O)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O) (ORk)-O-, -O-P(O)(ORk)-S-, -S-P(O)(ORk)-S-, -O-P(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S-P(O)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(O)(Rk)-S-, and -O-P(S)(Rk)-S-, where Rk can be hydrogen or alkyl. Specific embodiments include -O-P(O)(OH)-O-, -O-P(S)(OH)-O- -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O- -O-P(S)(H)-O- -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, and -O-P(S)(H)-S- Another specific embodiment is -O-P(0)(0H)-0- These candidate linkers can be evaluated using methods analogous to those described above.

[0104] In other embodiments, the linkers may comprise acid cleavable groups, which are groups that are cleaved under acidic conditions. In some embodiments, acid cleavable groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.5, 5.0, or lower), or by agents, such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes, can provide a cleaving environment for acid cleavable groups. Examples of acid cleavable linking groups include, but are not limited to, hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula -C=NN-, C(O)O, or -OC(O). A specific embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl, pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

[0105] In other embodiments, the linkers may comprise ester-based cleavable groups, which are cleaved by enzymes, such as esterases and amidases in cells. Examples of ester-based cleavable groups include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups. 2024201349   29 Feb 2024 Ester cleavable groups have the general formula -C(O)O- or -OC(O) -. These candidate linkers can be evaluated using methods analogous to those described above.

[0106] In further embodiments, the linkers may comprise peptide-based cleavable groups, which are cleaved by enzymes, such as peptidases and proteases in cells. Peptide-based cleavable groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (-C(O)NH-). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula -NHCHRAC(O)NHCHRBC(O) -, where RA and RB are the side chains of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

[0107] Exemplary linkers that can be employed for attaching ligands, particularly ligands comprising a GalNAc moiety, to the sense strand in the RNAi constructs of the invention, are shown in Formulas A-K below.

[0108] In one embodiment, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula A, wherein n is 1 or 2, R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: R-HN O-R' FORMULA A

[0109] In another embodiment, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula B, wherein n is 1, 2, or 3, R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: 2024201349   29 Feb 2024 HO R' FORMULA B

[0110] In yet another embodiment, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula C, wherein n is 1 or 2, R = ligand (e.g., moiety containing 3 to 4 GalNAc units), R' = 3' end of sense strand of a double stranded RNA molecule, and R" = H, alkyl, functionalized alkyl: NHR" HN R O n R' FORMULA C

[0111] In certain embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula D, wherein R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: Ox R' FORMULA D

[0112] In certain other embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula E, wherein R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: HO R' FORMULAE

[0113] In some embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula F, wherein R = ligand 2024201349   29 Feb 2024 (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: HO R FORMULA F

[0114] In other embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula G, wherein R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: HO R' 0., R FORMULA G

[0115] In certain other embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula H, wherein R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: H r'n OH cl R FORMULA H

[0116] In some embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula J, wherein R = ligand (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: OR' HO NHR FORMULA J

[0117] In other embodiments, the linker for attaching a ligand to the 3' end of the sense strand of an RNAi construct of the invention has the following structure of Formula K, wherein R = ligand 2024201349   29 Feb 2024 (e.g., moiety containing 3 to 4 GalNAc units) and R' = 3' end of sense strand of a double stranded RNA molecule: HO NHR OR'^ FORMULA K

[0118] Other types of linkers suitable for attaching ligands to the sense or antisense strands in the RNAi constructs of the invention are known in the art and can include the linkers described in U.S. Patent Nos. 7,723,509; 8,017,762; 8,828,956 ; 8,877,917; and 9,181,551, all of which are hereby incorporated by reference in their entireties.

[0119] In certain embodiments, the ligand covalently attached to the sense or antisense strand of the RNAi constructs of the invention comprises a GalNAc moiety, e.g, a multivalent GalNAc moiety. In some embodiments, the multivalent GalNAc moiety is a trivalent GalNAc moiety and is attached to the 3' end of the sense strand. In other embodiments, the multivalent GalNAc moiety is a trivalent GalNAc moiety and is attached to the 5' end of the sense strand. In yet other embodiments, the multivalent GalNAc moiety is a tetravalent GalNAc moiety and is attached to the 3' end of the sense strand. In still other embodiments, the multivalent GalNAc moiety is a tetravalent GalNAc moiety and is attached to the 5' end of the sense strand. Exemplary trivalent and tetravalent GalNAc moieties and linkers that can be attached to the double-stranded RNA molecules in the RNAi constructs of the invention are provided in the structural formulas IXXIX below.

[0120] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula I, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024

[0121] In another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula II, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024

[0122] In yet another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula III, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): FORMULA III 2024201349   29 Feb 2024

[0123] In still another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula IV, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0124] In still another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula V, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024

[0125] In another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula VI, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024

[0126] In one particular embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula VII, wherein the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): FORMULA VII

[0127] In another particular embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula VIII, wherein the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 FORMULA VIII

[0128] In certain embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula IX, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0129] In other embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula X, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, 2024201349   29 Feb 2024 and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): FORMULA X

[0130] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XI, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): OH FORMULA XI 2024201349   29 Feb 2024

[0131] In another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XII, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): HO / OH OH                      FORMULA XII

[0132] In yet another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XIII, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, and the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 FORMULA XIII

[0133] In certain embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XIV, wherein each n is independently 1 to 3, k is 1 to 3, and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 HO OH FORMULA XIV

[0134] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XV, wherein each n is independently 1 to 3 and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 ''NHAc FORMULA XV

[0135] In other embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XVI, wherein each n is independently 1 to 3, k is 1 to 3, and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): HO. NHAc OH FORMULA XVI

[0136] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XVII, wherein each n is independently 1 to 3 and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 FORMULA XVII

[0137] In certain other embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XVIII, wherein each n is independently 1 to 3, k is 1 to 3, and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024

[0138] In one particular embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XIX, wherein each n is independently 1 to 3 and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0139] In some embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XX, wherein each n is independently 1 to 3, k is 1 to 3, and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024

[0140] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XXI, wherein each n is independently 1 to 3, and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): FORMULA XXI

[0141] In certain embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XXII, wherein each n is independently 1 to 3, k is 1 to 3, and the 2024201349   29 Feb 2024 ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0142] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XXIII, wherein each n is independently 1 to 3 and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by 2024201349   29 Feb 2024

[0143] In certain other embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XXIV, wherein each n is independently 1 to 3 and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): FORMULA XXIV

[0144] In another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XXV, wherein each n is independently 1 to 3 and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 FORMULA XXV

[0145] In certain embodiments, the RNAi construct comprises a ligand and linker having the following structure of Formula XXVI, wherein the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): " °'1 ■FORMULA XXVI

[0146] In one embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XXVII, wherein each n is independently 1 to 3, k is 1 to 9, m is 1 or 2, and the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 FORMULA XXVII

[0147] In another embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XXVIII, wherein the ligand is attached to the 5' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): NHAc FORMULA XXVIII

[0148] In one particular embodiment, the RNAi construct comprises a ligand and linker having the following structure of Formula XXIX, wherein the ligand is attached to the 3' end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line): 2024201349   29 Feb 2024 FORMULA XXIX

[0149] In some embodiments, the RNAi constructs of the invention may be delivered to a cell or tissue of interest by administering a vector that encodes and controls the intracellular expression of the RNAi construct. A “vector” (also referred to herein as an “expression vector) is a composition of matter which can be used to deliver a nucleic acid of interest to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and the like. A vector can be replicated in a living cell, or it can be made synthetically.

[0150] Generally, a vector for expressing an RNAi construct of the invention will comprise one or more promoters operably linked to sequences encoding the RNAi construct. The phrase “operably linked” or “under transcriptional control” as used herein means that the promoter is in the correct location and orientation in relation to a polynucleotide sequence to control the initiation of transcription by RNA polymerase and expression of the polynucleotide sequence. A “promoter” refers to a sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene sequence. Suitable 2024201349   29 Feb 2024 promoters include, but are not limited to, RNA pol I, pol II, Hl or U6 RNA pol III, and viral promoters (e.g. human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, and the Rous sarcoma virus long terminal repeat). In some embodiments, a Hl or U6 RNA pol III promoter is preferred. The promoter can be a tissue-specific or inducible promoter. Of particular interest are liver-specific promoters, such as promoter sequences from human alpha 1-antitrypsin gene, albumin gene, hemopexin gene, and hepatic lipase gene. Inducible promoters include promoters regulated by ecdysone, estrogen, progesterone, tetracycline, and isopropyl-P-D1-thiogalactopyranoside (IPTG).

[0151] In some embodiments in which the RNAi construct comprises a siRNA, the two separate strands (sense and antisense strand) can be expressed from a single vector or two separate vectors. For example, in one embodiment, the sequence encoding the sense strand is operably linked to a promoter on a first vector and the sequence encoding the antisense strand is operably linked to a promoter on a second vector. In such an embodiment, the first and second vectors are co-introduced, e.g., by infection or transfection, into a target cell, such that the sense and antisense strands, once transcribed, will hybridize intracellularly to form the siRNA molecule. In another embodiment, the sense and antisense strands are transcribed from two separate promoters located in a single vector. In some such embodiments, the sequence encoding the sense strand is operably linked to a first promoter and the sequence encoding the antisense strand is operably linked to a second promoter, wherein the first and second promoters are located in a single vector. In one embodiment, the vector comprises a first promoter operably linked to a sequence encoding the siRNA molecule, and a second promoter operably linked to the same sequence in the opposite direction, such that transcription of the sequence from the first promoter results in the synthesis of the sense strand of the siRNA molecule and transcription of the sequence from the second promoter results in synthesis of the antisense strand of the siRNA molecule.

[0152] In other embodiments in which the RNAi construct comprises a shRNA, a sequence encoding the single, at least partially self-complementary RNA molecule is operably linked to a promoter to produce a single transcript. In some embodiments, the sequence encoding the shRNA comprises an inverted repeat joined by a linker polynucleotide sequence to produce the the stem and loop structure of the shRNA following transcription. 2024201349   29 Feb 2024

[0153] In some embodiments, the vector encoding an RNAi construct of the invention is a viral vector. Various viral vector systems that are suitable to express the RNAi constructs described herein include, but are not limited to, adenoviral vectors, retroviral vectors (e.g., lentiviral vectors, moloney murine leukemia virus), adeno- associated viral vectors; herpes simplex viral vectors; SV40 vectors; polyoma viral vectors; papilloma viral vectors; picornaviral vectors; and pox viral vectors (e.g. vaccinia virus). In certain embodiments, the viral vector is a retroviral vector (e.g. lentiviral vector).

[0154] Various vectors suitable for use in the invention, methods for inserting nucleic acid sequences encoding siRNA or shRNA molecules into vectors, and methods of delivering the vectors to the cells of interest are within the skill of those in the art. See, e.g., Dornburg , Gene Therap., Vol. 2: 301-310, 1995; Eglitis, Biotechniques, Vol. 6: 608-614, 1988; Miller, Hum Gene Therap., Vol. 1: 5-14, 1990; Anderson, Nature, Vol. 392: 25-30, 1998; RubinsonD \el al., Nat. Genet., Vol. 33: 401-406, 2003; Brummelkamp et al., Science, Vol. 296: 550-553, 2002; Brummelkamp et al., Cancer Cell, Vol. 2: 243-247, 2002; Lee et al., Nat Biotechnol, Vol. 20: 500-505, 2002; Miyagishi et al., Nat Biotechnol, Vol. 20: 497-500, 2002; Paddison etal., Genes Dev, Vol. 16: 948-958, 2002; Paul et al., Nat Biotechnol, Vol. 20: 505-508, 2002; Sui et al., Proc Natl Acad Sci USA, Vol. 99: 5515-5520, 2002; and Yu etal., Proc Natl Acad Sci USA, Vol. 99: 6047-6052, 2002, all of which are hereby incorporated by reference in their entireties.

[0155] The present invention also includes pharmaceutical compositions and formulations comprising the RNAi constructs described herein and pharmaceutically acceptable carriers, excipients, or diluents. Such compositions and formulations are useful for reducing expression of ASGR1 in a subject in need thereof. Where clinical applications are contemplated, pharmaceutical compositions and formulations will be prepared in a form appropriate for the intended application. Generally, this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.

[0156] The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, “pharmaceutically acceptable carrier, excipient, or diluent” includes solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for 2024201349   29 Feb 2024 administration to humans. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the RNAi constructs of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions, provided they do not inactivate the vectors or RNAi constructs of the compositions.

[0157] Compositions and methods for the formulation of pharmaceutical compositions depend on a number of criteria, including, but not limited to, route of administration, type and extent of disease or disorder to be treated, or dose to be administered. In some embodiments, the pharmaceutical compositions are formulated based on the intended route of delivery. For instance, in certain embodiments, the pharmaceutical compositions are formulated for parenteral delivery. Parenteral forms of delivery include intravenous, intraarterial, subcutaneous, intrathecal, intraperitoneal or intramuscular injection or infusion. In one embodiment, the pharmaceutical composition is formulated for intravenous delivery. In such an embodiment, the pharmaceutical composition may include a lipid-based delivery vehicle. In another embodiment, the pharmaceutical composition is formulated for subcutaneous delivery. In such an embodiment, the pharmaceutical composition may include a targeting ligand (e.g. GalNAc-containing or antibody-containing ligands described herein).

[0158] In some embodiments, the pharmaceutical compositions comprise an effective amount of an RNAi construct described herein. An “effective amount” is an amount sufficient to produce a beneficial or desired clinical result. In some embodiments, an effective amount is an amount sufficient to reduce ASGR1 expression in hepatocytes of a subject. In some embodiments, an effective amount may be an amount sufficient to only partially reduce ASGR1 expression, for example, to a level comparable to expression of the wild-type ASGR1 allele in human heterozygotes. Human heterozygous carriers of loss of function ASGR1 variant alleles were reported to have lower serum levels of non- HDL cholesterol and a lower risk of coronary artery disease and myocardial infarction as compared to non-carriers (Nioi et al., New England Journal of Medicine, Vol. 374(22):2131-2141, 2016). Thus, without being bound by theory, it is believed that partial reduction of ASGR1 expression may be sufficient to achieve the benefical reduction of serum non-HDL cholesterol and reduction of risk of coronary artery disease and myocardial infarction. 2024201349   29 Feb 2024

[0159] An effective amount of an RNAi construct of the invention may be from about 0.01 mg / kg body weight to about 100 mg / kg body weight, about 0.05 mg / kg body weight to about 75 mg / kg body weight, about 0.1 mg / kg body weight to about 50 mg / kg body weight, about 1 mg / kg to about 30 mg / kg body weight, about 2.5 mg / kg of body weight to about 20 mg / kg body weight, or about 5 mg / kg body weight to about 15 mg / kg body weight. In certain embodiments, a single effective dose of an RNAi construct of the invention may be about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, or about 10 mg / kg. The pharmaceutical composition comprising an effective amount of RNAi construct can be administered weekly, biweekly, monthly, quarterly, or biannually. The precise determination of what would be considered an effective amount and frequency of administration may be based on several factors, including a patient’s size, age, and general condition, type of disorder to be treated (e.g. myocardial infarction, heart failure, coronary artery disease, hypercholesterolemia), particular RNAi construct employed, and route of administration. Estimates of effective dosages and in vivo half-lives for any particular RNAi construct of the invention can be ascertained using conventional methods and / or testing in appropriate animal models.

[0160] Administration of the pharmaceutical compositions of the present invention may be via any common route so long as the target tissue is available via that route. Such routes include, but are not limited to, parenteral (e.g., subcutaneous, intramuscular, intraperitoneal or intravenous), oral, nasal, buccal, intradermal, transdermal, and sublingual routes, or by direct injection into liver tissue or delivery through the hepatic portal vein. In some embodiments, the pharmaceutical composition is administered parenterally. For instance, in certain embodiments, the pharmaceutical composition is administered intravenously. In other embodiments, the pharmaceutical composition is administered subcutaneously.

[0161] Colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes, may be used as delivery vehicles for the RNAi constructs of the invention or vectors encoding such constructs. Commercially available fat emulsions that are suitable for delivering the nucleic acids of the invention include Intralipid® (Baxter International Inc.), Liposyn® (Abbott Pharmaceuticals), Liposyn®II (Hospira), Liposyn®III (Hospira), Nutrilipid (B. Braun Medical Inc.), and other similar lipid emulsions. A preferred colloidal 2024201349   29 Feb 2024 system for use as a delivery vehicle in vivo is a liposome (i.e., an artificial membrane vesicle). The RNAi constructs of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, RNAi constructs of the invention may be complexed to lipids, in particular to cationic lipids. Suitable lipids and liposomes include neutral (e.g., dioleoylphosphatidyl ethanolamine (DOPE), dimyristoylphosphatidyl choline (DMPC), and dipalmitoyl phosphatidylcholine (DPPC)), distearolyphosphatidyl choline), negative (e.g., dimyristoylphosphatidyl glycerol (DMPG)), and cationic (e.g., di oleoyltetramethylaminopropyl (DOTAP) and di oleoylphosphatidyl ethanolamine (DOTMA)). The preparation and use of such colloidal disperson systems is well known in the art. Exemplary formulations are also disclosed in U.S. Pat. No. 5,981,505; U.S. Pat. No. 6,217,900; U.S. Pat. No. 6,383,512; U.S. Pat. No. 5,783,565; U.S. Pat. No. 7,202,227; U.S. Pat. No. 6,379,965; U.S. Pat. No. 6,127,170; U.S. Pat. No. 5,837,533; U.S. Pat. No. 6,747,014; and WO03 / 093449.

[0162] In some embodiments, the RNAi constructs of the invention are fully encapsulated in a lipid formulation, e.g., to form a SPLP, pSPLP, SNALP, or other nucleic acid-lipid particle. As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle, including SPLP. As used herein, the term “SPLP” refers to a nucleic acid-lipid particle comprising plasmid DNA encapsulated within a lipid vesicle. SNALPs and SPLPs typically contain a cationic lipid, a noncationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). SNALPs and SPLPs are exceptionally useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous injection and accumulate at distal sites (e.g., sites physically separated from the administration site). SPLPs include “pSPLP,” which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00 / 03683. The nucleic acid-lipid particles typically have a mean diameter of about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, or about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; and PCT Publication No. WO 96 / 40964. 2024201349   29 Feb 2024

[0163] The pharmaceutical compositions suitable for injectable use include, for example, sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Generally, these preparations are sterile and fluid to the extent that easy injectability exists. Preparations should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Appropriate solvents or dispersion media may contain, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial an antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0164] Sterile injectable solutions may be prepared by incorporating the active compounds in an appropriate amount into a solvent along with any other ingredients (for example as enumerated above) as desired, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the desired other ingredients, e.g., as enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation include vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient(s) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0165] The compositions of the present invention generally may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include, for example, acid addition salts (formed with free amino groups) derived from inorganic acids (e.g., hydrochloric or phosphoric acids), or from organic acids (e.g., acetic, oxalic, tartaric, mandelic, and the like). Salts formed with the free carboxyl groups can also be derived from inorganic bases (e.g., sodium, potassium, 2024201349   29 Feb 2024 ammonium, calcium, or ferric hydroxides) or from organic bases (e.g., isopropylamine, trimethylamine, histidine, procaine and the like).

[0166] For parenteral administration in an aqueous solution, for example, the solution generally is suitably buffered and the liquid diluent first rendered isotonic for example with sufficient saline or glucose. Such aqueous solutions may be used, for example, for intravenous, intramuscular, subcutaneous and intraperitoneal administration. Preferably, sterile aqueous media are employed as is known to those of skill in the art, particularly in light of the present disclosure. By way of illustration, a single dose may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 10351038 and 1570-1580). For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA standards. In certain embodiments, a pharmaceutical composition of the invention comprises or consists of a sterile saline solution and an RNAi construct described herein. In other embodiments, a pharmaceutical composition of the invention comprises or consists of an RNAi construct described herein and sterile water (e.g. water for injection, WFI). In still other embodiments, a pharmaceutical composition of the invention comprises or consists of an RNAi construct described herein and phosphate-buffered saline (PBS).

[0167] In some embodiments, the pharmaceutical compositions of the invention are packaged with or stored within a device for administration. Devices for injectable formulations include, but are not limited to, injection ports, pre-filled syringes, autoinjectors, injection pumps, on-body injectors, and injection pens. Devices for aerosolized or powder formulations include, but are not limited to, inhalers, insufflators, aspirators, and the like. Thus, the present invention includes administration devices comprising a pharmaceutical composition of the invention for treating or preventing one or more of the disorders described herein.

[0168] The present invention provides methods for reducing or inhibiting expression of ASGR1 in a subject in need thereof as well as methods of treating or preventing conditions, diseases, or disorders associated with ASGR1 expression or activity. A “condition, disease, or disorder associated with ASGR1 expression” refers to conditions, diseases, or disorders in which ASGR1 expression levels are altered or where elevated expression levels of ASGR1 are associated with an increased risk of developing the condition, disease or disorder. A condition, disease, or 2024201349   29 Feb 2024 disorder associated with ASGR1 expression can also include conditions, diseases, or disorders resulting from aberrant changes in lipoprotein metabolism, such as changes resulting in abnormal levels of cholesterol, lipids, triglycerides, etc. or impaired clearance of these molecules. Recently, human carriers of loss of function variant alleles of the ASGR1 subunit of the asialoglycoprotein receptor were reported to have lower serum levels of non- HDL cholesterol and a lower risk of coronary artery disease and myocardial infarction as compared to non-carriers (Nioi et al., New England Journal of Medicine, Vol. 374(22):2131-2141, 2016, which is hereby incorporated by reference in its entirety). Thus, in certain embodiments, the RNAi constructs of the invention are particularly useful for treating or preventing cardiovascular disease (e.g. coronary artery disease and myocardial infarction) and cholesterol-related disorders (e.g. hy per chol esterol emi a).

[0169] Conditions, diseases, and disorders associated with ASGR1 expression that can be treated or prevented according to the methods of the invention include, but are not limited to, cardiovascular disease, such as myocardial infarction, heart failure, stroke (ischemic and hemorrhagic), atherosclerosis, coronary artery disease, peripheral vascular disease (e.g. peripheral artery disease), vulnerable plaque, hypercholesterolemia, and dyslipidemia (manifesting, e.g., as elevated total cholesterol, elevated low-density lipoprotein (LDL), elevated very low-density lipoprotein (VLDL), elevated triglycerides, and / or low levels of high-density lipoprotein (HDL)).

[0170] In certain embodiments, the present invention provides a method for reducing the expression of ASGR1 in a patient in need thereof comprising administering to the patient any of the RNAi constructs described herein. The term “patient,” as used herein, refers to a mammal, including humans, and can be used interchangeably with the term “subject.” Preferably, the expression level of ASGR1 in hepatocytes in the patient is reduced following administration of the RNAi construct as compared to the ASGR1 expression level in a patient not receiving the RNAi construct.

[0171] In some embodiments, a patient in need of reduction of ASGR1 expression is a patient who is at risk of having a myocardial infarction. A patient who is at risk of having a myocardial infarction may be a patient who has a history of myocardial infarction (e.g. has had a previous myocardial infarction). A patient at risk of having a myocardial infarction may also be a patient who has a familial history of myocardial infarction or who has one or more risk factors of 2024201349   29 Feb 2024 myocardial infarction. Such risk factors include, but are not limited to, hypertension, elevated levels of non-HDL cholesterol, elevated levels of triglycerides, diabetes, obesity, or history of autoimmune diseases (e.g. rheumatoid arthritis, lupus). In one embodiment, a patient who is at risk of having a myocardial infarction is a patient who has or is diagnosed with coronary artery disease. The risk of myocardial infarction in these and other patients can be reduced by administering to the patients any of the RNAi constructs described herein. Accordingly, the present invention provides a method for reducing the risk of myocardial infarction in a patient in need thereof comprising administering to the patient an RNAi construct described herein. In some embodiments, the present invention includes use of any of the RNAi constructs described herein in the preparation of a medicament for reducing the risk of myocardial infarction in a patient in need thereof. In other embodiments, the present invention provides an ASGR1-targeting RNAi construct for use in a method for reducing the risk of myocardial infarction in a patient in need thereof.

[0172] In certain embodiments, a patient in need of reduction of ASGR1 expression is a patient who is diagnosed with or at risk of cardiovascular disease. Thus, the present invention includes a method for treating or preventing cardiovascular disease in a patient in need thereof by administering any of the RNAi constructs of the invention. In some embodiments, the present invention includes use of any of the RNAi constructs described herein in the preparation of a medicament for treating or preventing cardiovascular disease in a patient in need thereof. In other embodiments, the present invention provides an ASGR1-targeting RNAi construct for use in a method for treating or preventing cardiovascular disease in a patient in need thereof. Cardiovascular disease includes myocardial infarction, heart failure, stroke (ischemic and hemorrhagic), atherosclerosis, coronary artery disease, peripheral vascular disease (e.g. peripheral artery disease), and vulnerable plaque. In some embodiments, the cardiovascular disease to be treated or prevented according to the methods of the invention is coronary artery disease. In other embodiments, the cardiovascular disease to be treated or prevented according to the methods of the invention is myocardial infarction. In certain embodiments, administration of the RNAi constructs described herein reduces the risk of non-fatal myocardial infarctions, fatal and non-fatal strokes, certain types of heart surgery (e.g. angioplasty, bypass), hospitalization for heart failure, chest pain in patients with heart disease, and / or cardiovascular events in patients with established heart disease (e.g. prior myocardial infarction, prior heart 2024201349   29 Feb 2024 surgery, and / or chest pain with evidence of blocked arteries). In some embodiments, administration of the RNAi constructs described herein according to the methods of the invention can be used to reduce the risk of recurrent cardiovascular events.

[0173] In certain other embodiments, a patient in need of reduction of ASGR1 expression is a patient who has elevated levels of non-HDL cholesterol. Accordingly, in some embodiments, the present invention provides a method for reducing non-HDL cholesterol in a patient in need thereof by administering to the patient any of the RNAi constructs described herein. In some embodiments, the present invention includes use of any of the RNAi constructs described herein in the preparation of a medicament for reducing non-HDL cholesterol in a patient in need thereof. In other embodiments, the present invention provides an ASGR1-targeting RNAi construct for use in a method for reducing non-HDL cholesterol in a patient in need thereof. Non-HDL cholesterol is a measure of all cholesterol-containing proatherogenic lipoproteins, including LDL cholesterol, very low-density lipoprotein, intermediate-density lipoprotein, lipoprotein(a), chylomicron, and chylomicron remnants. Non-HDL cholesterol has been reported to be a good predictor of cardiovascular risk (Rana etal., Curr. Atheroscler. Rep., Vol. 14:130134, 2012). Non-HDL cholesterol levels can be calculated by subtracting HDL cholesterol levels from total cholesterol levels. In one embodiment, a patient’s LDL cholesterol levels are reduced following administration of the RNAi construct. In another embodiment, a patient’s lipoprotein (a) levels are reduced following administration of the RNAi construct.

[0174] In some embodiments, a patient to be treated according to the methods of the invention is a patient who has elevated levels of non-HDL cholesterol (e.g. elevated serum levels of non-HDL cholesterol). Ideally, levels of non-HDL cholesterol should be about 30 mg / dL above the target for LDL cholesterol levels for any given patient. In particular embodiments, a patient is administered an RNAi construct of the invention if the patient has a non-HDL cholesterol level of about 130 mg / dL or greater. In one embodiment, a patient is administered an RNAi construct of the invention if the patient has a non-HDL cholesterol level of about 160 mg / dL or greater. In another embodiment, a patient is administered an RNAi construct of the invention if the patient has a non-HDL cholesterol level of about 190 mg / dL or greater. In still another embodiment, a patient is administered an RNAi construct of the invention if the patient has a non-HDL cholesterol level of about 220 mg / dL or greater. In certain embodiments, a patient is administered an RNAi construct of the invention if the patient is at a high or very high risk of 2024201349   29 Feb 2024 cardiovascular disease according to the 2013 ACC / AHA Guideline on the Assessment of Cardiovascular Risk (Goff et al., ACC / AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000-000) and has a non-HDL cholesterol level of about 100 mg / dL or greater.

[0175] In some embodiments of the methods of the invention, a patient is administered an RNAi construct described herein if they are at a moderate risk or higher for cardiovascular disease according to the 2013 ACC / AHA Guideline on the Assessment of Cardiovascular Risk (referred to herein as the “2013 Guidelines”). In certain embodiments, an RNAi construct of the invention is administered to a patient if the patient’s LDL cholesterol level is greater than about 160 mg / dL. In other embodiments, an RNAi construct of the invention is administered to a patient if the patient’s LDL cholesterol level is greater than about 130 mg / dL and the patient has a moderate risk of cardiovascular disease according to the 2013 Guidelines. In still other embodiments, an RNAi construct of the invention is administered to a patient if the patient’s LDL cholesterol level is greater than 100 mg / dL and the patient has a high or very high risk of cardiovascular disease according to the 2013 Guidelines.

[0176] In certain embodiments, a patient to be treated according to the methods of the invention is a patient who has a vulnerable plaque (also referred to as unstable plaque). Vulnerable plaques are a build-up of macrophages and lipids containing predominantly cholesterol that lie underneath the endothelial lining of the arterial wall. These vulnerable plaques can rupture resulting in the formation of a blood clot, which can potentially block blood flow through the artery and cause a myocardial infarction or stroke. Vulnerable plaques can be identified by methods known in the art, including, but not limited to, intravascular ultrasound and computed tomography (Sahara et al., European Heart Journal, Vol. 25: 2026-2033, 2004; Budhoff, J. Am. Coll. Cardiol., Vol. 48: 319-321, 2006; Hausleiter etal., J. Am. Coll. Cardiol., Vol. 48: 312-318, 2006).

[0177] In some embodiments of the methods of the invention, the RNAi construct is administered in combination with another therapeutic agent, such as a therapeutic agent for treating or preventing cardiovascular disease. In one embodiment, an RNAi construct of the invention is administered alone or in combination with other agents useful for treating the condition with which the patient is afflicted. Examples of such agents include both 2024201349   29 Feb 2024 proteinaceous and non-proteinaceous drugs. When multiple therapeutics are co-administered, dosages may be adjusted accordingly, as is recognized in the pertinent art. “Co-administration” and combination therapy are not limited to simultaneous administration, but also include treatment regimens in which an RNAi construct of the invention is administered at least once during a course of treatment that involves administering at least one other therapeutic agent to the patient. In certain embodiments, an RNAi construct of the invention is administered prior to the administration of at least one other therapeutic agent. In other embodiments, an RNAi construct of the invention is administered concurrent with the administration of at least one other therapeutic agent. In some embodiments, an RNAi construct of the invention is administered subsequent to the administration of at least one other therapeutic agent.

[0178] In certain embodiments of the methods of the invention, the RNAi construct is administered to a patient in combination with a PCSK9 antagonist, such as an anti-hPCSK9 antibody (e.g., Repatha® (evolocumab)). In another embodiment, the RNAi construct of the invention is administered to a patient in combination with at least one other cholesterol-lowering (serum and / or total body cholesterol) agent. In some embodiments, the agent increases the expression of LDLR, has been observed to increase serum HDL levels, lower LDL levels, or lower triglyceride levels. Exemplary agents include, but are not limited to, statins (e.g., atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin); nicotinic acid (Niacin) (NIACOR, NIASPAN (slow release niacin), SLO-NIACIN (slow release niacin)); fibric acid (LOPID (Gemfibrozil), TRICOR (fenofibrate)); bile acid sequestrants (QUESTRAN (cholestyramine), colesevelam (WELCHOL), COLESTID (colestipol)); cholesterol absorption inhibitors (ZETIA (ezetimibe)), combining nicotinic acid with statin (ADVICOR (LOVASTATIN and NIASPAN), combinations of a statin with an absorption inhibitor (VYTORIN (ZOCOR and ZETIA); and / or lipid modifying agents.

[0179] In some embodiments, the RNAi construct of the invention is combined with PPAR gamma agonists, PPAR alpha / gamma agonists, squalene synthase inhibitors, CETP inhibitors, anti-hypertensives, anti-diabetic agents (such as sulphonyl ureas, insulin, GLP-1 analogs, DDPIV inhibitors), ApoB modulators, MTP inhibitors and / or arteriosclerosis obliterans treatments. In certain embodiments, the RNAi construct of the invention is combined with an agent that increases the level of LDL receptor (LDLR) protein in a patient, such as statins, certain cytokines, like oncostatin M, estrogen, and / or certain herbal ingredients, such as berberine. 2024201349   29 Feb 2024

[0180] In some embodiments, the RNAi construct of the invention is combined with an agent that increases serum cholesterol levels in a patient (such as certain anti-psycotic agents, certain HIV protease inhibitors, dietary factors such as high fructose, sucrose, cholesterol or certain fatty acids and certain nuclear receptor agonists and antagonists for RXR, RAR, LXR, FXR). In certain embodiments, the RNAi construct of the invention is combined with an agent that increases the level of PCSK9 protein in a subject, such as statins and / or insulin. The administration of RNAi constructs in such embodiments can allow for the RNAi construct to mitigate the undesirable side-effects of these other agents, such as increases in serum non-HDL cholesterol.

[0181] It is understood that all ribonucleic acid sequences disclosed herein can be converted to deoxyribonucleic acid sequences by substituting a thymine base for a uracil base in the sequence. Likewise, all deoxyribonucleic acid sequences disclosed herein can be converted to ribonucleic acid sequences by substituting a uracil base for a thymine base in the sequence. Deoxyribonucleic acid sequences, ribonucleic acid sequences, and sequences containing mixtures of deoxyribonucleotides and ribonucleotides of all sequences disclosed herein are included in the invention.

[0182] Additionally, any nucleic acid sequences disclosed herein may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified polynucleotides is, in certain instances, arbitrary. For example, a polynucleotide comprising a nucleotide having a 2'-OH substituent on the ribose sugar and a thymine base could be described as a DNA molecule having a modified sugar (2'-OH for the natural 2'-H of DNA) or as an RNA molecule having a modified base (thymine (methylated uracil) for natural uracil of RNA).

[0183] Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and / or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of a further example and without limitation, a polynucleotide having the sequence “ATCGATCG” encompasses any polynucleotides having such a sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG” and polynucleotides having other modified bases, 2024201349   29 Feb 2024 such as “ATmeCGAUCG,” wherein meC indicates a cytosine base comprising a methyl group at the 5-position.

[0184] The following examples, including the experiments conducted and the results achieved, are provided for illustrative purposes only and are not to be construed as limiting the scope of the appended claims. EXAMPLES Example 1. Selection and Design of ASGR1 siRNA Sequences

[0185] The identification and selection of optimal sequences for therapeutic siRNA molecules targeting the human asialoglycoprotein receptor 1 (ASGR1) proceeded in two phases. Candidate sequences for inclusion in an initial Tier 1 screening set were identified using a bioinformatics analysis of two alternatively spliced transcripts for human ASGR1: transcript variant 1 encoding the longer isoform A (NCBI Reference Sequence No. NM_001671.4; see Figure 1A) and transcript variant 2 encoding the shorter isoform B (NCBI Reference Sequence No. NM_001197216.2; see Figure IB). The two human ASGR1 transcript sequences were analyzed using an in-house siRNA design algorithm, which identifies 19mer sequences having a particular base content at certain positions or regions within the 19mer sequences. Sequences were also evaluated for identity to ASGR1 sequences in the mouse (NCBI Reference No. NM_009714.2; see Figure 2), rat (Figure 3), and cynomolgus monkey (NCBI Reference No. XM_005582698.1; see Figure 4). 19mer sequences were also evaluated for sequence identity to other human gene sequences to predict off-target effects and for overlap with known single nucleotide polymorphisms. Based on the results of the bioinformatics analysis, 211 sequences were included in the Tier 1 screening set. A UU dinucleotide was added to the 3' end of the selected 19mer sense and antisense sequences to produce siRNA molecules with 19 base pair duplex regions and a 2 nucleotide overhang at the 3' ends of both strands.

[0186] The second phase of siRNA sequence selection was directed to identifying additional active siRNAs targeting the human ASGR1 mRNA that may have been excluded as a result of the bioinformatics analysis. All overlapping 19mer sequences from the human ASGR1 transcript variants 1 and 2 (NCBI Reference Sequence Nos. NM_001671.4 and NM_001197216.2; see Figures 1A and IB) were extracted and reverse complement antisense sequences designed. 1284 sequences that were not included in Tier 1 were included as part of the Tier 2 sequences. Like 2024201349   29 Feb 2024 the Tier 1 sequences, the Tier 2 sequences were converted to 21mers by adding a UU dinucleotide to the 3' ends of the sense and antisense strand to produce siRNA molecules with 19 base pair duplex regions and 2 nucleotide overhangs at each 3' end. Tier 2 also included 55 sequences identified in Tier 1 for resynthesis and testing. The combined Tier 1 and Tier 2 screening sets included 1495 19mer sequences across the human ASGR1 mRNA transcripts. The sense and antisense sequences of the siRNA molecules included in both Tier 1 and Tier 2 screening sets, as well as the sequences for 8 additional siRNA molecules that target the terminal regions of the transcripts, are shown in Table 1 below. The site within each of the human ASGR1 transcripts that is targeted by each of the siRNA molecules is also listed in Table 1. Table 1. ASGR1 siRNA Sequences Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1000 1000 1018 883-901 UGUCCAGCACCACAUAGGCUU 5 GCCUAUGUGGUGCUGGACAUU 1508 D-1001 1001 1019 884-902 GUCCAGCACCACAUAGGCCUU 6 GGCCUAUGUGGUGCUGGACUU 1509 D-1002 100-118 100-118 CACCCCCACACUCCCCUAAUU 7 UUAGGGGAGUGUGGGGGUGUU 1510 D-1003 1002 1020 885-903 UCCAGCACCACAUAGGCCCUU 8 GGGCCUAUGUGGUGCUGGAUU 1511 D-1004 1003 1021 886-904 CCAGCACCACAUAGGCCCUUU 9 AGGGCCUAUGUGGUGCUGGUU 1512 D-1005 1004 1022 887-905 CAGCACCACAUAGGCCCUGUU 10 CAGGGCCUAUGUGGUGCUGUU 1513 D-1006 1005 1023 888-906 AGCACCACAUAGGCCCUGUUU 11 ACAGGGCCUAUGUGGUGCUUU 1514 D-1007 1006 1024 889-907 GCACCACAUAGGCCCUGUGUU 12 CACAGGGCCUAUGUGGUGCUU 1515 D-1008 1007 1025 890-908 CACCACAUAGGCCCUGUGAUU 13 UCACAGGGCCUAUGUGGUGUU 1516 D-1009 1008 1026 891-909 ACCACAUAGGCCCUGUGAAUU 14 UUCACAGGGCCUAUGUGGUUU 1517 D-1010 1009 1027 892-910 CCACAUAGGCCCUGUGAACUU 15 GUUCACAGGGCCUAUGUGGUU 1518 D-1011 1010 1028 893-911 CACAUAGGCCCUGUGAACAUU 16 UGUUCACAGGGCCUAUGUGUU 1519 D-1012 1011 1029 894-912 ACAUAGGCCCUGUGAACACUU 17 GUGUUCACAGGGCCUAUGUUU 1520 D-1013 101-119 101-119 ACCCCCACACUCCCCUAAG U U 18 CUUAGGGGAGUGUGGGGGUUU 1521 D-1014 1012 1030 895-913 CAUAGGCCCUGUGAACACCUU 19 GGUGUUCACAGGGCCUAUGUU 1522 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1015 1013 1031 896-914 AUAGGCCCUGUGAACACCUUU 20 AGGUGUUCACAGGGCCUAUUU 1523 D-1016 1014 1032 897-915 UAGGCCCUGUGAACACCUGUU 21 CAGGUGUUCACAGGGCCUAUU 1524 D-1017 1015 1033 898-916 AGGCCCUGUGAACACCUGGUU 22 CCAGGUGUUCACAGGGCCUUU 1525 D-1018 1016 1034 899-917 GGCCCUGUGAACACCUGGAUU 23 UCCAGGUGUUCACAGGGCCUU 1526 D-1019 1017 1035 900-918 GCCCUGUGAACACCUGGAUUU 24 AUCCAGGUGUUCACAGGGCUU 1527 D-1020 1018 1036 901-919 CCCUGUGAACACCUGGAUGUU 25 CAUCCAGGUGUUCACAGGGUU 1528 D-1021 1019 1037 902-920 CCUGUGAACACCUGGAUGGUU 26 CCAU CCAG G U G U U CACAGG U U 1529 D-1022 1020 1038 903-921 CUGUGAACACCUGGAUGGGUU T1 CCCAUCCAGGUGUUCACAGUU 1530 D-1023 1021 1039 904-922 UGUGAACACCUGGAUGGGCUU 28 GCCCAUCCAGGUGUUCACAUU 1531 D-1024 102-120 102-120 CCCCCACACUCCCCUAAGUUU 29 ACUUAGGGGAGUGUGGGGGUU 1532 D-1025 1022 1040 905-923 GUGAACACCUGGAUGGGCCUU 30 GGCCCAUCCAGGUGUUCACUU 1533 D-1026 1023 1041 906-924 UGAACACCUGGAUGGGCCUUU 31 AGGCCCAUCCAGGUGUUCAUU 1534 D-1027 1024 1042 907-925 GAACACCUGGAUGGGCCUCUU 32 GAGGCCCAUCCAGGUGUUCUU 1535 D-1028 1025 1043 908-926 AACACCUGGAUGGGCCUCCUU 33 GGAGGCCCAUCCAGGUGUUUU 1536 D-1029 1026 1044 909-927 ACACCUGGAUGGGCCUCCAUU 34 UGGAGGCCCAUCCAGGUGUUU 1537 D-1030 1027 1045 910-928 CACCUGGAUGGGCCUCCACUU 35 GUGGAGGCCCAUCCAGGUGUU 1538 D-1031 10-28 10-28 UGCACGGAAGAGUGAGGUGUU 36 CACCUCACUCUUCCGUGCAUU 1539 D-1032 1028 1046 911-929 ACCUGGAUGGGCCUCCACGUU 37 CGUGGAGGCCCAUCCAGGUUU 1540 D-1033 1029 1047 912-930 CCUGGAUGGGCCUCCACGAUU 38 UCGUGGAGGCCCAUCCAGGUU 1541 D-1034 1030 1048 913-931 CUGGAUGGGCCUCCACGACUU 39 GUCGUGGAGGCCCAUCCAGUU 1542 D-1035 1031 1049 914-932 UGGAUGGGCCUCCACGACCUU 40 GGUCGUGGAGGCCCAUCCAUU 1543 D-1036 103-121 103-121 CCCCACACUCCCCU AAGU U U U 41 AACUUAGGGGAGUGUGGGGUU 1544 D-1037 1032 1050 915-933 GGAUGGGCCUCCACGACCAUU 42 UGGUCGUGGAGGCCCAUCCUU 1545 D-1038 1033 1051 916-934 GAUGGGCCUCCACGACCAAUU 43 UUGGUCGUGGAGGCCCAUCUU 1546 D-1039 1034 1052 917-935 AUGGGCCUCCACGACCAAAUU 44 UUUGGUCGUGGAGGCCCAUUU 1547 D-1040 1035 1053 918-936 UGGGCCUCCACGACCAAAAUU 45 UUUUGGUCGUGGAGGCCCAUU 1548 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1041 1036 1054 919-937 GGGCCUCCACGACCAAAACUU 46 GUUUUGGUCGUGGAGGCCCUU 1549 D-1042 1037 1055 920-938 GGCCUCCACGACCAAAACGUU 47 CGUUUUGGUCGUGGAGGCCUU 1550 D-1043 1038 1056 921-939 GCCU CCACGACCAAAACGG U U 48 CCGUUUUGGUCGUGGAGGCUU 1551 D-1044 1039 1057 922-940 CCUCCACGACCAAAACGGGUU 49 CCCGUUUUGGUCGUGGAGGUU 1552 D-1045 1040 1058 923-941 CUCCACGACCAAAACGGGCUU 50 GCCCGUUUUGGUCGUGGAGUU 1553 D-1046 1041 1059 924-942 UCCACGACCAAAACGGGCCUU 51 GGCCCGUUUUGGUCGUGGAUU 1554 D-1047 104-122 104-122 CCCACACUCCCCUAAGUUCUU 52 GAACUUAGGGGAGUGUGGGUU 1555 D-1048 1042 1060 925-943 CCACGACCAAAACGGGCCCUU 53 GGGCCCGUUUUGGUCGUGGUU 1556 D-1049 1043 1061 926-944 CACGACCAAAACGGGCCCUUU 54 AGGGCCCGUUUUGGUCGUGUU 1557 D-1050 1044 1062 927-945 ACGACCAAAACGGGCCCUGUU 55 CAGGGCCCGUUUUGGUCGUUU 1558 D-1051 1045 1063 928-946 CGACCAAAACGGGCCCUGGUU 56 CCAGGGCCCGUUUUGGUCGUU 1559 D-1052 1046 1064 929-947 GACCAAAACGGGCCCUGGAUU 57 UCCAGGGCCCGUUUUGGUCUU 1560 D-1053 1047 1065 930-948 ACCAAAACGGGCCCUGGAAUU 58 UUCCAGGGCCCGUUUUGGUUU 1561 D-1054 1048 1066 931-949 CCAAAACGGGCCCUGGAAGUU 59 CUUCCAGGGCCCGUUUUGGUU 1562 D-1055 1049 1067 932-950 CAAAACGGGCCCUGGAAGUUU 60 ACUUCCAGGGCCCGUUUUGUU 1563 D-1056 1050 1068 933-951 AAAACGGGCCCUGGAAGUGUU 61 CACUUCCAGGGCCCGUUUUUU 1564 D-1057 1051 1069 934-952 AAACGGGCCCUGGAAGUGGUU 62 CCACUUCCAGGGCCCGUUUUU 1565 D-1058 105-123 105-123 CCACACUCCCCUAAGUUCCUU 63 GGAACUUAGGGGAGUGUGGUU 1566 D-1059 1052 1070 935-953 AACGGGCCCUGGAAGUGGGUU 64 CCCACUUCCAGGGCCCGUUUU 1567 D-1060 1053 1071 936-954 ACGGGCCCUGGAAGUGGGUUU 65 ACCCACUUCCAGGGCCCGUUU 1568 D-1061 1054 1072 937-955 CGGGCCCUGGAAGUGGGUGUU 66 CACCCACUUCCAGGGCCCGUU 1569 D-1062 1055 1073 938-956 GGGCCCUGGAAGUGGGUGGUU 67 CCACCCACUUCCAGGGCCCUU 1570 D-1063 1056 1074 939-957 GGCCCUGGAAGUGGGUGGAUU 68 UCCACCCACUUCCAGGGCCUU 1571 D-1064 1057 1075 940-958 GCCCUGGAAGUGGGUGGACUU 69 GUCCACCCACUUCCAGGGCUU 1572 D-1065 1058 1076 941-959 CCCUGGAAGUGGGUGGACGUU 70 CGUCCACCCACUUCCAGGGUU 1573 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1066 1059 1077 942-960 CCUGGAAGUGGGUGGACGGUU 71 CCG U CCACCCACU U CCAG G U U 1574 D-1067 1060 1078 943-961 CUGGAAGUGGGUGGACGGGUU 72 CCCG U CCACCCACU U CCAG U U 1575 D-1068 1061 1079 944-962 UGGAAGUGGGUGGACGGGAUU 73 UCCCGUCCACCCACUUCCAUU 1576 D-1069 106-124 106-124 CACACUCCCCUAAGUUCCAUU 74 UGGAACUUAGGGGAGUGUGUU 1577 D-1070 1062 1080 945-963 GGAAGUGGGUGGACGGGACUU 75 GUCCCGUCCACCCACUUCCUU 1578 D-1071 1063 1081 946-964 GAAGUGGGUGGACGGGACGUU 76 CGUCCCGUCCACCCACUUCUU 1579 D-1072 1064 1082 947-965 AAGUGGGUGGACGGGACGGUU 77 CCGUCCCGUCCACCCACUUUU 1580 D-1073 1065 1083 948-966 AGUGGGUGGACGGGACGGAUU 78 UCCGUCCCGUCCACCCACUUU 1581 D-1074 1066 1084 949-967 GUGGGUGGACGGGACGGACUU 79 GUCCGUCCCGUCCACCCACUU 1582 D-1075 1067 1085 950-968 UGGGUGGACGGGACGGACUUU 80 AGUCCGUCCCGUCCACCCAUU 1583 D-1076 1068 1086 951-969 GGGUGGACGGGACGGACUAUU 81 UAGUCCGUCCCGUCCACCCUU 1584 D-1077 1069 1087 952-970 GGUGGACGGGACGGACUACUU 82 GUAGUCCGUCCCGUCCACCUU 1585 D-1078 1070 1088 953-971 GUGGACGGGACGGACUACGUU 83 CGUAGUCCGUCCCGUCCACUU 1586 D-1079 1071 1089 954-972 UGGACGGGACGGACUACGAUU 84 UCGUAGUCCGUCCCGUCCAUU 1587 D-1080 107-125 107-125 ACACUCCCCUAAG U UCCAAU U 85 UUGGAACUUAGGGGAGUGUUU 1588 D-1081 1072 1090 955-973 GGACGGGACGGACUACGAGUU 86 CUCGUAGUCCGUCCCGUCCUU 1589 D-1082 1073 1091 956-974 GACGGGACGGACUACGAGAU U 87 UCUCGUAGUCCGUCCCGUCUU 1590 D-1083 1074 1092 957-975 ACGGGACGGACUACGAGACUU 88 GUCUCGUAGUCCGUCCCGUUU 1591 D-1084 1075 1093 958-976 CGGGACGGACUACGAGACGUU 89 CGUCUCGUAGUCCGUCCCGUU 1592 D-1085 1076 1094 959-977 GGGACGGACUACGAGACGGUU 90 CCGUCUCGUAGUCCGUCCCUU 1593 D-1086 1077 1095 960-978 GGACGGACUACGAGACGGGUU 91 CCCGUCUCGUAGUCCGUCCUU 1594 D-1087 1078 1096 961-979 GACGGACUACGAGACGGGCUU 92 GCCCGUCUCGUAGUCCGUCUU 1595 D-1088 1079 1097 962-980 ACGGACUACGAGACGGGCUUU 93 AGCCCGUCUCGUAGUCCGUUU 1596 D-1089 1080 1098 963-981 CGGACUACGAGACGGGCUUUU 94 AAGCCCGUCUCGUAGUCCGUU 1597 D-1090 1081 1099 964-982 GGACUACGAGACGGGCUUCUU 95 GAAGCCCGUCUCGUAGUCCUU 1598 D-1091 108-126 108-126 CACUCCCCUAAGUUCCAAUUU 96 AUUGGAACUUAGGGGAGUGUU 1599 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1092 1082 1100 965-983 GACUACGAGACGGGCUUCAUU 97 UGAAGCCCGUCUCGUAGUCUU 1600 D-1093 1083 1101 966-984 ACUACGAGACGGGCUUCAAUU 98 UUGAAGCCCGUCUCGUAGUUU 1601 D-1094 1084 1102 967-985 CUACGAGACGGGCUUCAAGUU 99 CUUGAAGCCCGUCUCGUAGUU 1602 D-1095 1085 1103 968-986 UACGAGACGGGCUUCAAGAUU 100 UCUUGAAGCCCGUCUCGUAUU 1603 D-1096 1086 1104 969-987 ACGAGACGGGCUUCAAGAAUU 101 UUCUUGAAGCCCGUCUCGUUU 1604 D-1097 1087 1105 970-988 CGAGACGGGCUUCAAGAACUU 102 GUUCUUGAAGCCCGUCUCGUU 1605 D-1098 1088 1106 971-989 GAGACGGGCUUCAAGAACUUU 103 AGUUCUUGAAGCCCGUCUCUU 1606 D-1099 1089 1107 972-990 AGACGGGCUUCAAGAACUGUU 104 CAGUUCUUGAAGCCCGUCUUU 1607 D-1100 1090 1108 973-991 GACGGGCUUCAAGAACUGGUU 105 CCAGUUCUUGAAGCCCGUCUU 1608 D-1101 1091 1109 974-992 ACGGGCUUCAAGAACUGGAUU 106 UCCAGUUCUUGAAGCCCGUUU 1609 D-1102 109-127 109-127 ACUCCCCUAAGUUCCAAUCUU 107 GAUUGGAACUUAGGGGAGUUU 1610 D-1103 1092 1110 975-993 CGGGCUUCAAGAACUGGAGUU 108 CUCCAGUUCUUGAAGCCCGUU 1611 D-1104 1093 1111 976-994 GGGCUUCAAGAACUGGAGGUU 109 CCUCCAGUUCUUGAAGCCCUU 1612 D-1105 1094 1112 977-995 GGCUUCAAGAACUGGAGGCUU 110 GCCUCCAGUUCUUGAAGCCUU 1613 D-1106 1095 1113 978-996 GCUUCAAGAACUGGAGGCCUU 111 GGCCUCCAGUUCUUGAAGCUU 1614 D-1107 1096 1114 979-997 CUUCAAGAACUGGAGGCCGUU 112 CGGCCUCCAGUUCUUGAAGUU 1615 D-1108 1097 1115 980-998 UUCAAGAACUGGAGGCCGGUU 113 CCGGCCUCCAGUUCUUGAAUU 1616 D-1109 1098 1116 981-999 UCAAGAACUGGAGGCCGGAUU 114 UCCGGCCUCCAGUUCUUGAUU 1617 D-1110 1099 1117 982-1000 CAAGAACUGGAGGCCGGAGUU 115 CUCCGGCCUCCAGUUCUUGUU 1618 D-llll 1100 1118 983-1001 AAGAACUGGAGGCCGGAGCUU 116 GCUCCGGCCUCCAGUUCUUUU 1619 D-1112 1101 1119 984-1002 AGAACUGGAGGCCGGAGCAUU 117 UGCUCCGGCCUCCAGUUCUUU 1620 D-1113 110-128 110-128 CUCCCCUAAGUUCCAAUCCUU 118 GGAUUGGAACUUAGGGGAGUU 1621 D-1114 1102 1120 985-1003 GAACUGGAGGCCGGAGCAGUU 119 CUGCUCCGGCCUCCAGUUCUU 1622 D-1115 1103 1121 986-1004 AACUGGAGGCCGGAGCAGCUU 120 GCUGCUCCGGCCUCCAGUUUU 1623 D-1116 1104 1122 987-1005 ACUGGAGGCCGGAGCAGCCUU 121 GGCUGCUCCGGCCUCCAGUUU 1624 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1117 1105 1123 988-1006 CUGGAGGCCGGAGCAGCCGUU 122 CGGCUGCUCCGGCCUCCAGUU 1625 D-1118 1106 1124 989-1007 UGGAGGCCGGAGCAGCCGGUU 123 CCGGCUGCUCCGGCCUCCAUU 1626 D-1119 1107 1125 990-1008 GGAGGCCGGAGCAGCCGGAUU 124 UCCGGCUGCUCCGGCCUCCUU 1627 D-1120 1108 1126 991-1009 GAGGCCGGAGCAGCCGGACUU 125 GUCCGGCUGCUCCGGCCUCUU 1628 D-1121 1109 1127 992-1010 AGGCCGGAGCAGCCGGACGUU 126 CGUCCGGCUGCUCCGGCCUUU 1629 D-1122 1110 1128 993-1011 GGCCGGAGCAGCCGGACGAUU 127 UCGUCCGGCUGCUCCGGCCUU 1630 D-1123 1111 1129 994-1012 GCCGGAGCAGCCGGACGACUU 128 GUCGUCCGGCUGCUCCGGCUU 1631 D-1124 111-129 111-129 U CCCCUAAG U U CCAAU CCAU U 129 UGGAUUGGAACUUAGGGGAUU 1632 D-1125 1112 1130 995-1013 CCGGAGCAGCCGGACGACUUU 130 AGUCGUCCGGCUGCUCCGGUU 1633 D-1126 1113 1131 996-1014 CGGAGCAGCCGGACGACUGUU 131 CAGUCGUCCGGCUGCUCCGUU 1634 D-1127 1114 1132 997-1015 GGAGCAGCCGGACGACUGGUU 132 CCAGUCGUCCGGCUGCUCCUU 1635 D-1128 1115 1133 998-1016 GAGCAGCCGGACGACUGGUUU 133 ACCAGUCGUCCGGCUGCUCUU 1636 D-1129 1116 1134 999-1017 AGCAGCCGGACGACUGGUAUU 134 UACCAGUCGUCCGGCUGCUUU 1637 D-1130 1117 1135 1000-1018 GCAGCCGGACGACUGGUACUU 135 GUACCAGUCGUCCGGCUGCUU 1638 D-1131 1118 1136 1001-1019 CAGCCGGACGACUGGUACGUU 136 CGUACCAGUCGUCCGGCUGUU 1639 D-1132 1119 1137 1002-1020 AGCCGGACGACUGGUACGGUU 137 CCGUACCAGUCGUCCGGCUUU 1640 D-1133 1120 1138 1003-1021 GCCGGACGACUGGUACGGCUU 138 GCCGUACCAGUCGUCCGGCUU 1641 D-1134 1121 1139 1004-1022 CCGGACGACUGGUACGGCCUU 139 GGCCGUACCAGUCGUCCGGUU 1642 D-1135 112-130 112-130 CCCCUAAGUUCCAAUCCAUUU 140 AUGGAUUGGAACUUAGGGGUU 1643 D-1136 1122 1140 1005-1023 CGGACGACUGGUACGGCCAUU 141 UGGCCGUACCAGUCGUCCGUU 1644 D-1137 1123 1141 1006-1024 GGACGACUGGUACGGCCACUU 142 GUGGCCGUACCAGUCGUCCUU 1645 D-1138 1124 1142 1007-1025 GACGACUGGUACGGCCACGUU 143 CGUGGCCGUACCAGUCGUCUU 1646 D-1139 1125 1143 1008-1026 ACGACUGGUACGGCCACGGUU 144 CCGUGGCCGUACCAGUCGUUU 1647 D-1140 1126 1144 1009-1027 CGACUGGUACGGCCACGGGUU 145 CCCGUGGCCGUACCAGUCGUU 1648 D-1141 1127 1145 1010-1028 GACUGGUACGGCCACGGGCUU 146 GCCCGUGGCCGUACCAGUCUU 1649 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1142 1128 1146 1011-1029 ACUGGUACGGCCACGGGCUUU 147 AGCCCGUGGCCGUACCAGUUU 1650 D-1143 11-29 11-29 GCACGGAAGAGUGAGGUGAUU 148 UCACCUCACUCUUCCGUGCUU 1651 D-1144 1129 1147 1012-1030 CUGGUACGGCCACGGGCUCUU 149 GAGCCCGUGGCCGUACCAGUU 1652 D-1145 1130 1148 1013-1031 UGGUACGGCCACGGGCUCGUU 150 CGAGCCCGUGGCCGUACCAUU 1653 D-1146 1131 1149 1014-1032 GGUACGGCCACGGGCUCGGUU 151 CCGAGCCCGUGGCCGUACCUU 1654 D-1147 113-131 113-131 CCCUAAGUUCCAAUCCAUUUU 152 AAUGGAUUGGAACUUAGGGUU 1655 D-1148 1132 1150 1015-1033 GUACGGCCACGGGCUCGGAUU 153 UCCGAGCCCGUGGCCGUACUU 1656 D-1149 1133 1151 1016-1034 UACGGCCACGGGCUCGGAGUU 154 CUCCGAGCCCGUGGCCGUAUU 1657 D-1150 1134 1152 1017-1035 ACGGCCACGGGCUCGGAGGUU 155 CCUCCGAGCCCGUGGCCGUUU 1658 D-1151 1135 1153 1018-1036 CGGCCACGGGCUCGGAGGAUU 156 UCCUCCGAGCCCGUGGCCGUU 1659 D-1152 1136 1154 1019-1037 GGCCACGGGCUCGGAGGAGUU 157 CUCCUCCGAGCCCGUGGCCUU 1660 D-1153 1137 1155 1020-1038 GCCACGGGCUCGGAGGAGGUU 158 CCUCCUCCGAGCCCGUGGCUU 1661 D-1154 1138 1156 1021-1039 CCACGGGCUCGGAGGAGGCUU 159 GCCUCCUCCGAGCCCGUGGUU 1662 D-1155 1139 1157 1022-1040 CACGGGCUCGGAGGAGGCGUU 160 CGCCUCCUCCGAGCCCGUGUU 1663 D-1156 1140 1158 1023-1041 ACGGGCUCGGAGGAGGCGAUU 161 UCGCCUCCUCCGAGCCCGUUU 1664 D-1157 1141 1159 1024-1042 CGGGCUCGGAGGAGGCGAGUU 162 CUCGCCUCCUCCGAGCCCGUU 1665 D-1158 114-132 114-132 CCUAAGUUCCAAUCCAUUUUU 163 AAAUGGAUUGGAACUUAGGUU 1666 D-1159 1142 1160 1025-1043 GGGCUCGGAGGAGGCGAGGUU 164 CCUCGCCUCCUCCGAGCCCUU 1667 D-1160 1143 1161 1026-1044 GGCUCGGAGGAGGCGAGGAUU 165 UCCUCGCCUCCUCCGAGCCUU 1668 D-1161 1144 1162 1027-1045 GCUCGGAGGAGGCGAGGACUU 166 GUCCUCGCCUCCUCCGAGCUU 1669 D-1162 1145 1163 1028-1046 CUCGGAGGAGGCGAGGACUUU 167 AGUCCUCGCCUCCUCCGAGUU 1670 D-1163 1146 1164 1029-1047 UCGGAGGAGGCGAGGACUGUU 168 CAGUCCUCGCCUCCUCCGAUU 1671 D-1164 1147 1165 1030-1048 CGGAGGAGGCGAGGACUGUUU 169 ACAGUCCUCGCCUCCUCCGUU 1672 D-1165 1148 1166 1031-1049 GGAGGAGGCGAGGACUGUGUU 170 CACAGUCCUCGCCUCCUCCUU 1673 D-1166 1149 1167 1032-1050 GAGGAGGCGAGGACUGUGCUU 171 GCACAGUCCUCGCCUCCUCUU 1674 D-1167 1150 1168 1033-1051 AGGAGGCGAGGACUGUGCCUU 172 GGCACAGUCCUCGCCUCCUUU 1675 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1168 1151 1169 1034-1052 GGAGGCGAGGACUGUGCCCUU 173 GGGCACAGUCCUCGCCUCCUU 1676 D-1169 115-133 115-133 CUAAGUUCCAAUCCAUUUCUU 174 GAAAUGGAUUGGAACUUAGUU 1677 D-1170 1152 1170 1035-1053 GAGGCGAGGACUGUGCCCAUU 175 UGGGCACAGUCCUCGCCUCUU 1678 D-1171 1153 1171 1036-1054 AGGCGAGGACUGUGCCCACUU 176 GUGGGCACAGUCCUCGCCUUU 1679 D-1172 1154 1172 1037-1055 GGCGAGGACUGUGCCCACUUU 177 AGUGGGCACAGUCCUCGCCUU 1680 D-1173 1155 1173 1038-1056 GCGAGGACUGUGCCCACUUUU 178 AAGUGGGCACAGUCCUCGCUU 1681 D-1174 1156 1174 1039-1057 CGAGGACUGUGCCCACUUCUU 179 GAAGUGGGCACAGUCCUCGUU 1682 D-1175 1157 1175 1040-1058 GAGGACUGUGCCCACUUCAUU 180 UGAAGUGGGCACAGUCCUCUU 1683 D-1176 1158 1176 1041-1059 AGGACUGUGCCCACUUCACUU 181 GUGAAGUGGGCACAGUCCUUU 1684 D-1177 1159 1177 1042-1060 GGACUGUGCCCACUUCACCUU 182 GGUGAAGUGGGCACAGUCCUU 1685 D-1178 1160 1178 1043-1061 GACUGUGCCCACUUCACCGUU 183 CGGUGAAGUGGGCACAGUCUU 1686 D-1179 1161 1179 1044-1062 ACUGUGCCCACUUCACCGAUU 184 UCGGUGAAGUGGGCACAGUUU 1687 D-1180 116-134 116-134 UAAGUUCCAAUCCAUUUCCUU 185 GGAAAUGGAUUGGAACUUAUU 1688 D-1181 1162 1180 1045-1063 CUGUGCCCACUUCACCGACUU 186 GUCGGUGAAGUGGGCACAGUU 1689 D-1182 1163 1181 1046-1064 UGUGCCCACUUCACCGACGUU 187 CGUCGGUGAAGUGGGCACAUU 1690 D-1183 1164 1182 1047-1065 GUGCCCACUUCACCGACGAUU 188 UCGUCGGUGAAGUGGGCACUU 1691 D-1184 1165 1183 1048-1066 UGCCCACUUCACCGACGACUU 189 GUCGUCGGUGAAGUGGGCAUU 1692 D-1185 1166 1184 1049-1067 GCCCACUUCACCGACGACGUU 190 CGUCGUCGGUGAAGUGGGCUU 1693 D-1186 1167 1185 1050-1068 CCCACUUCACCGACGACGGUU 191 CCGUCGUCGGUGAAGUGGGUU 1694 D-1187 1168 1186 1051-1069 CCACUUCACCGACGACGGCUU 192 GCCGUCGUCGGUGAAGUGGUU 1695 D-1188 1169 1187 1052-1070 CACUUCACCGACGACGGCCUU 193 GGCCGUCGUCGGUGAAGUGUU 1696 D-1189 1170 1188 1053-1071 ACUUCACCGACGACGGCCGUU 194 CGGCCGUCGUCGGUGAAGUUU 1697 D-1190 1171 1189 1054-1072 CUUCACCGACGACGGCCGCUU 195 GCGGCCGUCGUCGGUGAAGUU 1698 D-1191 117-135 117-135 AAGUUCCAAUCCAUUUCCAUU 196 UGGAAAUGGAUUGGAACUUUU 1699 D-1192 1172 1190 1055-1073 UUCACCGACGACGGCCGCUUU 197 AGCGGCCGUCGUCGGUGAAUU 1700 D-1193 1173 1191 1056-1074 UCACCGACGACGGCCGCUGUU 198 CAGCGGCCGUCGUCGGUGAUU 1701 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1194 1174 1192 1057-1075 CACCGACGACGGCCGCUGGUU 199 CCAGCGGCCGUCGUCGGUGUU 1702 D-1195 1175 1193 1058-1076 ACCGACGACGGCCGCUGGAUU 200 UCCAGCGGCCGUCGUCGGUUU 1703 D-1196 1176 1194 1059-1077 CCGACGACGGCCGCUGGAAUU 201 UUCCAGCGGCCGUCGUCGGUU 1704 D-1197 1177 1195 1060-1078 CGACGACGGCCGCUGGAACUU 202 GUUCCAGCGGCCGUCGUCGUU 1705 D-1198 1178 1196 1061-1079 GACGACGGCCGCUGGAACGUU 203 CGUUCCAGCGGCCGUCGUCUU 1706 D-1199 1179 1197 1062-1080 ACGACGGCCGCUGGAACGAUU 204 UCGUUCCAGCGGCCGUCGUUU 1707 D-1200 1180 1198 1063-1081 CGACGGCCGCUGGAACGACUU 205 GUCGUUCCAGCGGCCGUCGUU 1708 D-1201 1181 1199 1064-1082 GACGGCCGCUGGAACGACGUU 206 CGUCGUUCCAGCGGCCGUCUU 1709 D-1202 118-136 118-136 AGUUCCAAUCCAUUUCCACUU 207 GUGGAAAUGGAUUGGAACUUU 1710 D-1203 1182 1200 1065-1083 ACGGCCGCUGGAACGACGAUU 208 UCGUCGUUCCAGCGGCCGUUU 1711 D-1204 1183 1201 1066-1084 CGGCCGCUGGAACGACGACUU 209 GUCGUCGUUCCAGCGGCCGUU 1712 D-1205 1184 1202 1067-1085 GGCCGCUGGAACGACGACGUU 210 CGUCGUCGUUCCAGCGGCCUU 1713 D-1206 1185 1203 1068-1086 GCCGCUGGAACGACGACGUUU 211 ACGUCGUCGUUCCAGCGGCUU 1714 D-1207 1186 1204 1069-1087 CCGCUGGAACGACGACGUCUU 212 GACGUCGUCGUUCCAGCGGUU 1715 D-1208 1187 1205 1070-1088 CGCUGGAACGACGACGUCUUU 213 AGACGUCGUCGUUCCAGCGUU 1716 D-1209 1188 1206 1071-1089 GCUGGAACGACGACGUCUGUU 214 CAGACGUCGUCGUUCCAGCUU 1717 D-1210 1189 1207 1072-1090 CUGGAACGACGACGUCUGCUU 215 GCAGACG UCG UCG U UCCAG U U 1718 D-1211 1-19 1-19 CCCAAACG G U G CACG G AAG U U 216 CUUCCGUGCACCGUUUGGGUU 1719 D-1212 1190 1208 1073-1091 UGGAACGACGACGUCUGCCUU 217 GGCAGACGUCGUCGUUCCAUU 1720 D-1213 1191 1209 1074-1092 GGAACGACGACGUCUGCCAUU 218 UGGCAGACGUCGUCGUUCCUU 1721 D-1214 119-137 119-137 GUUCCAAUCCAUUUCCACCUU 219 GGUGGAAAUGGAUUGGAACUU 1722 D-1215 1192 1210 1075-1093 GAACGACGACGUCUGCCAGUU 220 CUGGCAGACGUCGUCGUUCUU 1723 D-1216 1193 1211 1076-1094 AACGACGACGUCUGCCAGAUU 221 UCUGGCAGACGUCGUCGUUUU 1724 D-1217 1194 1212 1077-1095 ACGACGACGUCUGCCAGAGUU 222 CUCUGGCAGACGUCGUCGUUU 1725 D-1218 1195 1213 1078-1096 CGACGACGUCUGCCAGAGGUU 223 CCUCUGGCAGACGUCGUCGUU 1726 D-1219 1196 1214 1079-1097 GACGACGUCUGCCAGAGGCUU 224 GCCUCUGGCAGACGUCGUCUU 1727 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1220 1197 1215 1080-1098 ACGACGUCUGCCAGAGGCCUU 225 GGCCUCUGGCAGACGUCGUUU 1728 D-1221 1198 1216 1081-1099 CGACGUCUGCCAGAGGCCCUU 226 GGGCCUCUGGCAGACGUCGUU 1729 D-1222 1199 1217 1082-1100 GACGUCUGCCAGAGGCCCUUU 227 AGGGCCUCUGGCAGACGUCUU 1730 D-1223 1200 1218 1083-1101 ACGUCUGCCAGAGGCCCUAUU 228 UAGGGCCUCUGGCAGACGUUU 1731 D-1224 1201 1219 1084-1102 CGUCUGCCAGAGGCCCUACUU 229 GUAGGGCCUCUGGCAGACGUU 1732 D-1225 120-138 120-138 UUCCAAUCCAUUUCCACCUUU 230 AGGUGGAAAUGGAUUGGAAUU 1733 D-1226 1202 1220 1085-1103 GUCUGCCAGAGGCCCUACCUU 231 GGUAGGGCCUCUGGCAGACUU 1734 D-1227 1203 1221 1086-1104 UCUGCCAGAGGCCCUACCGUU 232 CGGUAGGGCCUCUGGCAGAUU 1735 D-1228 1204 1222 1087-1105 CUGCCAGAGGCCCUACCGCUU 233 GCGGUAGGGCCUCUGGCAGUU 1736 D-1229 1205 1223 1088-1106 UGCCAGAGGCCCUACCGCUUU 234 AGCGGUAGGGCCUCUGGCAUU 1737 D-1230 1206 1224 1089-1107 GCCAGAGGCCCUACCGCUGUU 235 CAGCGGUAGGGCCUCUGGCUU 1738 D-1231 1207 1225 1090-1108 CCAGAGGCCCUACCGCUGGUU 236 CCAGCGGUAGGGCCUCUGGUU 1739 D-1232 1208 1226 1091-1109 CAGAGGCCCUACCGCUGGGUU 237 CCCAGCGGUAGGGCCUCUGUU 1740 D-1233 1209 1227 1092-1110 AGAGGCCCUACCGCUGGGUUU 238 ACCCAGCGGUAGGGCCUCUUU 1741 D-1234 1210 1228 1093-1111 GAGGCCCUACCGCUGGGUCUU 239 GACCCAGCGGUAGGGCCUCUU 1742 D-1235 1211 1229 1094-1112 AGGCCCUACCGCUGGGUCUUU 240 AGACCCAGCGGUAGGGCCUUU 1743 D-1236 121-139 121-139 UCCAAUCCAUUUCCACCUCUU 241 GAGGUGGAAAUGGAUUGGAUU 1744 D-1237 1212 1230 1095-1113 GGCCCUACCGCUGGGUCUGUU 242 CAGACCCAGCGGUAGGGCCUU 1745 D-1238 1213 1231 1096-1114 GCCCUACCGCUGGGUCUGCUU 243 GCAGACCCAGCGGUAGGGCUU 1746 D-1239 1214 1232 1097-1115 CCCUACCGCUGGGUCUGCGUU 244 CGCAGACCCAGCGGUAGGGUU 1747 D-1240 1215 1233 1098-1116 CCUACCGCUGGGUCUGCGAUU 245 UCGCAGACCCAGCGGUAGGUU 1748 D-1241 1216 1234 1099-1117 CUACCGCUGGGUCUGCGAGUU 246 CUCGCAGACCCAGCGGUAGUU 1749 D-1242 1217 1235 1100-1118 UACCGCUGGGUCUGCGAGAUU 247 UCUCGCAGACCCAGCGGUAUU 1750 D-1243 1218 1236 1101-1119 ACCGCUGGGUCUGCGAGACUU 248 GUCUCGCAGACCCAGCGGUUU 1751 D-1244 1219 1237 1102-1120 CCGCUGGGUCUGCGAGACAUU 249 UGUCUCGCAGACCCAGCGGUU 1752 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1245 1220 1238 1103-1121 CGCUGGGUCUGCGAGACAGUU 250 CUGUCUCGCAGACCCAGCGUU 1753 D-1246 1221 1239 1104-1122 GCUGGGUCUGCGAGACAGAUU 251 UCUGUCUCGCAGACCCAGCUU 1754 D-1247 122-140 122-140 CCAAUCCAUUUCCACCUCUUU 252 AGAGGUGGAAAUGGAUUGGUU 1755 D-1248 1222 1240 1105-1123 CUGGGUCUGCGAGACAGAGUU 253 CUCUGUCUCGCAGACCCAGUU 1756 D-1249 1223 1241 1106-1124 UGGGUCUGCGAGACAGAGCUU 254 GCUCUGUCUCGCAGACCCAUU 1757 D-1250 1224 1242 1107-1125 GGGUCUGCGAGACAGAGCUUU 255 AGCUCUGUCUCGCAGACCCUU 1758 D-1251 1225 1243 1108-1126 GGUCUGCGAGACAGAGCUGUU 256 CAGCUCUGUCUCGCAGACCUU 1759 D-1252 1226 1244 1109-1127 GUCUGCGAGACAGAGCUGGUU 257 CCAGCUCUGUCUCGCAGACUU 1760 D-1253 1227 1245 1110-1128 UCUGCGAGACAGAGCUGGAUU 258 UCCAGCUCUGUCUCGCAGAUU 1761 D-1254 1228 1246 1111-1129 CUGCGAGACAGAGCUGGACUU 259 GUCCAGCUCUGUCUCGCAGUU 1762 D-1255 1229 1247 1112-1130 UGCGAGACAGAGCUGGACAUU 260 UGUCCAGCUCUGUCUCGCAUU 1763 D-1256 12-30 12-30 CACGGAAGAGUGAGGUGACUU 261 GUCACCUCACUCUUCCGUGUU 1764 D-1257 1230 1248 1113-1131 GCGAGACAGAGCUGGACAAUU 262 UUGUCCAGCUCUGUCUCGCUU 1765 D-1258 1231 1249 1114-1132 CGAGACAGAGCUGGACAAGUU 263 CUUGUCCAGCUCUGUCUCGUU 1766 D-1259 123-141 123-141 CAAUCCAUUUCCACCUCUGUU 264 CAGAGGUGGAAAUGGAUUGUU 1767 D-1260 1232 1250 1115-1133 GAGACAGAGCUGGACAAGGUU 265 CCUUGUCCAGCUCUGUCUCUU 1768 D-1261 1233 1251 1116-1134 AGACAGAGCUGGACAAGGCUU 266 GCCUUGUCCAGCUCUGUCUUU 1769 D-1262 1234 1252 1117-1135 GACAGAGCUGGACAAGGCCUU 267 GGCCUUGUCCAGCUCUGUCUU 1770 D-1263 1235 1253 1118-1136 ACAGAGCUGGACAAGGCCAUU 268 UGGCCUUGUCCAGCUCUGUUU 1771 D-1264 1236 1254 1119-1137 CAGAGCUGGACAAGGCCAGUU 269 CUGGCCUUGUCCAGCUCUGUU 1772 D-1265 1237 1255 1120-1138 AGAGCUGGACAAGGCCAGCUU 270 GCUGGCCUUGUCCAGCUCUUU 1773 D-1266 1238 1256 1121-1139 GAGCUGGACAAGGCCAGCCUU 271 GGCUGGCCUUGUCCAGCUCUU 1774 D-1267 1239 1257 1122-1140 AGCUGGACAAGGCCAGCCAUU 272 UGGCUGGCCUUGUCCAGCUUU 1775 D-1268 1240 1258 1123-1141 GCUGGACAAGGCCAGCCAGUU 273 CUGGCUGGCCUUGUCCAGCUU 1776 D-1269 1241 1259 1124-1142 CU G G ACAAG G CCAG CCAG G U U 274 CCUGGCUGGCCUUGUCCAGUU 1777 D-1270 124-142 124-142 AAUCCAUUUCCACCUCUGUUU 275 ACAGAGGUGGAAAUGGAUUUU 1778 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1271 1242 1260 1125-1143 UGGACAAGGCCAGCCAGGAUU 276 UCCUGGCUGGCCUUGUCCAUU 1779 D-1272 1243 1261 1126-1144 GGACAAGGCCAGCCAGGAGUU m CUCCUGGCUGGCCUUGUCCUU 1780 D-1273 1244 1262 1127-1145 GACAAGGCCAGCCAGGAGCUU nz GCUCCUGGCUGGCCUUGUCUU 1781 D-1274 1245 1263 1128-1146 ACAAGGCCAGCCAGGAGCCUU 279 GGCUCCUGGCUGGCCUUGUUU 1782 D-1275 1246 1264 1129-1147 CAAG G CCAG CCAG GAG CCAU U 280 UGGCUCCUGGCUGGCCUUGUU 1783 D-1276 1247 1265 1130-1148 AAGGCCAGCCAGGAGCCACUU 281 GUGGCUCCUGGCUGGCCUUUU 1784 D-1277 1248 1266 1131-1149 AGGCCAGCCAGGAGCCACCUU 282 GGUGGCUCCUGGCUGGCCUUU 1785 D-1278 1249 1267 1132-1150 GGCCAGCCAGGAGCCACCUUU 283 AGGUGGCUCCUGGCUGGCCUU 1786 D-1279 1250 1268 1133-1151 GCCAGCCAGGAGCCACCUCUU 284 GAGGUGGCUCCUGGCUGGCUU 1787 D-1280 1251 1269 1134-1152 CCAGCCAGGAGCCACCUCUUU 285 AGAGGUGGCUCCUGGCUGGUU 1788 D-1281 125-143 125-143 AUCCAUUUCCACCUCUGUUUU 286 AACAGAGGUGGAAAUGGAUUU 1789 D-1282 1252 1270 1135-1153 CAGCCAGGAGCCACCUCUCUU 287 GAGAGGUGGCUCCUGGCUGUU 1790 D-1283 1253 1271 1136-1154 AGCCAGGAGCCACCUCUCCUU 288 GGAGAGGUGGCUCCUGGCUUU 1791 D-1284 1254 1272 1137-1155 GCCAGGAGCCACCUCUCCUUU 289 AGGAGAGGUGGCUCCUGGCUU 1792 D-1285 1255 1273 1138-1156 CCAGGAGCCACCUCUCCUUUU 290 AAGGAGAGGUGGCUCCUGGUU 1793 D-1286 1256 1274 1139-1157 CAGGAGCCACCUCUCCUUUUU 291 AAAGGAGAGGUGGCUCCUGUU 1794 D-1287 1257 1275 1140-1158 AGGAGCCACCUCUCCUUUAUU 292 UAAAGGAGAGGUGGCUCCUUU 1795 D-1288 1258 1276 1141-1159 GGAGCCACCUCUCCUUUAAUU 293 UUAAAGGAGAGGUGGCUCCUU 1796 D-1289 1259 1277 1142-1160 GAGCCACCUCUCCUUUAAUUU 294 AUUAAAGGAGAGGUGGCUCUU 1797 D-1290 1260 1278 1143-1161 AGCCACCUCUCCUUUAAUUUU 295 AAUUAAAGGAGAGGUGGCUUU 1798 D-1291 1261 1279 1144-1162 GCCACCUCUCCUUUAAUUUUU 296 AAAUUAAAGGAGAGGUGGCUU 1799 D-1292 126-144 126-144 UCCAUUUCCACCUCUGUUUUU 297 AAACAGAGGUGGAAAUGGAUU 1800 D-1293 1262 1280 1145-1163 CCACCUCUCCUUUAAUUUAUU 298 UAAAUUAAAGGAGAGGUGGUU 1801 D-1294 1263 1281 1146-1164 CACCUCUCCUUUAAUUUAUUU 299 AUAAAUUAAAGGAGAGGUGUU 1802 D-1295 1264 1282 1147-1165 ACCUCUCCUUUAAUUUAUUUU 300 AAUAAAU UAAAGGAGAGG U U U 1803 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1296 1265 1283 1148-1166 CCUCUCCUUUAAUUUAUUUUU 301 AAAUAAAUUAAAGGAGAGGUU 1804 D-1297 1266 1284 1149-1167 CUCUCCUUUAAUUUAUUUCUU 302 GAAAUAAAUUAAAGGAGAGUU 1805 D-1298 1267 1285 1150-1168 UCUCCUUUAAUUUAUUUCUUU 303 AGAAAUAAAUUAAAGGAGAUU 1806 D-1299 1268 1286 1151-1169 CUCCUUUAAUUUAUUUCUUUU 304 AAGAAAUAAAUUAAAGGAGUU 1807 D-1300 1269 1287 1152-1170 UCCUUUAAUUUAUUUCUUCUU 305 GAAGAAAUAAAU UAAAGGAU U 1808 D-1301 1270 1288 1153-1171 CCUUUAAUUUAUUUCUUCAUU 306 UGAAGAAAUAAAUUAAAGGUU 1809 D-1302 1271 1289 1154-1172 CUUUAAUUUAUUUCUUCAAUU 307 U UGAAGAAAUAAAU UAAAG U U 1810 D-1303 127-145 127-145 CCAUUUCCACCUCUGUUUAUU 308 UAAACAGAGGUGGAAAUGGUU 1811 D-1304 1272 1290 1155-1173 UUUAAUUUAUUUCUUCAAUUU 309 AUUGAAGAAAUAAAUUAAAUU 1812 D-1305 1273 1291 1156-1174 UUAAUUUAUUUCUUCAAUGUU 310 CAUUGAAGAAAUAAAUUAAUU 1813 D-1306 1274 1292 1157-1175 UAAUUUAUUUCUUCAAUGCUU 311 GCAUUGAAGAAAUAAAUUAUU 1814 D-1307 1275 1293 1158-1176 AAUUUAUUUCUUCAAUGCCUU 312 GGCAUUGAAGAAAUAAAUUUU 1815 D-1308 1276 1294 1159-1177 AUUUAUUUCUUCAAUGCCUUU 313 AGGCAUUGAAGAAAUAAAUUU 1816 D-1309 1277 1295 1160-1178 UUUAUUUCUUCAAUGCCUCUU 314 GAGGCAUUGAAGAAAUAAAUU 1817 D-1310 1278 1296 1161-1179 UUAUUUCUUCAAUGCCUCGUU 315 CGAGGCAUUGAAGAAAUAAUU 1818 D-1311 1279 1297 1162-1180 UAUUUCUUCAAUGCCUCGAUU 316 UCGAGGCAUUGAAGAAAUAUU 1819 D-1312 1280 1298 1163-1181 AUUUCUUCAAUGCCUCGACUU 317 GUCGAGGCAUUGAAGAAAUUU 1820 D-1313 1281 1299 1164-1182 UUUCUUCAAUGCCUCGACCUU 318 GGUCGAGGCAUUGAAGAAAUU 1821 D-1314 128-146 128-146 CAUUUCCACCUCUGUUUACUU 319 GUAAACAGAGGUGGAAAUGUU 1822 D-1315 1282 1300 1165-1183 UUCUUCAAUGCCUCGACCUUU 320 AGGUCGAGGCAUUGAAGAAUU 1823 D-1316 1283 1301 1166-1184 UCUUCAAUGCCUCGACCUGUU 321 CAGGUCGAGGCAUUGAAGAUU 1824 D-1317 1284 1302 1167-1185 CUUCAAUGCCUCGACCUGCUU 322 GCAGGUCGAGGCAUUGAAGUU 1825 D-1318 1285 1303 1168-1186 UUCAAUGCCUCGACCUGCCUU 323 GGCAGGUCGAGGCAUUGAAUU 1826 D-1319 1286 1304 1169-1187 UCAAUGCCUCGACCUGCCGUU 324 CGGCAGGUCGAGGCAUUGAUU 1827 D-1320 1287 1305 1170-1188 CAAUGCCUCGACCUGCCGCUU 325 GCGGCAGGUCGAGGCAUUGUU 1828 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1321 1288 1306 1171-1189 AAUGCCUCGACCUGCCGCAUU 326 UGCGGCAGGUCGAGGCAUUUU 1829 D-1322 1289 1307 1172-1190 AUGCCUCGACCUGCCGCAGUU 327 CUGCGGCAGGUCGAGGCAUUU 1830 D-1323 1290 1308 1173-1191 UGCCUCGACCUGCCGCAGGUU 328 CCUGCGGCAGGUCGAGGCAUU 1831 D-1324 1291 1309 1174-1192 GCCUCGACCUGCCGCAGGGUU 329 CCCUGCGGCAGGUCGAGGCUU 1832 D-1325 129-147 129-147 AUUUCCACCUCUGUUUACUUU 330 AG UAAACAGAGGU GGAAAU U U 1833 D-1326 1292 1310 1175-1193 CCUCGACCUGCCGCAGGGGUU 331 CCCCUGCGGCAGGUCGAGGUU 1834 D-1327 1293 1311 1176-1194 CUCGACCUGCCGCAGGGGUUU 332 ACCCCUGCGGCAGGUCGAGUU 1835 D-1328 1294 1312 1177-1195 UCGACCUGCCGCAGGGGUCUU 333 GACCCCUGCGGCAGGUCGAUU 1836 D-1329 1295 1313 1178-1196 CGACCUGCCGCAGGGGUCCUU 334 GGACCCCUGCGGCAGGUCGUU 1837 D-1330 1296 1314 1179-1197 GACCUGCCGCAGGGGUCCGUU 335 CGGACCCCUGCGGCAGGUCUU 1838 D-1331 1297 1315 1180-1198 ACCUGCCGCAGGGGUCCGGUU 336 CCGGACCCCUGCGGCAGGUUU 1839 D-1332 1298 1316 1181-1199 CCUGCCGCAGGGGUCCGGGUU 337 CCCGGACCCCUGCGGCAGGUU 1840 D-1333 1299 1317 1182-1200 CUGCCGCAGGGGUCCGGGAUU 338 UCCCGGACCCCUGCGGCAGUU 1841 D-1334 1300 1318 1183-1201 UGCCGCAGGGGUCCGGGAUUU 339 AUCCCGGACCCCUGCGGCAUU 1842 D-1335 1301 1319 1184-1202 GCCGCAGGGGUCCGGGAUUUU 340 AAUCCCGGACCCCUGCGGCUU 1843 D-1336 130-148 130-148 UUUCCACCUCUGUUUACUGUU 341 CAGUAAACAGAGGUGGAAAUU 1844 D-1337 1302 1320 1185-1203 CCGCAGGGGUCCGGGAUUGUU 342 CAAUCCCGGACCCCUGCGGUU 1845 D-1338 1303 1321 1186-1204 CGCAGGGGUCCGGGAUUGGUU 343 CCAAUCCCGGACCCCUGCGUU 1846 D-1339 1304 1322 1187-1205 GCAGGGGUCCGGGAUUGGGUU 344 CCCAAUCCCGGACCCCUGCUU 1847 D-1340 1305 1323 1188-1206 CAGGGGUCCGGGAUUGGGAUU 345 UCCCAAUCCCGGACCCCUGUU 1848 D-1341 1306 1324 1189-1207 AGGGGUCCGGGAUUGGGAAUU 346 UUCCCAAUCCCGGACCCCUUU 1849 D-1342 1307 1325 1190-1208 GGGGUCCGGGAUUGGGAAUUU 347 AUUCCCAAUCCCGGACCCCUU 1850 D-1343 1308 1326 1191-1209 GGGUCCGGGAUUGGGAAUCUU 348 GAUUCCCAAUCCCGGACCCUU 1851 D-1344 1309 1327 1192-1210 GGUCCGGGAUUGGGAAUCCUU 349 GGAUUCCCAAUCCCGGACCUU 1852 D-1345 1310 1328 1193-1211 GUCCGGGAUUGGGAAUCCGUU 350 CGGAUUCCCAAUCCCGGACUU 1853 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1346 1311 1329 1194-1212 UCCGGGAUUGGGAAUCCGCUU 351 GCGGAUUCCCAAUCCCGGAUU 1854 D-1347 131-149 131-149 UUCCACCUCUGUUUACUGUUU 352 ACAGUAAACAGAGGUGGAAUU 1855 D-1348 1312 1330 1195-1213 CCGGGAUUGGGAAUCCGCCUU 353 GGCGGAUUCCCAAUCCCGGUU 1856 D-1349 1313 1331 1196-1214 CGGGAUUGGGAAUCCGCCCUU 354 GGGCGGAUUCCCAAUCCCGUU 1857 D-1350 1314 1332 1197-1215 GGGAUUGGGAAUCCGCCCAUU 355 UGGGCGGAUUCCCAAUCCCUU 1858 D-1351 1315 1333 1198-1216 GGAUUGGGAAUCCGCCCAUUU 356 AUGGGCGGAUUCCCAAUCCUU 1859 D-1352 1316 1334 1199-1217 GAUUGGGAAUCCGCCCAUCUU 357 GAUGGGCGGAUUCCCAAUCUU 1860 D-1353 1317 1335 1200-1218 AUUGGGAAUCCGCCCAUCUUU 358 AGAUGGGCGGAUUCCCAAUUU 1861 D-1354 1318 1336 1201-1219 UUGGGAAUCCGCCCAUCUGUU 359 CAGAUGGGCGGAUUCCCAAUU 1862 D-1355 1319 1337 1202-1220 UGGGAAUCCGCCCAUCUGGUU 360 CCAGAUGGGCGGAUUCCCAUU 1863 D-1356 1320 1338 1203-1221 GGGAAUCCGCCCAUCUGGGUU 361 CCCAGAUGGGCGGAUUCCCUU 1864 D-1357 1321 1339 1204-1222 GGAAUCCGCCCAUCUGGGGUU 362 CCCCAGAUGGGCGGAUUCCUU 1865 D-1358 132-150 132-150 UCCACCUCUGUUUACUGUCUU 363 GACAGUAAACAGAGGUGGAUU 1866 D-1359 1322 1340 1205-1223 GAAUCCGCCCAUCUGGGGGUU 364 CCCCCAGAUGGGCGGAUUCUU 1867 D-1360 1323 1341 1206-1224 AAUCCGCCCAUCUGGGGGCUU 365 GCCCCCAGAUGGGCGGAUUUU 1868 D-1361 1324 1342 1207-1225 AUCCGCCCAUCUGGGGGCCUU 366 GGCCCCCAGAUGGGCGGAUUU 1869 D-1362 1325 1343 1208-1226 UCCGCCCAUCUGGGGGCCUUU 367 AGGCCCCCAGAUGGGCGGAUU 1870 D-1363 1326 1344 1209-1227 CCGCCCAUCUGGGGGCCUCUU 368 GAGGCCCCCAGAUGGGCGGUU 1871 D-1364 1327 1345 1210-1228 CGCCCAUCUGGGGGCCUCUUU 369 AGAGGCCCCCAGAUGGGCGUU 1872 D-1365 1328 1346 1211-1229 GCCCAUCUGGGGGCCUCUUUU 370 AAGAGGCCCCCAGAUGGGCUU 1873 D-1366 1329 1347 1212-1230 CCCAUCUGGGGGCCUCUUCUU 371 GAAGAGGCCCCCAGAUGGGUU 1874 D-1367 1330 1348 1213-1231 CCAUCUGGGGGCCUCUUCUUU 372 AGAAGAGGCCCCCAGAUGGUU 1875 D-1368 13-31 13-31 ACGGAAGAGUGAGGUGACUUU 373 AGUCACCUCACUCUUCCGUUU 1876 D-1369 1331 1349 1214-1232 CAUCUGGGGGCCUCUUCUGUU 374 CAGAAGAGGCCCCCAGAUGUU 1877 D-1370 133-151 133-151 CCACCUCUGUUUACUGUCCUU 375 GGACAG UAAACAGAGGU GG U U 1878 D-1371 1332 1350 1215-1233 AUCUGGGGGCCUCUUCUGCUU 376 GCAGAAGAGGCCCCCAGAUUU 1879 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1372 1333 1351 1216-1234 UCUGGGGGCCUCUUCUGCUUU 377 AGCAGAAGAGGCCCCCAGAU U 1880 D-1373 1334 1352 1217-1235 CUGGGGGCCUCUUCUGCUUUU 378 AAGCAGAAGAGGCCCCCAGUU 1881 D-1374 1335 1353 1218-1236 UGGGGGCCUCUUCUGCUUUUU 379 AAAGCAGAAGAGGCCCCCAUU 1882 D-1375 1336 1354 1219-1237 GGGGGCCUCUUCUGCUUUCUU 380 GAAAGCAGAAGAGGCCCCCU U 1883 D-1376 1337 1355 1220-1238 GGGGCCUCUUCUGCUUUCUUU 381 AGAAAGCAGAAGAGGCCCCUU 1884 D-1377 1338 1356 1221-1239 GGGCCUCUUCUGCUUUCUCUU 382 GAGAAAGCAGAAGAGGCCCUU 1885 D-1378 1339 1357 1222-1240 GGCCUCUUCUGCUUUCUCGUU 383 CGAGAAAGCAGAAGAGGCCUU 1886 D-1379 1340 1358 1223-1241 GCCUCUUCUGCUUUCUCGGUU 384 CCGAGAAAGCAGAAGAGGCUU 1887 D-1380 1341 1359 1224-1242 CCUCUUCUGCUUUCUCGGGUU 385 CCCGAGAAAGCAGAAGAGG U U 1888 D-1381 134-152 134-152 CACCUCUGUUUACUGUCCAUU 386 UGGACAGUAAACAGAGGUGUU 1889 D-1382 1342 1360 1225-1243 CUCUUCUGCUUUCUCGGGAUU 387 UCCCGAGAAAGCAGAAGAGUU 1890 D-1383 1343 1361 1226-1244 UCUUCUGCUUUCUCGGGAAUU 388 UUCCCGAGAAAGCAGAAGAUU 1891 D-1384 1344 1362 1227-1245 CUUCUGCUUUCUCGGGAAUUU 389 AU UCCCGAGAAAGCAGAAG U U 1892 D-1385 1345 1363 1228-1246 UUCUGCUUUCUCGGGAAUUUU 390 AAUUCCCGAGAAAGCAGAAUU 1893 D-1386 1346 1364 1229-1247 UCUGCUUUCUCGGGAAUUUUU 391 AAAUUCCCGAGAAAGCAGAUU 1894 D-1387 1347 1365 1230-1248 CUGCUUUCUCGGGAAUUUUUU 392 AAAAU U CCCGAGAAAG CAG U U 1895 D-1388 1348 1366 1231-1249 UGCUUUCUCGGGAAUUUUCUU 393 GAAAAUUCCCGAGAAAGCAUU 1896 D-1389 1349 1367 1232-1250 GCUUUCUCGGGAAUUUUCAUU 394 UGAAAAUUCCCGAGAAAGCUU 1897 D-1390 1350 1368 1233-1251 CUUUCUCGGGAAUUUUCAUUU 395 AUGAAAAUUCCCGAGAAAGUU 1898 D-1391 1351 1369 1234-1252 UUUCUCGGGAAUUUUCAUCUU 396 GAUGAAAAUUCCCGAGAAAUU 1899 D-1392 135-153 135-153 ACCUCUGUUUACUGUCCAAUU 397 UUGGACAGUAAACAGAGGUUU 1900 D-1393 1352 1370 1235-1253 UUCUCGGGAAUUUUCAUCUUU 398 AGAUGAAAAUUCCCGAGAAUU 1901 D-1394 1353 1371 1236-1254 UCUCGGGAAUUUUCAUCUAUU 399 UAGAUGAAAAUUCCCGAGAUU 1902 D-1395 1354 1372 1237-1255 CUCGGGAAUUUUCAUCUAGUU 400 CUAGAUGAAAAUUCCCGAGUU 1903 D-1396 1355 1373 1238-1256 UCGGGAAUUUUCAUCUAGGUU 401 CCUAGAUGAAAAUUCCCGAUU 1904 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1397 1356 1374 1239-1257 CGGGAAUUUUCAUCUAGGAUU 402 UCCUAGAUGAAAAUUCCCGUU 1905 D-1398 1357 1375 1240-1258 GGGAAUUUUCAUCUAGGAUUU 403 AUCCUAGAUGAAAAUUCCCUU 1906 D-1399 1358 1376 1241-1259 GGAAUUUUCAUCUAGGAUUUU 404 AAUCCUAGAUGAAAAUUCCUU 1907 D-1400 1359 1377 1242-1260 GAAUUUUCAUCUAGGAUUUUU 405 AAAUCCUAGAUGAAAAUUCUU 1908 D-1401 1360 1378 1243-1261 AAUUUUCAUCUAGGAUUUUUU 406 AAAAUCCUAGAUGAAAAUUUU 1909 D-1402 1361 1379 1244-1262 AUUUUCAUCUAGGAUUUUAUU 407 UAAAAUCCUAGAUGAAAAUUU 1910 D-1403 136-154 136-154 CCUCUGUUUACUGUCCAAAUU 408 UUUGGACAGUAAACAGAGGUU 1911 D-1404 1362 1380 1245-1263 UUUUCAUCUAGGAUUUUAAUU 409 UUAAAAUCCUAGAUGAAAAUU 1912 D-1405 1363 1381 1246-1264 UUUCAUCUAGGAUUUUAAGUU 410 CU UAAAAUCCUAGAUGAAAU U 1913 D-1406 1364 1382 1247-1265 UUCAUCUAGGAUUUUAAGGUU 411 CCUUAAAAUCCUAGAUGAAUU 1914 D-1407 1365 1383 1248-1266 UCAUCUAGGAUUUUAAGGGUU 412 CCCUUAAAAUCCUAGAUGAUU 1915 D-1408 1366 1384 1249-1267 CAUCUAGGAUUUUAAGGGAUU 413 UCCCUUAAAAUCCUAGAUGUU 1916 D-1409 1367 1385 1250-1268 AUCUAGGAUUUUAAGGGAAUU 414 UUCCCUUAAAAUCCUAGAUUU 1917 D-1410 1368 1386 1251-1269 UCUAGGAUUUUAAGGGAAGUU 415 CUUCCCUUAAAAUCCUAGAUU 1918 D-1411 1369 1387 1252-1270 CUAGGAUUUUAAGGGAAGGUU 416 CCUUCCCUUAAAAUCCUAGUU 1919 D-1412 1370 1388 1253-1271 UAGGAUUUUAAGGGAAGGGUU 417 CCCUUCCCUUAAAAUCCUAUU 1920 D-1413 1371 1389 1254-1272 AGGAUUUUAAGGGAAGGGGUU 418 CCCCUUCCCUUAAAAUCCUUU 1921 D-1414 137-155 137-155 CUCUGUUUACUGUCCAAAGUU 419 CU U UGGACAGUAAACAGAG U U 1922 D-1415 1372 1390 1255-1273 GGAUUUUAAGGGAAGGGGAUU 420 UCCCCUUCCCUUAAAAUCCUU 1923 D-1416 1373 1391 1256-1274 GAUUUUAAGGGAAGGGGAAUU 421 UUCCCCUUCCCUUAAAAUCUU 1924 D-1417 1374 1392 1257-1275 AUUUUAAGGGAAGGGGAAGUU 422 CUUCCCCUUCCCUUAAAAUUU 1925 D-1418 1375 1393 1258-1276 UUUUAAGGGAAGGGGAAGGUU 423 CCUUCCCCUUCCCUUAAAAUU 1926 D-1419 1376 1394 1259-1277 UUUAAGGGAAGGGGAAGGAUU 424 UCCUUCCCCUUCCCUUAAAUU 1927 D-1420 1377 1395 1260-1278 UUAAGGGAAGGGGAAGGAUUU 425 AUCCUUCCCCUUCCCUUAAUU 1928 D-1421 1378 1396 1261-1279 UAAGGGAAGGGGAAGGAUAUU 426 UAUCCUUCCCCUUCCCUUAUU 1929 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1422 1379 1397 1262-1280 AAGGGAAGGGGAAGGAUAGUU 427 CUAUCCUUCCCCUUCCCUUUU 1930 D-1423 1380 1398 1263-1281 AGGGAAGGGGAAGGAUAGGUU 428 CCUAUCCUUCCCCUUCCCUUU 1931 D-1424 1381 1399 1264-1282 GGGAAGGGGAAGGAUAGGGUU 429 CCCUAUCCUUCCCCUUCCCUU 1932 D-1425 138-156 138-156 UCUGUUUACUGUCCAAAGUUU 430 ACU U U GG ACAG U AAACAG AU U 1933 D-1426 1382 1400 1265-1283 GGAAGGGGAAGGAUAGGGUUU 431 ACCCUAUCCUUCCCCUUCCUU 1934 D-1427 1383 1401 1266-1284 GAAGGGGAAGGAUAGGGUGUU 432 CACCCUAUCCUUCCCCUUCUU 1935 D-1428 1384 1402 1267-1285 AAGGGGAAGGAUAGGGUGAUU 433 UCACCCUAUCCUUCCCCUUUU 1936 D-1429 1385 1403 1268-1286 AGGGGAAGGAUAGGGUGAUUU 434 AUCACCCUAUCCUUCCCCUUU 1937 D-1430 1386 1404 1269-1287 GGGGAAGGAUAGGGUGAUGUU 435 CAUCACCCUAUCCUUCCCCUU 1938 D-1431 1387 1405 1270-1288 GGGAAGGAUAGGGUGAUGUUU 436 ACAUCACCCUAUCCUUCCCUU 1939 D-1432 1388 1406 1271-1289 GGAAGGAUAGGGUGAUGUUUU 437 AACAUCACCCUAUCCUUCCUU 1940 D-1433 1389 1407 1272-1290 GAAGGAUAGGGUGAUGUUCUU 438 GAACAUCACCCUAUCCUUCUU 1941 D-1434 1390 1408 1273-1291 AAGGAUAGGGUGAUGUUCCUU 439 GGAACAUCACCCUAUCCUUUU 1942 D-1435 1391 1409 1274-1292 AGGAUAGGGUGAUGUUCCGUU 440 CGGAACAUCACCCUAUCCUUU 1943 D-1436 139-157 139-157 CUGUUUACUGUCCAAAGUCUU 441 GACUUUGGACAGUAAACAGUU 1944 D-1437 1392 1410 1275-1293 GGAUAGGGUGAUGUUCCGAUU 442 UCGGAACAUCACCCUAUCCU U 1945 D-1438 1393 1411 1276-1294 GAUAGGGUGAUGUUCCGAAUU 443 UUCGGAACAUCACCCUAUCUU 1946 D-1439 1394 1412 1277-1295 AUAGGGUGAUGUUCCGAAGUU 444 CUUCGGAACAUCACCCUAUUU 1947 D-1440 1395 1413 1278-1296 UAGGGUGAUGUUCCGAAGGUU 445 CCU UCGGAACAUCACCCUAU U 1948 D-1441 1396 1414 1279-1297 AGGGUGAUGUUCCGAAGGUUU 446 ACCUUCGGAACAUCACCCUUU 1949 D-1442 1397 1415 1280-1298 GGGUGAUGUUCCGAAGGUGUU 447 CACCUUCGGAACAUCACCCUU 1950 D-1443 1398 1416 1281-1299 GGUGAUGUUCCGAAGGUGAUU 448 UCACCUUCGGAACAUCACCUU 1951 D-1444 1399 1417 1282-1300 GUGAUGUUCCGAAGGUGAGUU 449 CUCACCUUCGGAACAUCACUU 1952 D-1445 1400 1418 1283-1301 UGAUGUUCCGAAGGUGAGGUU 450 CCUCACCUUCGGAACAUCAUU 1953 D-1446 1401 1419 1284-1302 GAUGUUCCGAAGGUGAGGAUU 451 UCCUCACCUUCGGAACAUCUU 1954 D-1447 140-158 140-158 UGUUUACUGUCCAAAGUCCUU 452 GGACUUUGGACAGUAAACAUU 1955 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1448 1402 1420 1285-1303 AUGUUCCGAAGGUGAGGAGUU 453 CUCCUCACCUUCGGAACAUUU 1956 D-1449 1403 1421 1286-1304 UGUUCCGAAGGUGAGGAGCUU 454 GCUCCUCACCUUCGGAACAUU 1957 D-1450 1404 1422 1287-1305 GUUCCGAAGGUGAGGAGCUUU 455 AGCUCCUCACCUUCGGAACUU 1958 D-1451 1405 1423 1288-1306 UUCCGAAGGUGAGGAGCUUUU 456 AAGCUCCUCACCUUCGGAAUU 1959 D-1452 1406 1424 1289-1307 UCCGAAGGUGAGGAGCUUGUU 457 CAAGCUCCUCACCUUCGGAUU 1960 D-1453 1407 1425 1290-1308 CCGAAGGUGAGGAGCUUGAUU 458 UCAAGCUCCUCACCUUCGGUU 1961 D-1454 1408 1426 1291-1309 CGAAGGUGAGGAGCUUGAAUU 459 UUCAAGCUCCUCACCUUCGUU 1962 D-1455 1409 1427 1292-1310 GAAGGUGAGGAGCUUGAAAUU 460 UUUCAAGCUCCUCACCUUCUU 1963 D-1456 1410 1428 1293-1311 AAGGUGAGGAGCUUGAAACUU 461 GUUUCAAGCUCCUCACCUUUU 1964 D-1457 1411 1429 1294-1312 AGGUGAGGAGCUUGAAACCUU 462 GGUUUCAAGCUCCUCACCUUU 1965 D-1458 141-159 141-159 GUUUACUGUCCAAAGUCCCUU 463 GGGACUUUGGACAGUAAACUU 1966 D-1459 1412 1430 1295-1313 GGUGAGGAGCUUGAAACCCUU 464 GGGUUUCAAGCUCCUCACCUU 1967 D-1460 1413 1431 1296-1314 GUGAGGAGCUUGAAACCCGUU 465 CGGGUUUCAAGCUCCUCACUU 1968 D-1461 1414 1432 1297-1315 UGAGGAGCUUGAAACCCGUUU 466 ACGGGUUUCAAGCUCCUCAUU 1969 D-1462 1415 1433 1298-1316 GAGGAGCUUGAAACCCGUGUU 467 CACGGGUUUCAAGCUCCUCUU 1970 D-1463 1416 1434 1299-1317 AGGAGCUUGAAACCCGUGGUU 468 CCACGGGUUUCAAGCUCCUUU 1971 D-1464 1417 1435 1300-1318 GGAGCUUGAAACCCGUGGCUU 469 GCCACGGGUUUCAAGCUCCUU 1972 D-1465 1418 1436 1301-1319 GAGCUUGAAACCCGUGGCGUU 470 CGCCACGGGUUUCAAGCUCUU 1973 D-1466 1419 1437 1302-1320 AGCUUGAAACCCGUGGCGCUU 471 GCGCCACGGGUUUCAAGCUUU 1974 D-1467 1420 1438 1303-1321 GCUUGAAACCCGUGGCGCUUU 472 AGCGCCACGGGUUUCAAGCUU 1975 D-1468 1421 1439 1304-1322 CUUGAAACCCGUGGCGCUUUU 473 AAGCGCCACGGGUUUCAAGUU 1976 D-1469 142-160 142-160 UUUACUGUCCAAAGUCCCGUU 474 CGGGACUUUGGACAGUAAAUU 1977 D-1470 1422 1440 1305-1323 UUGAAACCCGUGGCGCUUUUU 475 AAAGCGCCACGGGUUUCAAUU 1978 D-1471 1423 1441 1306-1324 UGAAACCCGUGGCGCUUUCUU 476 GAAAG CGCCACGGGUUUCAUU 1979 D-1472 1424 1442 1307-1325 GAAACCCGUGGCGCUUUCUUU 477 AGAAAGCGCCACGGGUUUCUU 1980 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1473 1425 1443 1308-1326 AAACCCGUGGCGCUUUCUGUU 478 CAGAAAGCGCCACGGGUUUUU 1981 D-1474 1426 1444 1309-1327 AACCCGUGGCGCUUUCUGCUU 479 GCAGAAAGCGCCACGGGUUUU 1982 D-1475 1427 1445 1310-1328 ACCCGUGGCGCUUUCUGCAUU 480 UGCAGAAAGCGCCACGGGUUU 1983 D-1476 1428 1446 1311-1329 CCCGUGGCGCUUUCUGCAGUU 481 CUGCAGAAAGCGCCACGGGUU 1984 D-1477 1429 1447 1312-1330 CCGUGGCGCUUUCUGCAGUUU 482 ACU G CAGAAAG CGCCACGGUU 1985 D-1478 1430 1448 1313-1331 CGUGGCGCUUUCUGCAGUUUU 483 AACUGCAGAAAGCGCCACGUU 1986 D-1479 1431 1449 1314-1332 GUGGCGCUUUCUGCAGUUUUU 484 AAACUGCAGAAAGCGCCACUU 1987 D-1480 143-161 143-161 UUACUGUCCAAAGUCCCGGUU 485 CCGGGACUUUGGACAGUAAUU 1988 D-1481 14-32 14-32 CGGAAGAGUGAGGUGACUGUU 486 CAGUCACCUCACUCUUCCGUU 1989 D-1482 1432 1450 1315-1333 UGGCGCUUUCUGCAGUUUGUU 487 CAAACUGCAGAAAGCGCCAUU 1990 D-1483 1433 1451 1316-1334 GGCGCUUUCUGCAGUUUGCUU 488 GCAAACUGCAGAAAGCGCCUU 1991 D-1484 1434 1452 1317-1335 GCGCUUUCUGCAGUUUGCAUU 489 UGCAAACUGCAGAAAGCGCUU 1992 D-1485 1435 1453 1318-1336 CGCUUUCUGCAGUUUGCAGUU 490 CUGCAAACUGCAGAAAGCGUU 1993 D-1486 1436 1454 1319-1337 GCUUUCUGCAGUUUGCAGGUU 491 CCUGCAAACUGCAGAAAGCUU 1994 D-1487 1437 1455 1320-1338 CUUUCUGCAGUUUGCAGGUUU 492 ACCUGCAAACUGCAGAAAGUU 1995 D-1488 1438 1456 1321-1339 UUUCUGCAGUUUGCAGGUUUU 493 AACCUGCAAACUGCAGAAAUU 1996 D-1489 1439 1457 1322-1340 UUCUGCAGUUUGCAGGUUAUU 494 UAACCUGCAAACUGCAGAAUU 1997 D-1490 1440 1458 1323-1341 UCUGCAGUUUGCAGGUUAUUU 495 AUAACCUGCAAACUGCAGAUU 1998 D-1491 1441 1459 1324-1342 CUGCAGUUUGCAGGUUAUCUU 496 GAUAACCUGCAAACUGCAGUU 1999 D-1492 144-162 144-162 UACUGUCCAAAGUCCCGGGUU 497 CCCGGGACUUUGGACAGUAUU 2000 D-1493 1442 1460 1325-1343 UGCAGUUUGCAGGUUAUCAUU 498 UGAUAACCUGCAAACUGCAUU 2001 D-1494 1443 1461 1326-1344 GCAGUUUGCAGGUUAUCAUUU 499 AUGAUAACCUGCAAACUGCUU 2002 D-1495 1444 1462 1327-1345 CAGUUUGCAGGUUAUCAUUUU 500 AAUGAUAACCUGCAAACUGUU 2003 D-1496 1445 1463 1328-1346 AGUUUGCAGGUUAUCAUUGUU 501 CAAUGAUAACCUGCAAACUUU 2004 D-1497 1446 1464 1329-1347 GUUUGCAGGUUAUCAUUGUUU 502 ACAAUGAUAACCU GCAAACU U 2005 D-1498 1447 1465 1330-1348 UUUGCAGGUUAUCAUUGUGUU 503 CACAAUGAUAACCUGCAAAUU 2006 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1499 1448 1466 1331-1349 UUGCAGGUUAUCAUUGUGAUU 504 UCACAAUGAUAACCUGCAAUU 2007 D-1500 1449 1467 1332-1350 UGCAGGUUAUCAUUGUGAAUU 505 UUCACAAUGAUAACCUGCAUU 2008 D-1501 1450 1468 1333-1351 GCAGGUUAUCAUUGUGAACUU 506 GUUCACAAUGAUAACCUGCUU 2009 D-1502 1451 1469 1334-1352 CAGGUUAUCAUUGUGAACUUU 507 AGUUCACAAUGAUAACCUGUU 2010 D-1503 145-163 145-163 ACUGUCCAAAGUCCCGGGCUU 508 GCCCGGGACUUUGGACAGUUU 2011 D-1504 1452 1470 1335-1353 AGGUUAUCAUUGUGAACUUUU 509 AAGUUCACAAUGAUAACCUUU 2012 D-1505 1453 1471 1336-1354 GGUUAUCAUUGUGAACUUUUU 510 AAAGUUCACAAUGAUAACCUU 2013 D-1506 1454 1472 1337-1355 GUUAUCAUUGUGAACUUUUUU 511 AAAAGUUCACAAUGAUAACUU 2014 D-1507 1455 1473 1338-1356 UUAUCAUUGUGAACUUUUUUU 512 AAAAAGUUCACAAUGAUAAUU 2015 D-1508 1456 1474 1339-1357 UAUCAUUGUGAACUUUUUUUU 513 AAAAAAGUUCACAAUGAUAUU 2016 D-1509 1457 1475 1340-1358 AUCAUUGUGAACUUUUUUUUU 514 AAAAAAAGU U CACAAU GAU U U 2017 D-1510 1458 1476 1341-1359 UCAUUGUGAACUUUUUUUUUU 515 AAAAAAAAGUUCACAAUGAUU 2018 D-1511 1459 1477 1342-1360 CAUUGUGAACUUUUUUUUUUU 516 AAAAAAAAAG U U CACAAU G U U 2019 D-1512 1460 1478 1343-1361 AUUGUGAACUUUUUUUUUUUU 517 AAAAAAAAAAG U U CACAAU U U 2020 D-1513 1461 1479 1344-1362 UUGUGAACUUUUUUUUUUUUU 518 AAAAAAAAAAAG U U CACAAU U 2021 D-1514 146-164 146-164 CUGUCCAAAGUCCCGGGCAUU 519 UGCCCGGGACUUUGGACAGUU 2022 D-1515 1462 1480 1345-1363 UGUGAACUUUUUUUUUUUAUU 520 UAAAAAAAAAAAG U UCACAU U 2023 D-1516 1463 1481 1346-1364 GUGAACUUUUUUUUUUUAAUU 521 U UAAAAAAAAAAAG U UCACU U 2024 D-1517 1464 1482 1347-1365 UGAACUUUUUUUUUUUAAGUU 522 CUUAAAAAAAAAAAGUUCAUU 2025 D-1518 1465 1483 1348-1366 GAACUUUUUUUUUUUAAGAUU 523 UCU UAAAAAAAAAAAG U UCU U 2026 D-1519 1466 1484 1349-1367 AACUUUUUUUUUUUAAGAGUU 524 CUCU UAAAAAAAAAAAG U U U U 2027 D-1520 1467 1485 1350-1368 ACUUUUUUUUUUUAAGAGUUU 525 ACU CU U AAAAAAAAAAAG U U U 2028 D-1521 1468 1486 1351-1369 CUUUUUUUUUUUAAGAGUAUU 526 UACUCU UAAAAAAAAAAAG U U 2029 D-1522 1469 1487 1352-1370 UUUUUUUUUUUAAGAGUAAUU 527 UUACUCUUAAAAAAAAAAAUU 2030 D-1523 1470 1488 1353-1371 UUUUUUUUUUAAGAGUAAAUU 528 UUUACUCUUAAAAAAAAAAUU 2031 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1524 1471 1489 1354-1372 UUUUUUUUUAAGAGUAAAAUU 529 UUUUACUCUUAAAAAAAAAUU 2032 D-1525 147-165 147-165 UGUCCAAAGUCCCGGGCACUU 530 GUGCCCGGGACUUUGGACAUU 2033 D-1526 1472 1490 1355-1373 U U U U U U U U AAG AG U AAAAAU U 531 UUUUUACUCUUAAAAAAAAUU 2034 D-1527 1473 1491 1356-1374 U U U U U U U AAG AG U AAAAAG U U 532 CUUUUUACUCUUAAAAAAAUU 2035 D-1528 1474 1492 1357-1375 U U U U U UAAGAG UAAAAAGAU U 533 UCUUUUUACUCUUAAAAAAUU 2036 D-1529 1475 1493 1358-1376 U U U U UAAGAG U AAAAAG AAU U 534 UUCUUUUUACUCUUAAAAAUU 2037 D-1530 1476 1494 1359-1377 U U U UAAGAG UAAAAAGAAAU U 535 UUUCUUUUUACUCUUAAAAUU 2038 D-1531 1477 1495 1360-1378 UUUAAGAGUAAAAAGAAAUUU 536 AUUUCUUUUUACUCUUAAAUU 2039 D-1532 1478 1496 1361-1379 UUAAGAGUAAAAAGAAAUAUU 537 UAUUUCUUUUUACUCUUAAUU 2040 D-1533 1479 1497 1362-1380 UAAGAGUAAAAAGAAAUAU U U 538 AUAUUUCUUUUUACUCUUAUU 2041 D-1534 1480 1498 1363-1381 AAGAGUAAAAAGAAAUAUAUU 539 UAUAUUUCUUUUUACUCUUUU 2042 D-1535 1481 1499 1364-1382 AGAGUAAAAAGAAAUAUACUU 540 GUAUAUUUCUUUUUACUCUUU 2043 D-1536 148-166 148-166 GUCCAAAGUCCCGGGCACUUU 541 AGUGCCCGGGACUUUGGACUU 2044 D-1537 1482 1500 1365-1383 GAGUAAAAAGAAAUAUACCUU 542 GGUAUAUUUCUUUUUACUCUU 2045 D-1538 1483 1501 — AG UAAAAAGAAAUAUACCU U U 543 AGGUAUAUUUCUUUUUACUUU 2046 D-1539 1484 1502 — GUAAAAAGAAAUAUACCUAUU 544 UAGGUAUAUUUCUUUUUACUU 2047 D-1540 1485 1503 — UAAAAAGAAAUAUACCUAAUU 545 UUAGGUAUAUUUCUUUUUAUU 2048 D-1541 149-167 149-167 UCCAAAGUCCCGGGCACUGUU 546 CAGUGCCCGGGACUUUGGAUU 2049 D-1542 150-168 150-168 CCAAAGUCCCGGGCACUGGUU 547 CCAGUGCCCGGGACUUUGGUU 2050 D-1543 151-169 151-169 CAAAGUCCCGGGCACUGGAUU 548 UCCAGUGCCCGGGACUUUGUU 2051 D-1544 152-170 152-170 AAAGUCCCGGGCACUGGAGUU 549 CUCCAGUGCCCGGGACUUUUU 2052 D-1545 153-171 153-171 AAGUCCCGGGCACUGGAGAUU 550 UCUCCAGUGCCCGGGACUUUU 2053 D-1546 15-33 15-33 GGAAGAGUGAGGUGACUGGUU 551 CCAGUCACCUCACUCUUCCUU 2054 D-1547 154-172 154-172 AGUCCCGGGCACUGGAGAUUU 552 AUCUCCAGUGCCCGGGACUUU 2055 D-1548 155-173 155-173 GUCCCGGGCACUGGAGAUGUU 553 CAUCUCCAGUGCCCGGGACUU 2056 D-1549 156-174 156-174 UCCCGGGCACUGGAGAUGCUU 554 GCAUCUCCAGUGCCCGGGAUU 2057 D-1550 157-175 157-175 CCCGGGCACUGGAGAUGCCUU 555 GGCAUCUCCAGUGCCCGGGUU 2058 D-1551 158-176 158-176 CCGGGCACUGGAGAUGCCAUU 556 UGGCAUCUCCAGUGCCCGGUU 2059 D-1552 159-177 159-177 CGGGCACUGGAGAUGCCACUU 557 GUGGCAUCUCCAGUGCCCGUU 2060 D-1553 160-178 160-178 GGGCACUGGAGAUGCCACGUU 558 CGUGGCAUCUCCAGUGCCCUU 2061 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1554 161-179 161-179 GGCACUGGAGAUGCCACGUUU 559 ACGUGGCAUCUCCAGUGCCUU 2062 D-1555 162-180 162-180 GCACUGGAGAUGCCACGUUUU 560 AACGUGGCAUCUCCAGUGCUU 2063 D-1556 163-181 163-181 CACUGGAGAUGCCACGUUUUU 561 AAACGUGGCAUCUCCAGUGUU 2064 D-1557 16-34 16-34 GAAGAGUGAGGUGACUGGCUU 562 GCCAGUCACCUCACUCUUCUU 2065 D-1558 164-182 164-182 ACUGGAGAUGCCACGUUUGUU 563 CAAACGUGGCAUCUCCAGUUU 2066 D-1559 165-183 165-183 CUGGAGAUGCCACGUUUGGUU 564 CCAAACGUGGCAUCUCCAGUU 2067 D-1560 166-184 166-184 UGGAGAUGCCACGUUUGGCUU 565 GCCAAACGUGGCAUCUCCAUU 2068 D-1561 167-185 167-185 GGAGAUGCCACGUUUGGCGUU 566 CGCCAAACGUGGCAUCUCCUU 2069 D-1562 168-186 168-186 GAGAUGCCACGUUUGGCGUUU 567 ACGCCAAACGUGGCAUCUCUU 2070 D-1563 169-187 169-187 AGAUGCCACGUUUGGCGUGUU 568 CACG CCAAACG UGGCAUCUUU 2071 D-1564 170-188 170-188 GAUGCCACGUUUGGCGUGCUU 569 GCACGCCAAACGUGGCAUCUU 2072 D-1565 171-189 171-189 AUGCCACGUUUGGCGUGCUUU 570 AGCACGCCAAACGUGGCAUUU 2073 D-1566 172-190 172-190 UGCCACGUUUGGCGUGCUUUU 571 AAGCACGCCAAACGUGGCAUU 2074 D-1567 173-191 173-191 GCCACGUUUGGCGUGCUUGUU 572 CAAGCACGCCAAACGUGGCUU 2075 D-1568 17-35 17-35 AAGAGUGAGGUGACUGGCAUU 573 UGCCAGUCACCUCACUCUUUU 2076 D-1569 174-192 174-192 CCACGUUUGGCGUGCUUGGUU 574 CCAAGCACGCCAAACGUGGUU 2077 D-1570 175-193 175-193 CACGUUUGGCGUGCUUGGAUU 575 U CCAAG CACGCCAAACG U G U U 2078 D-1571 176-194 176-194 ACGUUUGGCGUGCUUGGACUU 576 GUCCAAGCACGCCAAACGUUU 2079 D-1572 177-195 177-195 CGUUUGGCGUGCUUGGACAUU 577 U G U CCAAG CACG CCAAACG U U 2080 D-1573 178-196 178-196 GUUUGGCGUGCUUGGACACUU 578 G U G U CCAAG CACGCCAAACU U 2081 D-1574 179-197 179-197 UUUGGCGUGCUUGGACACAUU 579 UGUGUCCAAGCACGCCAAAUU 2082 D-1575 180-198 180-198 UUGGCGUGCUUGGACACACUU 580 GUGUGUCCAAGCACGCCAAUU 2083 D-1576 181-199 181-199 UGGCGUGCUUGGACACACAUU 581 U G U G U G U CCAAG CACGCCAU U 2084 D-1577 182-200 182-200 GGCGUGCUUGGACACACAGUU 582 CUGUGUGUCCAAGCACGCCUU 2085 D-1578 183-201 183-201 GCGUGCUUGGACACACAGAUU 583 UCUGUGUGUCCAAGCACGCUU 2086 D-1579 18-36 18-36 AGAGUGAGGUGACUGGCAUUU 584 AUGCCAGUCACCUCACUCUUU 2087 D-1580 184-202 184-202 CGUGCUUGGACACACAGACUU 585 GUCUGUGUGUCCAAGCACGUU 2088 D-1581 185-203 185-203 GUGCUUGGACACACAGACAUU 586 UGUCUGUGUGUCCAAGCACUU 2089 D-1582 186-204 186-204 UGCUUGGACACACAGACACUU 587 GUGUCUGUGUGUCCAAGCAUU 2090 D-1583 187-205 187-205 GCU UGGACACACAGACACG U U 588 CGUGUCUGUGUGUCCAAGCUU 2091 D-1584 188-206 188-206 CUUGGACACACAGACACGCUU 589 GCGUGUCUGUGUGUCCAAGUU 2092 D-1585 189-207 189-207 U U G GACACACAGACACG CAU U 590 UGCGUGUCUGUGUGUCCAAUU 2093 D-1586 190-208 190-208 U G GACACACAGACACG CAG U U 591 CUGCGUGUCUGUGUGUCCAUU 2094 D-1587 191-209 191-209 GGACACACAGACACGCAGAUU 592 UCUGCGUGUCUGUGUGUCCUU 2095 D-1588 192-210 192-210 GACACACAGACACGCAGACUU 593 GUCUGCGUGUCUGUGUGUCUU 2096 D-1589 193-211 193-211 ACACACAGACACGCAGACAU U 594 UGUCUGCGUGUCUGUGUGUUU 2097 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1590 19-37 19-37 GAGUGAGGUGACUGGCAUGUU 595 CAUGCCAGUCACCUCACUCUU 2098 D-1591 194-212 194-212 CACACAGACACGCAGACACUU 596 GUGUCUGCGUGUCUGUGUGUU 2099 D-1592 195-213 195-213 ACACAGACACGCAGACACAUU 597 UGUGUCUGCGUGUCUGUGUUU 2100 D-1593 196-214 196-214 CACAGACACGCAGACACAG U U 598 CUGUGUCUGCGUGUCUGUGUU 2101 D-1594 197-215 197-215 ACAGACACGCAGACACAGAUU 599 UCUGUGUCUGCGUGUCUGUUU 2102 D-1595 198-216 198-216 CAGACACGCAGACACAGAG U U 600 CUCUGUGUCUGCGUGUCUGUU 2103 D-1596 199-217 199-217 AGACACGCAGACACAGAGAU U 601 UCUCUGUGUCUGCGUGUCUUU 2104 D-1597 200-218 200-218 GACACGCAGACACAGAGACUU 602 GUCUCUGUGUCUGCGUGUCUU 2105 D-1598 201-219 201-219 ACACGCAGACACAGAGACAUU 603 UGUCUCUGUGUCUGCGUGUUU 2106 D-1599 202-220 202-220 CACGCAGACACAGAGACACU U 604 GUGUCUCUGUGUCUGCGUGUU 2107 D-1600 203-221 203-221 ACGCAGACACAGAGACACCU U 605 GGUGUCUCUGUGUCUGCGUUU 2108 D-1601 20-38 20-38 AGUGAGGUGACUGGCAUGUUU 606 ACAUGCCAGUCACCUCACUUU 2109 D-1602 204-222 204-222 CGCAGACACAGAGACACCG U U 607 CGGUGUCUCUGUGUCUGCGUU 2110 D-1603 205-223 205-223 GCAGACACAGAGACACCGG U U 608 CCGGUGUCUCUGUGUCUGCUU 2111 D-1604 206-224 206-224 CAGACACAGAGACACCGGG U U 609 CCCGGUGUCUCUGUGUCUGUU 2112 D-1605 207-225 207-225 AGACACAGAGACACCGGGGUU 610 CCCCGGUGUCUCUGUGUCUUU 2113 D-1606 208-226 208-226 GACACAGAGACACCGGGGCUU 611 GCCCCGGUGUCUCUGUGUCUU 2114 D-1607 209-227 209-227 ACACAGAGACACCGGGGCCUU 612 GGCCCCGGUGUCUCUGUGUUU 2115 D-1608 210-228 210-228 CACAGAGACACCGGGGCCCUU 613 GGGCCCCGGUGUCUCUGUGUU 2116 D-1609 211-229 211-229 ACAGAGACACCGGGGCCCAUU 614 UGGGCCCCGGUGUCUCUGUUU 2117 D-1610 212-230 212-230 CAGAGACACCGGGGCCCAGUU 615 CUGGGCCCCGGUGUCUCUGUU 2118 D-1611 213-231 213-231 AGAGACACCGGGGCCCAGGUU 616 CCUGGGCCCCGGUGUCUCUUU 2119 D-1612 21-39 21-39 GUGAGGUGACUGGCAUGUGUU 617 CACAUGCCAGUCACCUCACUU 2120 D-1613 214-232 214-232 GAGACACCGGGGCCCAGGGUU 618 CCCUGGGCCCCGGUGUCUCUU 2121 D-1614 215-233 215-233 AGACACCGGGGCCCAGGGCUU 619 GCCCUGGGCCCCGGUGUCUUU 2122 D-1615 216-234 216-234 GACACCGGGGCCCAGGGCCUU 620 GGCCCUGGGCCCCGGUGUCUU 2123 D-1616 217-235 217-235 ACACCGGGGCCCAGGGCCCUU 621 GGGCCCUGGGCCCCGGUGUUU 2124 D-1617 218-236 218-236 CACCGGGGCCCAGGGCCCUUU 622 AGGGCCCUGGGCCCCGGUGUU 2125 D-1618 219-237 219-237 ACCGGGGCCCAGGGCCCUCUU 623 GAGGGCCCUGGGCCCCGGUUU 2126 D-1619 2-20 2-20 CCAAACGGUGCACGGAAGAUU 624 UCUUCCGUGCACCGUUUGGUU 2127 D-1620 220-238 220-238 CCGGGGCCCAGGGCCCUCCUU 625 GGAGGGCCCUGGGCCCCGGUU 2128 D-1621 221-239 221-239 CGGGGCCCAGGGCCCUCCUUU 626 AGGAGGGCCCUGGGCCCCGUU 2129 D-1622 222-240 222-240 GGGGCCCAGGGCCCUCCUAUU 627 UAGGAGGGCCCUGGGCCCCUU 2130 D-1623 223-241 223-241 GGGCCCAGGGCCCUCCUAUUU 628 AUAGGAGGGCCCUGGGCCCUU 2131 D-1624 22-40 22-40 UGAGGUGACUGGCAUGUGUUU 629 ACACAUGCCAGUCACCUCAUU 2132 D-1625 224-242 224-242 GGCCCAGGGCCCUCCUAUGUU 630 CAUAGGAGGGCCCUGGGCCUU 2133 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1626 225-243 225-243 GCCCAGGGCCCUCCUAUGGUU 631 CCAUAGGAGGGCCCUGGGCUU 2134 D-1627 226-244 226-244 CCCAGGGCCCUCCUAUGGAUU 632 UCCAUAGGAGGGCCCUGGGUU 2135 D-1628 227-245 227-245 CCAGGGCCCUCCUAUGGACUU 633 GUCCAUAGGAGGGCCCUGGUU 2136 D-1629 228-246 228-246 CAGGGCCCUCCUAUGGACCUU 634 GGUCCAUAGGAGGGCCCUGUU 2137 D-1630 229-247 229-247 AGGGCCCUCCUAUGGACCCUU 635 GGGUCCAUAGGAGGGCCCUUU 2138 D-1631 230-248 230-248 GGGCCCUCCUAUGGACCCUUU 636 AGGGUCCAUAGGAGGGCCCUU 2139 D-1632 231-249 231-249 GGCCCUCCUAUGGACCCUGUU 637 CAGGGUCCAUAGGAGGGCCUU 2140 D-1633 232-250 232-250 GCCCUCCUAUGGACCCUGCUU 638 GCAGGGUCCAUAGGAGGGCUU 2141 D-1634 233-251 233-251 CCCUCCUAUGGACCCUGCCUU 639 GGCAGGGUCCAUAGGAGGGUU 2142 D-1635 23-41 23-41 GAGGUGACUGGCAUGUGUGUU 640 CACACAUGCCAGUCACCUCUU 2143 D-1636 234-252 234-252 CCUCCUAUGGACCCUGCCCUU 641 GGGCAGGGUCCAUAGGAGGUU 2144 D-1637 235-253 235-253 CUCCUAUGGACCCUGCCCGUU 642 CGGGCAGGGUCCAUAGGAGUU 2145 D-1638 236-254 236-254 UCCUAUGGACCCUGCCCGCUU 643 GCGGGCAGGGUCCAUAGGAUU 2146 D-1639 237-255 237-255 CCUAUGGACCCUGCCCGCUUU 644 AGCGGGCAGGGUCCAUAGGUU 2147 D-1640 238-256 238-256 CUAUGGACCCUGCCCGCUCUU 645 GAGCGGGCAGGGUCCAUAGUU 2148 D-1641 239-257 239-257 UAUGGACCCUGCCCGCUCCUU 646 GGAGCGGGCAGGGUCCAUAUU 2149 D-1642 240-258 240-258 AUGGACCCUGCCCGCUCCCUU 647 GGGAGCGGGCAGGGUCCAUUU 2150 D-1643 241-259 241-259 UGGACCCUGCCCGCUCCCCUU 648 GGGGAGCGGGCAGGGUCCAUU 2151 D-1644 242-260 242-260 GGACCCUGCCCGCUCCCCUUU 649 AGGGGAGCGGGCAGGGUCCUU 2152 D-1645 243-261 243-261 GACCCUGCCCGCUCCCCUCUU 650 GAGGGGAGCGGGCAGGGUCUU 2153 D-1646 24-42 24-42 AGGUGACUGGCAUGUGUGGUU 651 CCACACAUGCCAGU CACCU U U 2154 D-1647 244-262 244-262 ACCCUGCCCGCUCCCCUCCUU 652 GGAGGGGAGCGGGCAGGGUUU 2155 D-1648 245-263 245-263 CCCUGCCCGCUCCCCUCCCUU 653 GGGAGGGGAGCGGGCAGGGUU 2156 D-1649 246-264 246-264 CCUGCCCGCUCCCCUCCCAUU 654 UGGGAGGGGAGCGGGCAGGUU 2157 D-1650 247-265 247-265 CUGCCCGCUCCCCUCCCAUUU 655 AUGGGAGGGGAGCGGGCAGUU 2158 D-1651 248-266 248-266 UGCCCGCUCCCCUCCCAUUUU 656 AAUGGGAGGGGAGCGGGCAUU 2159 D-1652 249-267 249-267 GCCCGCUCCCCUCCCAUUGUU 657 CAAUGGGAGGGGAGCGGGCUU 2160 D-1653 250-268 250-268 CCCGCUCCCCUCCCAUUGUUU 658 ACAAUGGGAGGGGAGCGGGUU 2161 D-1654 251-269 251-269 CCGCUCCCCUCCCAUUGUCUU 659 GACAAUGGGAGGGGAGCGGUU 2162 D-1655 252-270 252-270 CGCUCCCCUCCCAUUGUCCUU 660 GGACAAUGGGAGGGGAGCGUU 2163 D-1656 253-271 253-271 GCUCCCCUCCCAUUGUCCAUU 661 UGGACAAUGGGAGGGGAGCUU 2164 D-1657 254-272 254-272 CUCCCCUCCCAUUGUCCACUU 662 GUGGACAAUGGGAGGGGAGUU 2165 D-1658 25-43 25-43 GGUGACUGGCAUGUGUGGGUU 663 CCCACACAUGCCAGUCACCUU 2166 D-1659 255-273 255-273 UCCCCUCCCAUUGUCCACGUU 664 CGUGGACAAUGGGAGGGGAUU 2167 D-1660 256-274 256-274 CCCCUCCCAUUGUCCACGGUU 665 CCGUGGACAAUGGGAGGGGUU 2168 D-1661 257-275 257-275 CCCUCCCAUUGUCCACGGCUU 666 GCCGUGGACAAUGGGAGGGUU 2169 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1662 258-276 258-276 CCUCCCAUUGUCCACGGCUUU 667 AGCCGUGGACAAUGGGAGGUU 2170 D-1663 259-277 259-277 CUCCCAUUGUCCACGGCUGUU 668 CAGCCGUGGACAAUGGGAGUU 2171 D-1664 260-278 260-278 UCCCAUUGUCCACGGCUGUUU 669 ACAGCCGUGGACAAUGGGAUU 2172 D-1665 261-279 261-279 CCCAUUGUCCACGGCUGUCUU 670 GACAGCCGUGGACAAUGGGUU 2173 D-1666 262-280 262-280 CCAUUGUCCACGGCUGUCCUU 671 GGACAGCCGUGGACAAUGGUU 2174 D-1667 263-281 263-281 CAUUGUCCACGGCUGUCCGUU 672 CGGACAGCCGUGGACAAUGUU 2175 D-1668 264-282 264-282 AUUGUCCACGGCUGUCCGCUU 673 GCGGACAGCCGUGGACAAUUU 2176 D-1669 26-44 26-44 GUGACUGGCAUGUGUGGGGUU 674 CCCCACACAUGCCAGUCACUU 2177 D-1670 265-283 265-283 UUGUCCACGGCUGUCCGCCUU 675 GGCGGACAGCCGUGGACAAUU 2178 D-1671 266-284 266-284 UGUCCACGGCUGUCCGCCCUU 676 GGGCGGACAGCCGUGGACAUU 2179 D-1672 267-285 267-285 GUCCACGGCUGUCCGCCCAUU 677 UGGGCGGACAGCCGUGGACUU 2180 D-1673 268-286 268-286 UCCACGGCUGUCCGCCCACUU 678 GUGGGCGGACAGCCGUGGAUU 2181 D-1674 269-287 269-287 CCACGGCUGUCCGCCCACCUU 679 GGUGGGCGGACAGCCGUGGUU 2182 D-1675 270-288 270-288 CACGGCUGUCCGCCCACCCUU 680 GGGUGGGCGGACAGCCGUGUU 2183 D-1676 271-289 271-289 ACGGCUGUCCGCCCACCCCUU 681 GGGGUGGGCGGACAGCCGUUU 2184 D-1677 272-290 272-290 CGGCUGUCCGCCCACCCCCUU 682 GGGGGUGGGCGGACAGCCGUU 2185 D-1678 273-291 273-291 GGCUGUCCGCCCACCCCCAUU 683 UGGGGGUGGGCGGACAGCCUU 2186 D-1679 274-292 274-292 GCUGUCCGCCCACCCCCAUUU 684 AUGGGGGUGGGCGGACAGCUU 2187 D-1680 27-45 27-45 UGACUGGCAUGUGUGGGGGUU 685 CCCCCACACAUGCCAGUCAUU 2188 D-1681 275-293 275-293 CUGUCCGCCCACCCCCAUUUU 686 AAUGGGGGUGGGCGGACAGUU 2189 D-1682 276-294 276-294 UGUCCGCCCACCCCCAUUCUU 687 GAAUGGGGGUGGGCGGACAUU 2190 D-1683 277-295 277-295 GUCCGCCCACCCCCAUUCUUU 688 AGAAUGGGGGUGGGCGGACUU 2191 D-1684 278-296 278-296 UCCGCCCACCCCCAUUCUCUU 689 GAGAAUGGGGGUGGGCGGAUU 2192 D-1685 279-297 279-297 CCGCCCACCCCCAUUCUCCUU 690 GGAGAAUGGGGGUGGGCGGUU 2193 D-1686 280-298 280-298 CGCCCACCCCCAUUCUCCAUU 691 UGGAGAAUGGGGGUGGGCGUU 2194 D-1687 281-299 281-299 GCCCACCCCCAUUCUCCAAUU 692 UUGGAGAAUGGGGGUGGGCUU 2195 D-1688 282-300 282-300 CCCACCCCCAUUCUCCAAGUU 693 CUUGGAGAAUGGGGGUGGGUU 2196 D-1689 283-301 283-301 CCACCCCCAUUCUCCAAGCUU 694 GCUUGGAGAAUGGGGGUGGUU 2197 D-1690 284-302 284-302 CACCCCCAU UCUCCAAGCU U U 695 AGCUUGGAGAAUGGGGGUGUU 2198 D-1691 28-46 28-46 GACUGGCAUGUGUGGGGGCUU 696 GCCCCCACACAUGCCAGUCUU 2199 D-1692 285-303 285-303 ACCCCCAUUCUCCAAGCUUUU 697 AAGCUUGGAGAAUGGGGGUUU 2200 D-1693 286-304 286-304 CCCCCAUUCUCCAAGCUUCUU 698 GAAGCUUGGAGAAUGGGGGUU 2201 D-1694 287-305 287-305 CCCCAUUCUCCAAGCUUCAUU 699 UGAAGCUUGGAGAAUGGGGUU 2202 D-1695 288-306 288-306 CCCAUUCUCCAAGCUUCAGUU 700 CUGAAGCUUGGAGAAUGGGUU 2203 D-1696 289-307 289-307 CCAUUCUCCAAGCUUCAGCUU 701 GCUGAAGCUUGGAGAAUGGUU 2204 D-1697 290-308 290-308 CAUUCUCCAAGCUUCAGCCUU 702 GGCUGAAGCUUGGAGAAUGUU 2205 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1698 291-309 291-309 AUUCUCCAAGCUUCAGCCCUU 703 GGGCUGAAGCUUGGAGAAUUU 2206 D-1699 292-310 292-310 UUCUCCAAGCUUCAGCCCCUU 704 GGGGCUGAAGCUUGGAGAAUU 2207 D-1700 293-311 293-311 UCUCCAAGCUUCAGCCCCCUU 705 GGGGGCUGAAGCUUGGAGAUU 2208 D-1701 294-312 294-312 CUCCAAGCUUCAGCCCCCUUU 706 AGGGGGCUGAAGCUUGGAGUU 2209 D-1702 29-47 29-47 ACUGGCAUGUGUGGGGGCAUU 707 UGCCCCCACACAUGCCAGUUU 2210 D-1703 295-313 295-313 UCCAAGCUUCAGCCCCCUCUU 708 GAGGGGGCUGAAGCUUGGAUU 2211 D-1704 296-314 296-314 CCAAGCUUCAGCCCCCUCCUU 709 GGAGGGGGCUGAAGCUUGGUU 2212 D-1705 297-315 297-315 CAAGCUUCAGCCCCCUCCUUU 710 AGGAGGGGGCUGAAGCUUGUU 2213 D-1706 298-316 298-316 AAGCUUCAGCCCCCUCCUUUU 711 AAGGAGGGGGCUGAAGCUUUU 2214 D-1707 299-317 299-317 AGCUUCAGCCCCCUCCUUAUU 712 UAAGGAGGGGGCUGAAGCUUU 2215 D-1708 300-318 300-318 GCUUCAGCCCCCUCCUUAGUU 713 CUAAGGAGGGGGCUGAAGCUU 2216 D-1709 301-319 301-319 CUUCAGCCCCCUCCUUAGUUU 714 ACUAAGGAGGGGGCUGAAGUU 2217 D-1710 302-320 302-320 UUCAGCCCCCUCCUUAGUUUU 715 AACUAAGGAGGGGGCUGAAUU 2218 D-1711 303-321 303-321 UCAGCCCCCUCCUUAGUUCUU 716 GAACUAAGGAGGGGGCUGAUU 2219 D-1712 304-322 304-322 CAGCCCCCUCCUUAGUUCGUU 717 CGAACUAAGGAGGGGGCUGUU 2220 D-1713 30-48 30-48 CUGGCAUGUGUGGGGGCAAUU 718 U UGCCCCCACACAU GCCAG U U 2221 D-1714 305-323 305-323 AGCCCCCUCCUUAGUUCGGUU 719 CCGAACUAAGGAGGGGGCUUU 2222 D-1715 306-324 306-324 GCCCCCUCCUUAGUUCGGCUU 720 GCCGAACUAAGGAGGGGGCUU 2223 D-1716 307-325 307-325 CCCCCUCCUUAGUUCGGCAUU 721 UGCCGAACUAAGGAGGGGGUU 2224 D-1717 308-326 308-326 CCCCUCCUUAGUUCGGCAUUU 722 AUGCCGAACUAAGGAGGGGUU 2225 D-1718 309-327 309-327 CCCUCCUUAGUUCGGCAUCUU 723 GAUGCCGAACUAAGGAGGGUU 2226 D-1719 310-328 310-328 CCUCCUUAGUUCGGCAUCUUU 724 AGAUGCCGAACUAAGGAGGUU 2227 D-1720 311-329 311-329 CUCCUUAGUUCGGCAUCUGUU 725 CAGAUGCCGAACUAAGGAGUU 2228 D-1721 312-330 312-330 UCCUUAGUUCGGCAUCUGCUU 726 GCAGAUGCCGAACUAAGGAUU 2229 D-1722 313-331 313-331 CCUUAGUUCGGCAUCUGCAUU TH UGCAGAUGCCGAACUAAGGUU 2230 D-1723 314-332 314-332 CUUAGUUCGGCAUCUGCACUU 728 GUGCAGAUGCCGAACUAAGUU 2231 D-1724 31-49 31-49 UGGCAUGUGUGGGGGCAACUU 729 GUUGCCCCCACACAUGCCAUU 2232 D-1725 315-333 315-333 UUAGUUCGGCAUCUGCACAUU 730 UGUGCAGAUGCCGAACUAAUU 2233 D-1726 316-334 316-334 UAGUUCGGCAUCUGCACAGUU 731 CUGUGCAGAUGCCGAACUAUU 2234 D-1727 317-335 317-335 AGUUCGGCAUCUGCACAGCUU 732 GCUGUGCAGAUGCCGAACUUU 2235 D-1728 318-336 318-336 GUUCGGCAUCUGCACAGCAUU 733 UGCUGUGCAGAUGCCGAACUU 2236 D-1729 319-337 319-337 UUCGGCAUCUGCACAGCACUU 734 GUGCUGUGCAGAUGCCGAAUU 2237 D-1730 320-338 320-338 UCGGCAUCUGCACAGCACUUU 735 AGUGCUGUGCAGAUGCCGAUU 2238 D-1731 3-21 3-21 CAAACGGUGCACGGAAGAGUU 736 CUCUUCCGUGCACCGUUUGUU 2239 D-1732 321-339 321-339 CGGCAUCUGCACAGCACUGUU 737 CAGUGCUGUGCAGAUGCCGUU 2240 D-1733 322-340 322-340 GGCAUCUGCACAGCACUGAUU 738 UCAGUGCUGUGCAGAUGCCUU 2241 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1734 323-341 323-341 GCAUCUGCACAGCACUGAAUU 739 UUCAGUGCUGUGCAGAUGCUU 2242 D-1735 324-342 324-342 CAUCUGCACAGCACUGAAGUU 740 CUUCAGUGCUGUGCAGAUGUU 2243 D-1736 32-50 32-50 GGCAUGUGUGGGGGCAACAUU 741 UGUUGCCCCCACACAUGCCUU 2244 D-1737 325-343 325-343 AUCUGCACAGCACUGAAGAUU 742 UCUUCAGUGCUGUGCAGAUUU 2245 D-1738 326-344 326-344 UCUGCACAGCACUGAAGAAUU 743 UUCUUCAGUGCUGUGCAGAUU 2246 D-1739 327-345 327-345 CUGCACAGCACUGAAGAACUU 744 GUUCUUCAGUGCUGUGCAGUU 2247 D-1740 328-346 328-346 UGCACAGCACUGAAGAACCUU 745 GGUUCUUCAGUGCUGUGCAUU 2248 D-1741 329-347 329-347 GCACAGCACUGAAGAACCUUU 746 AGGUUCUUCAGUGCUGUGCUU 2249 D-1742 330-348 330-348 CACAGCACUGAAGAACCUGUU 747 CAGGUUCUUCAGUGCUGUGUU 2250 D-1743 331-349 331-349 ACAGCACUGAAGAACCUGGUU 748 CCAGGUUCUUCAGUGCUGUUU 2251 D-1744 332-350 332-350 CAGCACUGAAGAACCUGGGUU 749 CCCAGGUUCUUCAGUGCUGUU 2252 D-1745 333-351 333-351 AGCACUGAAGAACCUGGGAUU 750 UCCCAGGUUCUUCAGUGCUUU 2253 D-1746 334-352 334-352 GCACUGAAGAACCUGGGAAUU 751 UUCCCAGGUUCUUCAGUGCUU 2254 D-1747 33-51 33-51 GCAUGUGUGGGGGCAACACUU 752 GUGUUGCCCCCACACAUGCUU 2255 D-1748 335-353 335-353 CACUGAAGAACCUGGGAAUUU 753 AUUCCCAGGUUCUUCAGUGUU 2256 D-1749 336-354 336-354 ACUGAAGAACCUGGGAAUCUU 754 GAUUCCCAGGUUCUUCAGUUU 2257 D-1750 337-355 337-355 CUGAAGAACCUGGGAAUCAUU 755 UGAUUCCCAGGUUCUUCAGUU 2258 D-1751 338-356 338-356 UGAAGAACCUGGGAAUCAGUU 756 CUGAUUCCCAGGUUCUUCAUU 2259 D-1752 339-357 339-357 GAAGAACCUGGGAAUCAGAUU 757 UCUGAUUCCCAGGUUCUUCUU 2260 D-1753 340-358 340-358 AAGAACCUGGGAAUCAGACUU 758 GUCUGAUUCCCAGGUUCUUUU 2261 D-1754 341-359 341-359 AGAACCUGGGAAUCAGACCUU 759 GGUCUGAUUCCCAGGUUCUUU 2262 D-1755 342-360 342-360 GAACCUGGGAAUCAGACCCU U 760 GGGUCUGAUUCCCAGGUUCUU 2263 D-1756 343-361 343-361 AACCUGGGAAUCAGACCCUUU 761 AGGGUCUGAUUCCCAGGUUUU 2264 D-1757 344-362 344-362 ACCUGGGAAUCAGACCCUGUU 762 CAGGGUCUGAUUCCCAGGUUU 2265 D-1758 34-52 34-52 CAUGUGUGGGGGCAACACGUU 763 CG U G U U G CCCCCACACAU G U U 2266 D-1759 345-363 345-363 CCUGGGAAUCAGACCCUGAUU 764 UCAGGGUCUGAUUCCCAGGUU 2267 D-1760 346-364 346-364 CUGGGAAUCAGACCCUGAGUU 765 CUCAGGGUCUGAUUCCCAGUU 2268 D-1761 347-365 347-365 UGGGAAUCAGACCCUGAGAUU 766 UCUCAGGGUCUGAUUCCCAUU 2269 D-1762 348-366 348-366 GGGAAUCAGACCCUGAGACUU 767 GUCUCAGGGUCUGAUUCCCUU 2270 D-1763 349-367 349-367 GGAAUCAGACCCUGAGACCUU 768 GGUCUCAGGGUCUGAUUCCUU 2271 D-1764 350-368 350-368 GAAUCAGACCCUGAGACCCUU 769 GGGUCUCAGGGUCUGAUUCUU 2272 D-1765 351-369 351-369 AAUCAGACCCUGAGACCCUUU 770 AGGGUCUCAGGGUCUGAUUUU 2273 D-1766 352-370 352-370 AUCAGACCCUGAGACCCUGUU 771 CAGGGUCUCAGGGUCUGAUUU 2274 D-1767 353-371 353-371 UCAGACCCUGAGACCCUGAUU 772 UCAGGGUCUCAGGGUCUGAUU 2275 D-1768 354-372 354-372 CAGACCCUGAGACCCUGAGUU 773 CUCAGGGUCUCAGGGUCUGUU 2276 D-1769 35-53 35-53 AUGUGUGGGGGCAACACGAUU 774 UCGUGUUGCCCCCACACAUUU 2277 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1770 355-373 355-373 AGACCCUGAGACCCUGAGCUU 775 GCUCAGGGUCUCAGGGUCUUU 2278 D-1771 356-374 356-374 GACCCUGAGACCCUGAGCAUU 776 UGCUCAGGGUCUCAGGGUCUU 2279 D-1772 357-375 357-375 ACCCUGAGACCCUGAGCAAUU 777 UUGCUCAGGGUCUCAGGGUUU 2280 D-1773 358-376 358-376 CCCUGAGACCCUGAGCAAUUU 778 AUUGCUCAGGGUCUCAGGGUU 2281 D-1774 359-377 359-377 CCUGAGACCCUGAGCAAUCUU 779 GAUUGCUCAGGGUCUCAGGUU 2282 D-1775 360-378 360-378 CUGAGACCCUGAGCAAUCCUU 780 GGAUUGCUCAGGGUCUCAGUU 2283 D-1776 361-379 361-379 UGAGACCCUGAGCAAUCCCUU 781 GGGAUUGCUCAGGGUCUCAUU 2284 D-1777 362-380 362-380 GAGACCCUGAGCAAUCCCAUU 782 UGGGAUUGCUCAGGGUCUCUU 2285 D-1778 363-381 363-381 AGACCCUGAGCAAUCCCAGUU 783 CUGGGAUUGCUCAGGGUCUUU 2286 D-1779 364-382 364-382 GACCCUGAGCAAU CCCAGG U U 784 CCUGGGAUUGCUCAGGGUCUU 2287 D-1780 365-383 365-383 ACCCUGAGCAAUCCCAGGUUU 785 ACCUGGGAUUGCUCAGGGUUU 2288 D-1781 36-54 36-54 UGUGUGGGGGCAACACGAUUU 786 AUCGUGUUGCCCCCACACAUU 2289 D-1782 366-384 366-384 CCCUGAGCAAUCCCAGGUCUU 787 GACCUGGGAUUGCUCAGGGUU 2290 D-1783 367-385 367-385 CCUGAGCAAUCCCAGGUCCUU 788 GGACCUGGGAUUGCUCAGGUU 2291 D-1784 368-386 368-386 CUGAGCAAUCCCAGGUCCAUU 789 UGGACCUGGGAUUGCUCAGUU 2292 D-1785 369-387 369-387 UGAGCAAUCCCAGGUCCAGUU 790 CUGGACCUGGGAUUGCUCAUU 2293 D-1786 370-388 370-388 GAGCAAUCCCAGGUCCAGCUU 791 GCUGGACCUGGGAUUGCUCUU 2294 D-1787 371-389 371-389 AG CAAU CCCAG GUCCAGCGUU 792 CGCUGGACCUGGGAUUGCUUU 2295 D-1788 372-390 372-390 GCAAUCCCAGGUCCAGCGCUU 793 GCGCUGGACCUGGGAUUGCUU 2296 D-1789 373-391 373-391 CAAUCCCAGGUCCAGCGCCUU 794 GGCGCUGGACCUGGGAUUGUU 2297 D-1790 374-392 374-392 AAUCCCAGGUCCAGCGCCAUU 795 UGGCGCUGGACCUGGGAUUUU 2298 D-1791 375-393 375-393 AU CCCAG G U CCAG CG CCAG U U 796 CUGGCGCUGGACCUGGGAUUU 2299 D-1792 37-55 37-55 GUGUGGGGGCAACACGAUUUU 797 AAUCGUGUUGCCCCCACACUU 2300 D-1793 376-394 376-394 UCCCAGGUCCAGCGCCAGCUU 798 GCUGGCGCUGGACCUGGGAUU 2301 D-1794 377-395 377-395 CCCAGGUCCAGCGCCAGCCUU 799 GGCUGGCGCUGGACCUGGGUU 2302 D-1795 378-396 378-396 CCAGGUCCAGCGCCAGCCCUU 800 GGGCUGGCGCUGGACCUGGUU 2303 D-1796 379-397 379-397 CAGGUCCAGCGCCAGCCCUUU 801 AGGGCUGGCGCUGGACCUGUU 2304 D-1797 380-398 380-398 AGGUCCAGCGCCAGCCCUAUU 802 UAGGGCUGGCGCUGGACCUUU 2305 D-1798 381-399 381-399 GGUCCAGCGCCAGCCCUAUUU 803 AUAGGGCUGGCGCUGGACCUU 2306 D-1799 382-400 382-400 GUCCAGCGCCAGCCCUAUCUU 804 GAUAGGGCUGGCGCUGGACUU 2307 D-1800 383-401 383-401 UCCAGCGCCAGCCCUAUCAUU 805 UGAUAGGGCUGGCGCUGGAUU 2308 D-1801 384-402 384-402 CCAGCGCCAGCCCUAUCAUUU 806 AUGAUAGGGCUGGCGCUGGUU 2309 D-1802 385-403 385-403 CAGCGCCAGCCCUAUCAUGUU 807 CAUGAUAGGGCUGGCGCUGUU 2310 D-1803 38-56 38-56 UGUGGGGGCAACACGAUUCUU 808 GAAUCGUGUUGCCCCCACAUU 2311 D-1804 386-404 386-404 AGCGCCAGCCCUAUCAUGAUU 809 UCAUGAUAGGGCUGGCGCUUU 2312 D-1805 387-405 387-405 GCGCCAGCCCUAUCAUGACUU 810 GUCAUGAUAGGGCUGGCGCUU 2313 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1806 388-406 388-406 CGCCAGCCCUAUCAUGACCUU 811 GGUCAUGAUAGGGCUGGCGUU 2314 D-1807 389-407 389-407 GCCAGCCCUAUCAUGACCAUU 812 UGGUCAUGAUAGGGCUGGCUU 2315 D-1808 390-408 390-408 CCAGCCCUAUCAUGACCAAUU 813 UUGGUCAUGAUAGGGCUGGUU 2316 D-1809 391-409 391-409 CAGCCCUAUCAU GACCAAG U U 814 CUUGGUCAUGAUAGGGCUGUU 2317 D-1810 392-410 392-410 AGCCCUAUCAUGACCAAGGUU 815 CCUUGGUCAUGAUAGGGCUUU 2318 D-1811 393-411 393-411 GCCCUAUCAUGACCAAGGAUU 816 UCCUUGGUCAUGAUAGGGCUU 2319 D-1812 394-412 394-412 CCCUAUCAU GACCAAGGAG U U 817 CUCCUUGGUCAUGAUAGGGUU 2320 D-1813 395-413 395-413 CCUAUCAUGACCAAGGAGUUU 818 ACUCCUUGGUCAUGAUAGGUU 2321 D-1814 39-57 39-57 GUGGGGGCAACACGAUUCUUU 819 AGAAUCGUGUUGCCCCCACUU 2322 D-1815 396-414 396-414 CUAUCAUGACCAAGGAGUAUU 820 UACUCCUUGGUCAUGAUAGUU 2323 D-1816 397-415 397-415 UAUCAUGACCAAGGAGUAUUU 821 AUACUCCUUGGUCAUGAUAUU 2324 D-1817 398-416 398-416 AUCAUGACCAAGGAGUAUCUU 822 GAUACUCCUUGGUCAUGAUUU 2325 D-1818 399-417 399-417 UCAUGACCAAGGAGUAUCAUU 823 UGAUACUCCUUGGUCAUGAUU 2326 D-1819 400-418 400-418 CAUGACCAAGGAGUAUCAAUU 824 UUGAUACUCCUUGGUCAUGUU 2327 D-1820 401-419 401-419 AU GACCAAGGAG UAUCAAG U U 825 CUUGAUACUCCUUGGUCAUUU 2328 D-1821 402-420 402-420 UGACCAAGGAGUAUCAAGAUU 826 UCUUGAUACUCCUUGGUCAUU 2329 D-1822 403-421 403-421 GACCAAGGAGUAUCAAGACUU 827 GUCUUGAUACUCCUUGGUCUU 2330 D-1823 404-422 404-422 ACCAAGGAGUAUCAAGACCUU 828 GGUCUUGAUACUCCUUGGUUU 2331 D-1824 405-423 405-423 CCAAGGAG UAUCAAGACCU U U 829 AGGUCUUGAUACUCCUUGGUU 2332 D-1825 40-58 40-58 UGGGGGCAACACGAUUCUCUU 830 GAGAAUCGUGUUGCCCCCAUU 2333 D-1826 406-424 406-424 CAAGGAGUAUCAAGACCUUUU 831 AAGGUCUUGAUACUCCUUGUU 2334 D-1827 407-425 407-425 AAGGAGUAUCAAGACCUUCUU 832 GAAGGUCUUGAUACUCCUUUU 2335 D-1828 408-426 408-426 AGGAGUAUCAAGACCUUCAUU 833 UGAAGGUCUUGAUACUCCUUU 2336 D-1829 409-427 409-427 GGAGUAUCAAGACCUUCAGUU 834 CUGAAGGUCUUGAUACUCCUU 2337 D-1830 410-428 410-428 GAGUAUCAAGACCUUCAGCUU 835 GCUGAAGGUCUUGAUACUCUU 2338 D-1831 411-429 411-429 AG UAUCAAGACCU UCAGCAU U 836 UGCUGAAGGUCUUGAUACUUU 2339 D-1832 412-430 412-430 GUAUCAAGACCUUCAGCAUUU 837 AUGCUGAAGGUCUUGAUACUU 2340 D-1833 413-431 413-431 UAUCAAGACCUUCAGCAUCUU 838 GAUGCUGAAGGUCUUGAUAUU 2341 D-1834 414-432 414-432 AUCAAGACCUUCAGCAUCUUU 839 AGAUGCUGAAGGUCUUGAUUU 2342 D-1835 415-433 415-433 UCAAGACCUUCAGCAUCUGUU 840 CAGAUGCUGAAGGUCUUGAUU 2343 D-1836 41-59 41-59 GGGGGCAACACGAUUCUCCUU 841 GGAGAAUCGUGUUGCCCCCUU 2344 D-1837 416-434 416-434 CAAGACCUUCAGCAUCUGGUU 842 CCAGAUGCUGAAGGUCUUGUU 2345 D-1838 417-435 417-435 AAGACCUUCAGCAUCUGGAUU 843 UCCAGAUGCUGAAGGUCUUUU 2346 D-1839 418-436 418-436 AGACCUUCAGCAUCUGGACUU 844 GUCCAGAUGCUGAAGGUCUUU 2347 D-1840 419-437 419-437 GACCUUCAGCAUCUGGACAUU 845 UGUCCAGAUGCUGAAGGUCUU 2348 D-1841 420-438 420-438 ACCUUCAGCAUCUGGACAAUU 846 UUGUCCAGAUGCUGAAGGUUU 2349 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1842 421-439 421-439 CCUUCAGCAUCUGGACAAUUU 847 AUUGUCCAGAUGCUGAAGGUU 2350 D-1843 4-22 4-22 AAACGGUGCACGGAAGAGUUU 848 ACUCUUCCGUGCACCGUUUUU 2351 D-1844 422-440 422-440 CUUCAGCAUCUGGACAAUGUU 849 CAUUGUCCAGAUGCUGAAGUU 2352 D-1845 423-441 423-441 UUCAGCAUCUGGACAAUGAUU 850 UCAUUGUCCAGAUGCUGAAUU 2353 D-1846 424-442 424-442 UCAGCAUCUGGACAAUGAGUU 851 CUCAUUGUCCAGAUGCUGAUU 2354 D-1847 425-443 425-443 CAGCAUCUGGACAAUGAGGUU 852 CCUCAUUGUCCAGAUGCUGUU 2355 D-1848 42-60 42-60 GGGGCAACACGAUUCUCCUUU 853 AGGAGAAUCGUGUUGCCCCUU 2356 D-1849 426-444 426-444 AGCAUCUGGACAAUGAGGAUU 854 UCCUCAUUGUCCAGAUGCUUU 2357 D-1850 427-445 427-445 GCAUCUGGACAAUGAGGAGUU 855 CUCCUCAUUGUCCAGAUGCUU 2358 D-1851 428-446 428-446 CAUCUGGACAAUGAGGAGAUU 856 UCUCCUCAUUGUCCAGAUGUU 2359 D-1852 429-447 429-447 AUCUGGACAAUGAGGAGAGUU 857 CUCUCCUCAUUGUCCAGAUUU 2360 D-1853 430-448 430-448 UCUGGACAAUGAGGAGAGUUU 858 ACUCUCCUCAUUGUCCAGAUU 2361 D-1854 431-449 431-449 CUGGACAAUGAGGAGAGUGUU 859 CACUCUCCUCAUUGUCCAGUU 2362 D-1855 432-450 432-450 UGGACAAUGAGGAGAGUGAUU 860 UCACUCUCCUCAUUGUCCAUU 2363 D-1856 433-451 433-451 GGACAAUGAGGAGAGUGACUU 861 GUCACUCUCCUCAUUGUCCUU 2364 D-1857 434-452 434-452 GACAAUGAGGAGAGUGACCUU 862 GGUCACUCUCCUCAUUGUCUU 2365 D-1858 435-453 435-453 ACAAUGAGGAGAGUGACCAUU 863 UGGUCACUCUCCUCAUUGUUU 2366 D-1859 43-61 43-61 GGGCAACACGAUUCUCCUCUU 864 GAGGAGAAUCGUGUUGCCCUU 2367 D-1860 436-454 436-454 CAAUGAGGAGAGUGACCACUU 865 GUGGUCACUCUCCUCAUUGUU 2368 D-1861 437-455 437-455 AAUGAGGAGAGUGACCACCUU 866 GGUGGUCACUCUCCUCAUUUU 2369 D-1862 438-456 438-456 AU GAGGAG AG UG ACCACCAU U 867 UGGUGGUCACUCUCCUCAUUU 2370 D-1863 439-457 439-457 UGAGGAGAGUGACCACCAUUU 868 AUGGUGGUCACUCUCCUCAUU 2371 D-1864 440-458 440-458 GAGGAGAGUGACCACCAUCUU 869 GAUGGUGGUCACUCUCCUCUU 2372 D-1865 441-459 441-459 AGGAGAGUGACCACCAUCAUU 870 UGAUGGUGGUCACUCUCCUUU 2373 D-1866 442-460 442-460 GGAGAG UG ACCACCAUCAG U U 871 CUGAUGGUGGUCACUCUCCUU 2374 D-1867 443-461 443-461 GAGAGUGACCACCAUCAGCUU 872 GCUGAUGGUGGUCACUCUCUU 2375 D-1868 444-462 444-462 AGAGUGACCACCAUCAGCUUU 873 AGCUGAUGGUGGUCACUCUUU 2376 D-1869 445-463 445-463 GAGUGACCACCAUCAGCUCUU 874 GAGCUGAUGGUGGUCACUCUU 2377 D-1870 44-62 44-62 GGCAACACGAUUCUCCUCCUU 875 GGAGGAGAAUCGUGUUGCCUU 2378 D-1871 446-464 446-464 AGUGACCACCAUCAGCUCAUU 876 UGAGCUGAUGGUGGUCACUUU 2379 D-1872 447-465 447-465 GUGACCACCAUCAGCUCAGUU 877 CUGAGCUGAUGGUGGUCACUU 2380 D-1873 448-466 448-466 UGACCACCAUCAGCUCAGAUU 878 UCUGAGCUGAUGGUGGUCAUU 2381 D-1874 449-467 449-467 GACCACCAUCAGCUCAGAAUU 879 UUCUGAGCUGAUGGUGGUCUU 2382 D-1875 450-468 450-468 ACCACCAUCAGCUCAGAAAUU 880 UUUCUGAGCUGAUGGUGGUUU 2383 D-1876 451-469 451-469 CCACCAUCAGCUCAGAAAAUU 881 UUUUCUGAGCUGAUGGUGGUU 2384 D-1877 452-470 452-470 CACCAUCAGCUCAGAAAAGUU 882 CUUUUCUGAGCUGAUGGUGUU 2385 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1878 453-471 — ACCAUCAGCUCAGAAAAGGUU 883 CCUUUUCUGAGCUGAUGGUUU 2386 D-1879 454-472 — CCAUCAGCUCAGAAAAGGGUU 884 CCCUUUUCUGAGCUGAUGGUU 2387 D-1880 455-473 — CAUCAGCUCAGAAAAGGGCUU 885 GCCCUUUUCUGAGCUGAUGUU 2388 D-1881 45-63 45-63 GCAACACGAUUCUCCUCCCUU 886 GGGAGGAGAAUCGUGUUGCUU 2389 D-1882 456-474 — AUCAGCUCAGAAAAGGGCCUU 887 GGCCCUUUUCUGAGCUGAUUU 2390 D-1883 457-475 — UCAGCUCAGAAAAGGGCCAUU 888 UGGCCCUUUUCUGAGCUGAUU 2391 D-1884 458-476 — CAGCUCAGAAAAGGGCCACUU 889 GUGGCCCUUUUCUGAGCUGUU 2392 D-1885 459-477 — AGCUCAGAAAAGGGCCACCUU 890 GGUGGCCCUUUUCUGAGCUUU 2393 D-1886 460-478 — GCUCAGAAAAGGGCCACCUUU 891 AGGUGGCCCUUUUCUGAGCUU 2394 D-1887 461-479 — CUCAGAAAAGGGCCACCUCUU 892 GAGGUGGCCCUUUUCUGAGUU 2395 D-1888 462-480 — UCAGAAAAGGGCCACCUCCUU 893 GGAGGUGGCCCUUUUCUGAUU 2396 D-1889 463-481 — CAGAAAAGGGCCACCUCCUUU 894 AGGAGGUGGCCCUUUUCUGUU 2397 D-1890 464-482 — AGAAAAGGGCCACCUCCUCUU 895 GAGGAGGUGGCCCUUUUCUUU 2398 D-1891 465-483 — GAAAAGGGCCACCUCCUCCUU 896 GGAGGAGGUGGCCCUUUUCUU 2399 D-1892 46-64 46-64 CAACACGAUUCUCCUCCCUUU 897 AGGGAGGAGAAUCGUGUUGUU 2400 D-1893 466-484 — AAAAGGGCCACCUCCUCCCUU 898 GGGAGGAGGUGGCCCUUUUUU 2401 D-1894 467-485 — AAAGGGCCACCUCCUCCCCUU 899 GGGGAGGAGGUGGCCCUUUUU 2402 D-1895 468-486 — AAGGGCCACCUCCUCCCCAUU 900 UGGGGAGGAGGUGGCCCUUUU 2403 D-1896 469-487 — AGGGCCACCUCCUCCCCAGUU 901 CUGGGGAGGAGGUGGCCCUUU 2404 D-1897 470-488 — GGGCCACCUCCUCCCCAGCUU 902 GCUGGGGAGGAGGUGGCCCUU 2405 D-1898 471-489 — GGCCACCUCCUCCCCAGCCUU 903 GGCUGGGGAGGAGGUGGCCUU 2406 D-1899 472-490 — GCCACCUCCUCCCCAGCCCUU 904 GGGCUGGGGAGGAGGUGGCUU 2407 D-1900 473-491 — CCACCUCCUCCCCAGCCCCUU 905 GGGGCUGGGGAGGAGGUGGUU 2408 D-1901 474-492 — CACCUCCU CCCCAGCCCCU U U 906 AGGGGCUGGGGAGGAGGUGUU 2409 D-1902 475-493 — ACCUCCUCCCCAGCCCCUCUU 907 GAGGGGCUGGGGAGGAGGUUU 2410 D-1903 476-494 — CCUCCUCCCCAGCCCCUCCUU 908 GGAGGGGCUGGGGAGGAGGUU 2411 D-1904 47-65 47-65 AACACGAUUCUCCUCCCUGUU 909 CAGGGAGGAGAAUCGUGUUUU 2412 D-1905 477-495 — CUCCUCCCCAGCCCCUCCUUU 910 AGGAGGGGCUGGGGAGGAGUU 2413 D-1906 478-496 — UCCUCCCCAGCCCCUCCUGUU 911 CAGGAGGGGCUGGGGAGGAUU 2414 D-1907 479-497 — CCUCCCCAGCCCCUCCUGCUU 912 GCAGGAGGGGCUGGGGAGGUU 2415 D-1908 480-498 — CUCCCCAGCCCCUCCUGCAUU 913 UGCAGGAGGGGCUGGGGAGUU 2416 D-1909 481-499 — UCCCCAGCCCCUCCUGCAGUU 914 CUGCAGGAGGGGCUGGGGAUU 2417 D-1910 482-500 — CCCCAGCCCCUCCUGCAGCUU 915 GCUGCAGGAGGGGCUGGGGUU 2418 D-1911 483-501 — CCCAGCCCCUCCUGCAGCGUU 916 CGCUGCAGGAGGGGCUGGGUU 2419 D-1912 484-502 — CCAGCCCCUCCUGCAGCGUUU 917 ACGCUGCAGGAGGGGCUGGUU 2420 D-1913 485-503 — CAGCCCCUCCUGCAGCGUCUU 918 GACGCUGCAGGAGGGGCUGUU 2421 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1914 486-504 — AGCCCCUCCUGCAGCGUCUUU 919 AGACGCUGCAGGAGGGGCUUU 2422 D-1915 48-66 48-66 ACACGAUUCUCCUCCCUGGUU 920 CCAGGGAGGAGAAUCGUGUUU 2423 D-1916 487-505 — GCCCCUCCUGCAGCGUCUCUU 921 GAGACGCUGCAGGAGGGGCUU 2424 D-1917 488-506 — CCCCUCCUGCAGCGUCUCUUU 922 AGAGACGCUGCAGGAGGGGUU 2425 D-1918 489-507 — CCCUCCUGCAGCGUCUCUGUU 923 CAGAGACGCUGCAGGAGGGUU 2426 D-1919 490-508 — CCUCCUGCAGCGUCUCUGCUU 924 GCAGAGACGCUGCAGGAGGUU 2427 D-1920 491-509 — CUCCUGCAGCGUCUCUGCUUU 925 AGCAGAGACGCUGCAGGAGUU 2428 D-1921 492-510 — UCCUGCAGCGUCUCUGCUCUU 926 GAGCAGAGACGCUGCAGGAUU 2429 D-1922 493-511 — CCUGCAGCGUCUCUGCUCCUU 927 GGAGCAGAGACGCUGCAGGUU 2430 D-1923 494-512 — CUGCAGCGUCUCUGCUCCGUU 928 CGGAGCAGAGACGCUGCAGUU 2431 D-1924 495-513 — UGCAGCGUCUCUGCUCCGGUU 929 CCGGAGCAGAGACGCUGCAUU 2432 D-1925 496-514 — GCAGCGUCUCUGCUCCGGAUU 930 UCCGGAGCAGAGACGCUGCUU 2433 D-1926 49-67 49-67 CACGAUUCUCCUCCCUGGGUU 931 CCCAGGGAGGAGAAUCGUGUU 2434 D-1927 497-515 — CAGCGUCUCUGCUCCGGACUU 932 GUCCGGAGCAGAGACGCUGUU 2435 D-1928 498-516 — AGCGUCUCUGCUCCGGACCUU 933 GGUCCGGAGCAGAGACGCUUU 2436 D-1929 499-517 — GCGUCUCUGCUCCGGACCUUU 934 AGGUCCGGAGCAGAGACGCUU 2437 D-1930 500-518 — CGUCUCUGCUCCGGACCUCUU 935 GAGGUCCGGAGCAGAGACGUU 2438 D-1931 501-519 — GUCUCUGCUCCGGACCUCGUU 936 CGAGGUCCGGAGCAGAGACUU 2439 D-1932 502-520 — UCUCUGCUCCGGACCUCGCUU 937 GCGAGGUCCGGAGCAGAGAUU 2440 D-1933 503-521 — CUCUGCUCCGGACCUCGCCUU 938 GGCGAGGUCCGGAGCAGAGUU 2441 D-1934 504-522 — UCUGCUCCGGACCUCGCCUUU 939 AGGCGAGGUCCGGAGCAGAUU 2442 D-1935 505-523 — CUGCUCCGGACCUCGCCUCUU 940 GAGGCGAGGUCCGGAGCAGUU 2443 D-1936 506-524 — UGCUCCGGACCUCGCCUCCUU 941 GGAGGCGAGGUCCGGAGCAUU 2444 D-1937 50-68 50-68 ACGAUUCUCCUCCCUGGGGUU 942 CCCCAGGGAGGAGAAUCGUUU 2445 D-1938 507-525 — GCUCCGGACCUCGCCUCCUUU 943 AGGAGGCGAGGUCCGGAGCUU 2446 D-1939 508-526 — CUCCGGACCUCGCCUCCUCUU 944 GAGGAGGCGAGGUCCGGAGUU 2447 D-1940 509-527 — UCCGGACCUCGCCUCCUCCUU 945 GGAGGAGGCGAGGUCCGGAUU 2448 D-1941 510-528 — CCGGACCUCGCCUCCUCCUUU 946 AGGAGGAGGCGAGGUCCGGUU 2449 D-1942 511-529 — CGGACCUCGCCUCCUCCUGUU 947 CAGGAGGAGGCGAGGUCCGUU 2450 D-1943 512-530 — GGACCUCGCCUCCUCCUGCUU 948 GCAGGAGGAGGCGAGGUCCUU 2451 D-1944 513-531 — GACCUCGCCUCCUCCUGCUUU 949 AGCAGGAGGAGGCGAGGUCUU 2452 D-1945 514-532 — ACCUCGCCUCCUCCUGCUCUU 950 GAGCAGGAGGAGGCGAGGUUU 2453 D-1946 515-533 — CCUCGCCUCCUCCUGCUCUUU 951 AGAGCAGGAGGAGGCGAGGUU 2454 D-1947 516-534 — CUCGCCUCCUCCUGCUCUCUU 952 GAGAGCAGGAGGAGGCGAGUU 2455 D-1948 51-69 51-69 CGAUUCUCCUCCCUGGGGAUU 953 UCCCCAGGGAGGAGAAUCGUU 2456 D-1949 517-535 — UCGCCUCCUCCUGCUCUCCUU 954 GGAGAGCAGGAGGAGGCGAUU 2457 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1950 518-536 — CGCCUCCUCCUGCUCUCCCUU 955 GGGAGAGCAGGAGGAGGCGUU 2458 D-1951 519-537 — GCCUCCUCCUGCUCUCCCUUU 956 AGGGAGAGCAGGAGGAGGCUU 2459 D-1952 520-538 — CCUCCUCCUGCUCUCCCUGUU 957 CAGGGAGAGCAGGAGGAGGUU 2460 D-1953 521-539 — CUCCUCCUGCUCUCCCUGGUU 958 CCAGGGAGAGCAGGAGGAGUU 2461 D-1954 522-540 — UCCUCCUGCUCUCCCUGGGUU 959 CCCAGGGAGAGCAGGAGGAUU 2462 D-1955 5-23 5-23 AACGGUGCACGGAAGAGUGUU 960 CACUCUUCCGUGCACCGUUUU 2463 D-1956 523-541 — CCUCCUGCUCUCCCUGGGCUU 961 GCCCAGGGAGAGCAGGAGGUU 2464 D-1957 524-542 — CUCCUGCUCUCCCUGGGCCUU 962 GGCCCAGGGAGAGCAGGAGUU 2465 D-1958 525-543 — UCCUGCUCUCCCUGGGCCUUU 963 AGGCCCAGGGAGAGCAGGAUU 2466 D-1959 526-544 — CCUGCUCUCCCUGGGCCUCUU 964 GAGGCCCAGGGAGAGCAGGUU 2467 D-1960 52-70 52-70 GAUUCUCCUCCCUGGGGAGUU 965 CUCCCCAGGGAGGAGAAUCUU 2468 D-1961 527-545 — CUGCUCUCCCUGGGCCUCAUU 966 UGAGGCCCAGGGAGAGCAGUU 2469 D-1962 528-546 — UGCUCUCCCUGGGCCUCAGUU 967 CUGAGGCCCAGGGAGAGCAUU 2470 D-1963 529-547 — GCUCUCCCUGGGCCUCAGCUU 968 GCUGAGGCCCAGGGAGAGCUU 2471 D-1964 530-548 — CUCUCCCUGGGCCUCAGCCUU 969 GGCUGAGGCCCAGGGAGAGUU 2472 D-1965 531-549 — UCUCCCUGGGCCUCAGCCUUU 970 AGGCUGAGGCCCAGGGAGAUU 2473 D-1966 532-550 — CUCCCUGGGCCUCAGCCUCUU 971 GAGGCUGAGGCCCAGGGAGUU 2474 D-1967 533-551 — UCCCUGGGCCUCAGCCUCCUU 972 GGAGGCUGAGGCCCAGGGAUU 2475 D-1968 534-552 — CCCUGGGCCUCAGCCUCCUUU 973 AGGAGGCUGAGGCCCAGGGUU 2476 D-1969 535-553 — CCUGGGCCUCAGCCUCCUGUU 974 CAGGAGGCUGAGGCCCAGGUU 2477 D-1970 536-554 — CUGGGCCUCAGCCUCCUGCUU 975 GCAGGAGGCUGAGGCCCAGUU 2478 D-1971 53-71 53-71 AUUCUCCUCCCUGGGGAGCUU 976 GCUCCCCAGGGAGGAGAAUUU 2479 D-1972 537-555 — UGGGCCUCAGCCUCCUGCUUU 977 AGCAGGAGGCUGAGGCCCAUU 2480 D-1973 538-556 — GGGCCUCAGCCUCCUGCUGUU 978 CAGCAGGAGGCUGAGGCCCUU 2481 D-1974 539-557 — GGCCUCAGCCUCCUGCUGCUU 979 GCAGCAGGAGGCUGAGGCCUU 2482 D-1975 540-558 — GCCUCAGCCUCCUGCUGCUUU 980 AGCAGCAGGAGGCUGAGGCUU 2483 D-1976 541-559 — CCUCAGCCUCCUGCUGCUUUU 981 AAGCAGCAGGAGGCUGAGGUU 2484 D-1977 542-560 — CUCAGCCUCCUGCUGCUUGUU 982 CAAGCAGCAGGAGGCUGAGUU 2485 D-1978 543-561 — UCAGCCUCCUGCUGCUUGUUU 983 ACAAGCAGCAGGAGGCUGAUU 2486 D-1979 544-562 — CAGCCUCCUGCUGCUUGUGUU 984 CACAAGCAG CAGGAGGCUGUU 2487 D-1980 545-563 — AGCCUCCUGCUGCUUGUGGUU 985 CCACAAGCAGCAGGAGGCUUU 2488 D-1981 546-564 — GCCUCCUGCUGCUUGUGGUUU 986 ACCACAAGCAGCAGGAGGCUU 2489 D-1982 54-72 54-72 UUCUCCUCCCUGGGGAGCAUU 987 UGCUCCCCAGGGAGGAGAAUU 2490 D-1983 547-565 — CCUCCUGCUGCUUGUGGUUUU 988 AACCACAAGCAGCAGGAGGUU 2491 D-1984 548-566 — CUCCUGCUGCUUGUGGUUGUU 989 CAACCACAAGCAGCAGGAGUU 2492 D-1985 549-567 — UCCUGCUGCUUGUGGUUGUUU 990 ACAACCACAAG CAG CAG G AU U 2493 no 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-1986 550-568 — CCUGCUGCUUGUGGUUGUCUU 991 GACAACCACAAG CAG CAG G U U 2494 D-1987 551-569 — CUGCUGCUUGUGGUUGUCUUU 992 AGACAACCACAAG CAG CAG U U 2495 D-1988 552-570 — UGCUGCUUGUGGUUGUCUGUU 993 CAGACAACCACAAGCAGCAUU 2496 D-1989 553-571 — GCUGCUUGUGGUUGUCUGUUU 994 ACAGACAACCACAAGCAGCUU 2497 D-1990 554-572 — CUGCUUGUGGUUGUCUGUGUU 995 CACAGACAACCACAAGCAG U U 2498 D-1991 555-573 — UGCUUGUGGUUGUCUGUGUUU 996 ACACAGACAACCACAAG CAU U 2499 D-1992 556-574 — GCUUGUGGUUGUCUGUGUGUU 997 CACACAGACAACCACAAG CU U 2500 D-1993 55-73 55-73 UCUCCUCCCUGGGGAGCAGUU 998 CUGCUCCCCAGGGAGGAGAUU 2501 D-1994 557-575 — CUUGUGGUUGUCUGUGUGAUU 999 U CACACAGACAACCACAAG U U 2502 D-1995 558-576 — UUGUGGUUGUCUGUGUGAUUU 1000 AUCACACAGACAACCACAAU U 2503 D-1996 559-577 — UGUGGUUGUCUGUGUGAUCUU 1001 GAUCACACAGACAACCACAUU 2504 D-1997 560-578 — GUGGUUGUCUGUGUGAUCGUU 1002 CGAUCACACAGACAACCACUU 2505 D-1998 561-579 — UGGUUGUCUGUGUGAUCGGUU 1003 CCGAUCACACAGACAACCAUU 2506 D-1999 562-580 — GGUUGUCUGUGUGAUCGGAUU 1004 UCCGAUCACACAGACAACCUU 2507 D-2000 563-581 — GUUGUCUGUGUGAUCGGAUUU 1005 AUCCGAUCACACAGACAACUU 2508 D-2001 564-582 — UUGUCUGUGUGAUCGGAUCUU 1006 GAUCCGAU CACACAGACAAU U 2509 D-2002 565-583 — UGUCUGUGUGAUCGGAUCCUU 1007 GGAUCCGAUCACACAGACAUU 2510 D-2003 566-584 — GUCUGUGUGAUCGGAUCCCUU 1008 GGGAUCCGAUCACACAGACUU 2511 D-2004 56-74 56-74 CUCCUCCCUGGGGAGCAGAUU 1009 UCUGCUCCCCAGGGAGGAGUU 2512 D-2005 567-585 — UCUGUGUGAUCGGAUCCCAUU 1010 UGGGAUCCGAUCACACAGAUU 2513 D-2006 568-586 — CUGUGUGAUCGGAUCCCAAUU 1011 UUGGGAUCCGAUCACACAGUU 2514 D-2007 569-587 — UGUGUGAUCGGAUCCCAAAUU 1012 UUUGGGAUCCGAUCACACAUU 2515 D-2008 570-588 — GUGUGAUCGGAUCCCAAAAUU 1013 UUUUGGGAUCCGAUCACACUU 2516 D-2009 571-589 — UGUGAUCGGAUCCCAAAACUU 1014 GUUUUGGGAUCCGAUCACAUU 2517 D-2010 572-590 — GUGAUCGGAUCCCAAAACUUU 1015 AGUUUUGGGAUCCGAUCACUU 2518 D-2011 573-591 — UGAUCGGAUCCCAAAACUCUU 1016 GAGUUUUGGGAUCCGAUCAUU 2519 D-2012 574-592 — GAUCGGAUCCCAAAACUCCUU 1017 GGAGUUUUGGGAUCCGAUCUU 2520 D-2013 575-593 — AUCGGAUCCCAAAACUCCCUU 1018 GGGAGUUUUGGGAUCCGAUUU 2521 D-2014 576-594 — UCGGAUCCCAAAACUCCCAUU 1019 UGGGAGUUUUGGGAUCCGAUU 2522 D-2015 57-75 57-75 UCCUCCCUGGGGAGCAGAGUU 1020 CUCUGCUCCCCAGGGAGGAUU 2523 D-2016 577-595 — CGGAUCCCAAAACUCCCAGUU 1021 CUGGGAGUUUUGGGAUCCGUU 2524 D-2017 578-596 — GGAUCCCAAAACUCCCAGCUU 1022 GCUGGGAGUUUUGGGAUCCUU 2525 D-2018 579-597 — GAUCCCAAAACUCCCAGCUUU 1023 AGCUGGGAGUUUUGGGAUCUU 2526 D-2019 580-598 — AUCCCAAAACUCCCAGCUGUU 1024 CAGCUGGGAGUUUUGGGAUUU 2527 D-2020 581-599 — UCCCAAAACUCCCAGCUGCUU 1025 GCAGCUGGGAGUUUUGGGAUU 2528 D-2021 582-600 — CCCAAAACUCCCAGCUGCAUU 1026 UGCAGCUGGGAGUUUUGGGUU 2529 in 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2022 583-601 — CCAAAACUCCCAGCUGCAGUU 1027 CUGCAGCUGGGAGUUUUGGUU 2530 D-2023 584-602 — CAAAACUCCCAGCUGCAGGUU 1028 CCUGCAGCUGGGAGUUUUGUU 2531 D-2024 585-603 — AAAACUCCCAGCUGCAGGAUU 1029 UCCUGCAGCUGGGAGUUUUUU 2532 D-2025 586-604 — AAACUCCCAGCUGCAGGAGUU 1030 CUCCUGCAGCUGGGAGUUUUU 2533 D-2026 58-76 58-76 CCUCCCUGGGGAGCAGAGCUU 1031 GCUCUGCUCCCCAGGGAGGUU 2534 D-2027 587-605 — AACUCCCAGCUGCAGGAGGUU 1032 CCUCCUGCAGCUGGGAGUUUU 2535 D-2028 588-606 471-489 ACUCCCAGCUGCAGGAGGAUU 1033 UCCUCCUGCAGCUGGGAGUUU 2536 D-2029 589-607 472-490 CUCCCAGCUGCAGGAGGAGUU 1034 CUCCUCCUGCAGCUGGGAGUU 2537 D-2030 590-608 473-491 UCCCAGCUGCAGGAGGAGCUU 1035 GCUCCUCCUGCAGCUGGGAUU 2538 D-2031 591-609 474-492 CCCAGCUGCAGGAGGAGCUUU 1036 AGCUCCUCCUGCAGCUGGGUU 2539 D-2032 592-610 475-493 CCAGCUGCAGGAGGAGCUGUU 1037 CAGCUCCUCCUGCAGCUGGUU 2540 D-2033 593-611 476-494 CAGCUGCAGGAGGAGCUGCUU 1038 GCAGCUCCUCCUGCAGCUGUU 2541 D-2034 594-612 477-495 AGCUGCAGGAGGAGCUGCGUU 1039 CGCAGCUCCUCCUGCAGCUUU 2542 D-2035 595-613 478-496 GCUGCAGGAGGAGCUGCGGUU 1040 CCGCAGCUCCUCCUGCAGCUU 2543 D-2036 596-614 479-497 CUGCAGGAGGAGCUGCGGGUU 1041 CCCGCAGCUCCUCCUGCAGUU 2544 D-2037 597-615 480-498 UGCAGGAGGAGCUGCGGGGUU 1042 CCCCGCAGCUCCUCCUGCAUU 2545 D-2038 59-77 59-77 CUCCCUGGGGAGCAGAGCAUU 1043 UGCUCUGCUCCCCAGGGAGUU 2546 D-2039 598-616 481-499 GCAGGAGGAGCUGCGGGGCUU 1044 GCCCCGCAGCUCCUCCUGCUU 2547 D-2040 599-617 482-500 CAGGAGGAGCUGCGGGGCCUU 1045 GGCCCCGCAGCUCCUCCUGUU 2548 D-2041 600-618 483-501 AGGAGGAGCUGCGGGGCCUUU 1046 AGGCCCCGCAGCUCCUCCUUU 2549 D-2042 601-619 484-502 GGAGGAGCUGCGGGGCCUGUU 1047 CAGGCCCCGCAGCUCCUCCUU 2550 D-2043 602-620 485-503 GAGGAGCUGCGGGGCCUGAUU 1048 UCAGGCCCCGCAGCUCCUCUU 2551 D-2044 603-621 486-504 AGGAGCUGCGGGGCCUGAGUU 1049 CUCAGGCCCCGCAGCUCCUUU 2552 D-2045 604-622 487-505 GGAGCUGCGGGGCCUGAGAUU 1050 UCUCAGGCCCCGCAGCUCCUU 2553 D-2046 605-623 488-506 GAGCUGCGGGGCCUGAGAGUU 1051 CUCUCAGGCCCCGCAGCUCUU 2554 D-2047 606-624 489-507 AGCUGCGGGGCCUGAGAGAUU 1052 UCUCUCAGGCCCCGCAGCUUU 2555 D-2048 607-625 490-508 GCUGCGGGGCCUGAGAGAGUU 1053 CUCUCUCAGGCCCCGCAGCUU 2556 D-2049 60-78 60-78 UCCCUGGGGAGCAGAGCAGUU 1054 CUGCUCUGCUCCCCAGGGAUU 2557 D-2050 608-626 491-509 CUGCGGGGCCUGAGAGAGAUU 1055 UCUCUCUCAGGCCCCGCAGUU 2558 D-2051 609-627 492-510 UGCGGGGCCUGAGAGAGACUU 1056 GUCUCUCUCAGGCCCCGCAUU 2559 D-2052 610-628 493-511 GCGGGGCCUGAGAGAGACGUU 1057 CGUCUCUCUCAGGCCCCGCUU 2560 D-2053 611-629 494-512 CGGGGCCUGAGAGAGACGUUU 1058 ACGUCUCUCUCAGGCCCCGUU 2561 D-2054 612-630 495-513 GGGGCCUGAGAGAGACGUUUU 1059 AACGUCUCUCUCAGGCCCCUU 2562 D-2055 613-631 496-514 GGGCCUGAGAGAGACGUUCUU 1060 GAACGUCUCUCUCAGGCCCUU 2563 D-2056 614-632 497-515 GGCCUGAGAGAGACGUUCAUU 1061 UGAACGUCUCUCUCAGGCCUU 2564 D-2057 615-633 498-516 GCCUGAGAGAGACGUUCAGUU 1062 CUGAACGUCUCUCUCAGGCUU 2565 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2058 616-634 499-517 CCUGAGAGAGACGUUCAGCUU 1063 GCUGAACGUCUCUCUCAGGUU 2566 D-2059 617-635 500-518 CUGAGAGAGACGUUCAGCAUU 1064 UGCUGAACGUCUCUCUCAGUU 2567 D-2060 61-79 61-79 CCCUGGGGAGCAGAGCAGAUU 1065 UCUGCUCUGCUCCCCAGGGUU 2568 D-2061 618-636 501-519 UGAGAGAGACG U UCAGCAAU U 1066 UUGCUGAACGUCUCUCUCAUU 2569 D-2062 619-637 502-520 GAGAGAGACG U UCAGCAACU U 1067 GUUGCUGAACGUCUCUCUCUU 2570 D-2063 620-638 503-521 AGAGAGACGUUCAGCAACUUU 1068 AGUUGCUGAACGUCUCUCUUU 2571 D-2064 621-639 504-522 GAGAGACGUUCAGCAACUUUU 1069 AAGUUGCUGAACGUCUCUCUU 2572 D-2065 622-640 505-523 AGAGACGUUCAGCAACUUCUU 1070 GAAGUUGCUGAACGUCUCUUU 2573 D-2066 623-641 506-524 GAGACG U UCAGCAACU UCAU U 1071 UGAAGUUGCUGAACGUCUCUU 2574 D-2067 6-24 6-24 ACGGUGCACGGAAGAGUGAUU 1072 UCACUCUUCCGUGCACCGUUU 2575 D-2068 624-642 507-525 AGACGUUCAGCAACUUCACUU 1073 GUGAAGUUGCUGAACGUCUUU 2576 D-2069 625-643 508-526 GACG U UCAGCAACU UCACAU U 1074 UGUGAAGUUGCUGAACGUCUU 2577 D-2070 626-644 509-527 ACG U U CAG CAACU U CACAG U U 1075 CUGUGAAGUUGCUGAACGUUU 2578 D-2071 627-645 510-528 CGUUCAGCAACUUCACAGCUU 1076 GCUGUGAAGUUGCUGAACGUU 2579 D-2072 62-80 62-80 CCUGGGGAGCAGAGCAGAGUU 1077 CUCUGCUCUGCUCCCCAGGUU 2580 D-2073 628-646 511-529 GUUCAGCAACUUCACAGCGUU 1078 CGCUGUGAAGUUGCUGAACUU 2581 D-2074 629-647 512-530 UUCAGCAACUUCACAGCGAUU 1079 UCGCUGUGAAGUUGCUGAAUU 2582 D-2075 630-648 513-531 UCAGCAACUUCACAGCGAGUU 1080 CUCGCUGUGAAGUUGCUGAUU 2583 D-2076 631-649 514-532 CAG CAACU U CACAG CGAG CU U 1081 GCUCGCUGUGAAGUUGCUGUU 2584 D-2077 632-650 515-533 AGCAACUUCACAGCGAGCAUU 1082 UGCUCGCUGUGAAGUUGCUUU 2585 D-2078 633-651 516-534 GCAACUUCACAGCGAGCACUU 1083 GUGCUCGCUGUGAAGUUGCUU 2586 D-2079 634-652 517-535 CAACU UCACAGCGAGCACG U U 1084 CGUGCUCGCUGUGAAGUUGUU 2587 D-2080 635-653 518-536 AACUUCACAGCGAGCACGGUU 1085 CCGUGCUCGCUGUGAAGUUUU 2588 D-2081 636-654 519-537 ACUUCACAGCGAGCACGGAUU 1086 UCCGUGCUCGCUGUGAAGUUU 2589 D-2082 637-655 520-538 CUUCACAGCGAGCACGGAGUU 1087 CUCCGUGCUCGCUGUGAAGUU 2590 D-2083 63-81 63-81 CUGGGGAGCAGAGCAGAGGUU 1088 CCUCUGCUCUGCUCCCCAGUU 2591 D-2084 638-656 521-539 UUCACAGCGAGCACGGAGGUU 1089 CCUCCGUGCUCGCUGUGAAUU 2592 D-2085 639-657 522-540 UCACAGCGAGCACGGAGGCUU 1090 GCCUCCGUGCUCGCUGUGAUU 2593 D-2086 640-658 523-541 CACAGCGAGCACGGAGGCCUU 1091 GGCCUCCGUGCUCGCUGUGUU 2594 D-2087 641-659 524-542 ACAGCGAGCACGGAGGCCCUU 1092 GGGCCUCCGUGCUCGCUGUUU 2595 D-2088 642-660 525-543 CAGCGAGCACGGAGGCCCAUU 1093 UGGGCCUCCGUGCUCGCUGUU 2596 D-2089 643-661 526-544 AGCGAGCACGGAGGCCCAGUU 1094 CUGGGCCUCCGUGCUCGCUUU 2597 D-2090 644-662 527-545 GCGAGCACGGAGGCCCAGGUU 1095 CCUGGGCCUCCGUGCUCGCUU 2598 D-2091 645-663 528-546 CGAGCACGGAGGCCCAGGUUU 1096 ACCUGGGCCUCCGUGCUCGUU 2599 D-2092 646-664 529-547 G AG CACG G AG G CCCAG G U CU U 1097 GACCUGGGCCUCCGUGCUCUU 2600 D-2093 647-665 530-548 AGCACGGAGGCCCAGGUCAUU 1098 UGACCUGGGCCUCCGUGCUUU 2601 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2094 64-82 64-82 UGGGGAGCAGAGCAGAGGCUU 1099 GCCUCUGCUCUGCUCCCCAUU 2602 D-2095 648-666 531-549 GCACGGAGGCCCAGGUCAAUU 1100 UUGACCUGGGCCUCCGUGCUU 2603 D-2096 649-667 532-550 CACGG AG G CCCAG G U CAAG U U 1101 CUUGACCUGGGCCUCCGUGUU 2604 D-2097 650-668 533-551 ACGGAGGCCCAGGUCAAGGUU 1102 CCUUGACCUGGGCCUCCGUUU 2605 D-2098 651-669 534-552 CGGAGGCCCAGGUCAAGGGUU 1103 CCCUUGACCUGGGCCUCCGUU 2606 D-2099 652-670 535-553 GGAGGCCCAGGUCAAGGGCUU 1104 GCCCUUGACCUGGGCCUCCUU 2607 D-2100 653-671 536-554 GAGGCCCAGGUCAAGGGCUUU 1105 AGCCCUUGACCUGGGCCUCUU 2608 D-2101 654-672 537-555 AGGCCCAGGUCAAGGGCUUUU 1106 AAGCCCUUGACCUGGGCCUUU 2609 D-2102 655-673 538-556 GGCCCAGGUCAAGGGCUUGUU 1107 CAAGCCCUUGACCUGGGCCUU 2610 D-2103 656-674 539-557 GCCCAGGUCAAGGGCUUGAUU 1108 UCAAGCCCUUGACCUGGGCUU 2611 D-2104 657-675 540-558 CCCAGGUCAAGGGCUUGAGUU 1109 CUCAAGCCCUUGACCUGGGUU 2612 D-2105 65-83 65-83 GGGGAGCAGAGCAGAGGCAUU 1110 UGCCUCUGCUCUGCUCCCCUU 2613 D-2106 658-676 541-559 CCAGGUCAAGGGCUUGAGCUU 1111 GCUCAAGCCCUUGACCUGGUU 2614 D-2107 659-677 542-560 CAGGUCAAGGGCUUGAGCAUU 1112 UGCUCAAGCCCUUGACCUGUU 2615 D-2108 660-678 543-561 AGGUCAAGGGCUUGAGCACUU 1113 GUGCUCAAGCCCUUGACCUUU 2616 D-2109 661-679 544-562 GGUCAAGGGCUUGAGCACCUU 1114 GGUGCUCAAGCCCUUGACCUU 2617 D-2110 662-680 545-563 GUCAAGGGCUUGAGCACCCUU 1115 GGGUGCUCAAGCCCUUGACUU 2618 D-2111 663-681 546-564 UCAAGGGCUUGAGCACCCAUU 1116 UGGGUGCUCAAGCCCUUGAUU 2619 D-2112 664-682 547-565 CAAGGGCUUGAGCACCCAGUU 1117 CUGGGUGCUCAAGCCCUUGUU 2620 D-2113 665-683 548-566 AAGGGCUUGAGCACCCAGGUU 1118 CCUGGGUGCUCAAGCCCUUUU 2621 D-2114 666-684 549-567 AGGGCUUGAGCACCCAGGGUU 1119 CCCUGGGUGCUCAAGCCCUUU 2622 D-2115 667-685 550-568 GGGCUUGAGCACCCAGGGAUU 1120 UCCCUGGGUGCUCAAGCCCUU 2623 D-2116 66-84 66-84 GGGAGCAGAGCAGAGGCAAUU 1121 UUGCCUCUGCUCUGCUCCCUU 2624 D-2117 668-686 551-569 GGCUUGAGCACCCAGGGAGUU 1122 CUCCCUGGGUGCUCAAGCCUU 2625 D-2118 669-687 552-570 GCUUGAGCACCCAGGGAGGUU 1123 CCUCCCUGGGUGCUCAAGCUU 2626 D-2119 670-688 553-571 CUUGAGCACCCAGGGAGGCUU 1124 GCCUCCCUGGGUGCUCAAGUU 2627 D-2120 671-689 554-572 UUGAGCACCCAGGGAGGCAUU 1125 UGCCUCCCUGGGUGCUCAAUU 2628 D-2121 672-690 555-573 UGAGCACCCAGGGAGGCAAUU 1126 UUGCCUCCCUGGGUGCUCAUU 2629 D-2122 673-691 556-574 GAGCACCCAGGGAGGCAAUUU 1127 AUUGCCUCCCUGGGUGCUCUU 2630 D-2123 674-692 557-575 AG CACCCAGG G AG G CAAU G U U 1128 CAUUGCCUCCCUGGGUGCUUU 2631 D-2124 675-693 558-576 GCACCCAGGGAGGCAAUGUUU 1129 ACAUUGCCUCCCUGGGUGCUU 2632 D-2125 676-694 559-577 CACCCAGGGAGGCAAUGUGUU 1130 CACAUUGCCUCCCUGGGUGUU 2633 D-2126 677-695 560-578 ACCCAGGGAGGCAAUGUGGUU 1131 CCACAUUGCCUCCCUGGGUUU 2634 D-2127 67-85 67-85 GGAGCAGAGCAGAGGCAACUU 1132 GUUGCCUCUGCUCUGCUCCUU 2635 D-2128 678-696 561-579 CCCAGGGAGGCAAUGUGGGUU 1133 CCCACAUUGCCUCCCUGGGUU 2636 D-2129 679-697 562-580 CCAGGGAGGCAAUGUGGGAUU 1134 UCCCACAUUGCCUCCCUGGUU 2637 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2130 680-698 563-581 CAGGGAGGCAAUGUGGGAAUU 1135 UUCCCACAUUGCCUCCCUGUU 2638 D-2131 681-699 564-582 AGGGAGGCAAUGUGGGAAGUU 1136 CUUCCCACAUUGCCUCCCUUU 2639 D-2132 682-700 565-583 GGGAGGCAAUGUGGGAAGAUU 1137 UCUUCCCACAUUGCCUCCCUU 2640 D-2133 683-701 566-584 GGAGGCAAUGUGGGAAGAAUU 1138 UUCUUCCCACAUUGCCUCCUU 2641 D-2134 684-702 567-585 GAGGCAAUGUGGGAAGAAAUU 1139 UUUCUUCCCACAUUGCCUCUU 2642 D-2135 685-703 568-586 AGGCAAUGUGGGAAGAAAGUU 1140 CUUUCUUCCCACAUUGCCUUU 2643 D-2136 686-704 569-587 GGCAAUGUGGGAAGAAAGAUU 1141 UCUUUCUUCCCACAUUGCCUU 2644 D-2137 687-705 570-588 GCAAUGUGGGAAGAAAGAUUU 1142 AUCUUUCUUCCCACAUUGCUU 2645 D-2138 68-86 68-86 GAGCAGAGCAGAGGCAACCUU 1143 GGUUGCCUCUGCUCUGCUCUU 2646 D-2139 688-706 571-589 CAAUGUGGGAAGAAAGAUGUU 1144 CAUCUUUCUUCCCACAUUGUU 2647 D-2140 689-707 572-590 AAUGUGGGAAGAAAGAUGAUU 1145 UCAUCUUUCUUCCCACAUUUU 2648 D-2141 690-708 573-591 AUGUGGGAAGAAAGAUGAAUU 1146 UUCAUCUUUCUUCCCACAUUU 2649 D-2142 691-709 574-592 UGUGGGAAGAAAGAUGAAGUU 1147 CUUCAUCUUUCUUCCCACAUU 2650 D-2143 692-710 575-593 GUGGGAAGAAAGAUGAAGUUU 1148 ACUUCAUCUUUCUUCCCACUU 2651 D-2144 693-711 576-594 UGGGAAGAAAGAUGAAGUCUU 1149 GACUUCAUCUUUCUUCCCAUU 2652 D-2145 694-712 577-595 GGGAAGAAAGAUGAAGUCGUU 1150 CGACUUCAUCUUUCUUCCCUU 2653 D-2146 695-713 578-596 GGAAGAAAGAUGAAGUCGCUU 1151 GCGACUUCAUCUUUCUUCCUU 2654 D-2147 696-714 579-597 GAAGAAAGAUGAAGUCGCUUU 1152 AGCGACUUCAUCUUUCUUCUU 2655 D-2148 697-715 580-598 AAGAAAGAUGAAGUCGCUAUU 1153 UAGCGACUUCAUCUUUCUUUU 2656 D-2149 69-87 69-87 AGCAGAGCAGAGGCAACCCUU 1154 GGGUUGCCUCUGCUCUGCUUU 2657 D-2150 698-716 581-599 AGAAAGAUGAAGUCGCUAGUU 1155 CUAGCGACUUCAUCUUUCUUU 2658 D-2151 699-717 581-600 GAAAGAUGAAGUCGCUAGAUU 1156 UCUAGCGACUUCAUCUUUCUU 2659 D-2152 700-718 581-601 AAAGAUGAAGUCGCUAGAGUU 1157 CUCUAGCGACUUCAUCUUUUU 2660 D-2153 701-719 581-602 AAGAUGAAGUCGCUAGAGUUU 1158 ACUCUAGCGACUUCAUCUUUU 2661 D-2154 702-720 581-603 AGAUGAAGUCGCUAGAGUCUU 1159 GACUCUAGCGACUUCAUCUUU 2662 D-2155 703-721 581-604 GAUGAAGUCGCUAGAGUCCUU 1160 GGACUCUAGCGACUUCAUCUU 2663 D-2156 704-722 581-605 AUGAAGUCGCUAGAGUCCCUU 1161 GGGACUCUAGCGACUUCAUUU 2664 D-2157 705-723 581-606 UGAAGUCGCUAGAGUCCCAUU 1162 UGGGACUCUAGCGACUUCAUU 2665 D-2158 706-724 581-607 GAAGUCGCUAGAGUCCCAGUU 1163 CUGGGACUCUAGCGACUUCUU 2666 D-2159 707-725 581-608 AAGUCGCUAGAGUCCCAGCUU 1164 GCUGGGACUCUAGCGACUUUU 2667 D-2160 708-726 581-609 AGUCGCUAGAGUCCCAGCUUU 1165 AGCUGGGACUCUAGCGACUUU 2668 D-2161 70-88 70-88 GCAGAGCAGAGGCAACCCAUU 1166 UGGGUUGCCUCUGCUCUGCUU 2669 D-2162 709-727 592-610 GUCGCUAGAGUCCCAGCUGUU 1167 CAGCUGGGACUCUAGCGACUU 2670 D-2163 710-728 593-611 UCGCUAGAGUCCCAGCUGGUU 1168 CCAGCUGGGACUCUAGCGAUU 2671 D-2164 711-729 594-612 CGCUAGAGUCCCAGCUGGAUU 1169 UCCAGCUGGGACUCUAGCGUU 2672 D-2165 712-730 595-613 GCUAGAGUCCCAGCUGGAGUU 1170 CUCCAGCUGGGACUCUAGCUU 2673 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2166 713-731 596-614 CUAGAGUCCCAGCUGGAGAUU 1171 UCUCCAGCUGGGACUCUAGUU 2674 D-2167 714-732 597-615 UAGAGUCCCAGCUGGAGAAUU 1172 UUCUCCAGCUGGGACUCUAUU 2675 D-2168 715-733 598-616 AGAGUCCCAGCUGGAGAAAUU 1173 UUUCUCCAGCUGGGACUCUUU 2676 D-2169 716-734 599-617 GAGUCCCAGCUGGAGAAACUU 1174 GUUUCUCCAGCUGGGACUCUU 2677 D-2170 717-735 600-618 AGUCCCAGCUGGAGAAACAUU 1175 UGUUUCUCCAGCUGGGACUUU 2678 D-2171 718-736 601-619 GUCCCAGCUGGAGAAACAGUU 1176 CUGUUUCUCCAGCUGGGACUU 2679 D-2172 71-89 71-89 CAGAGCAGAGGCAACCCAUUU 1177 AUGGGUUGCCUCUGCUCUGUU 2680 D-2173 719-737 602-620 UCCCAGCUGGAGAAACAGCUU 1178 GCUGUUUCUCCAGCUGGGAUU 2681 D-2174 720-738 603-621 CCCAGCUGGAGAAACAGCAUU 1179 UGCUGUUUCUCCAGCUGGGUU 2682 D-2175 721-739 604-622 CCAGCUGGAGAAACAGCAGUU 1180 CUGCUGUUUCUCCAGCUGGUU 2683 D-2176 722-740 605-623 CAGCUGGAGAAACAGCAGAUU 1181 UCUGCUGUUUCUCCAGCUGUU 2684 D-2177 723-741 606-624 AGCUGGAGAAACAGCAGAAUU 1182 UUCUGCUGUUUCUCCAGCUUU 2685 D-2178 724-742 607-625 GCU GGAGAAACAGCAGAAG U U 1183 CUUCUGCUGUUUCUCCAGCUU 2686 D-2179 7-25 7-25 CGGUGCACGGAAGAGUGAGUU 1184 CUCACUCUUCCGUGCACCGUU 2687 D-2180 725-743 608-626 CUGGAGAAACAGCAGAAGGUU 1185 CCUUCUGCUGUUUCUCCAGUU 2688 D-2181 726-744 609-627 UGGAGAAACAGCAGAAGGAUU 1186 UCCUUCUGCUGUUUCUCCAUU 2689 D-2182 727-745 610-628 GGAGAAACAGCAGAAGGACUU 1187 GUCCUUCUGCUGUUUCUCCUU 2690 D-2183 728-746 611-629 GAGAAACAGCAGAAGGACCUU 1188 GGUCCUUCUGCUGUUUCUCUU 2691 D-2184 72-90 72-90 AGAGCAGAGGCAACCCAUCUU 1189 GAUGGGUUGCCUCUGCUCUUU 2692 D-2185 729-747 612-630 AGAAACAGCAGAAGGACCUUU 1190 AGGUCCUUCUGCUGUUUCUUU 2693 D-2186 730-748 613-631 GAAACAGCAGAAGGACCUGUU 1191 CAGGUCCUUCUGCUGUUUCUU 2694 D-2187 731-749 614-632 AAACAGCAGAAGGACCUGAUU 1192 UCAGGUCCUUCUGCUGUUUUU 2695 D-2188 732-750 615-633 AACAGCAGAAGGACCU GAG U U 1193 CUCAGGUCCUUCUGCUGUUUU 2696 D-2189 733-751 616-634 ACAGCAGAAGGACCUGAG U U U 1194 ACUCAGGUCCUUCUGCUGUUU 2697 D-2190 734-752 617-635 CAGCAGAAGGACCUGAGUGUU 1195 CACUCAGGUCCUUCUGCUGUU 2698 D-2191 735-753 618-636 AGCAGAAGGACCUGAGUGAUU 1196 UCACUCAGGUCCUUCUGCUUU 2699 D-2192 736-754 619-637 GCAGAAGGACCUGAGUGAAUU 1197 UUCACUCAGGUCCUUCUGCUU 2700 D-2193 737-755 620-638 CAGAAGGACCUGAGUGAAGUU 1198 CUUCACUCAGGUCCUUCUGUU 2701 D-2194 738-756 621-639 AGAAGGACCUGAGUGAAGAUU 1199 UCUUCACUCAGGUCCUUCUUU 2702 D-2195 73-91 73-91 GAGCAGAGGCAACCCAUCCUU 1200 GGAUGGGUUGCCUCUGCUCUU 2703 D-2196 739-757 622-640 GAAGGACCUGAGUGAAGAUUU 1201 AUCUUCACUCAGGUCCUUCUU 2704 D-2197 740-758 623-641 AAGGACCUGAGUGAAGAUCUU 1202 GAUCUUCACUCAGGUCCUUUU 2705 D-2198 741-759 624-642 AGGACCUGAGUGAAGAUCAUU 1203 UGAUCUUCACUCAGGUCCUUU 2706 D-2199 742-760 625-643 GGACCUGAGUGAAGAUCACUU 1204 GUGAUCUUCACUCAGGUCCUU 2707 D-2200 743-761 626-644 GACCUGAGUGAAGAUCACUUU 1205 AGUGAUCUUCACUCAGGUCUU 2708 D-2201 744-762 627-645 ACCUGAGUGAAGAUCACUCUU 1206 GAGUGAUCUUCACUCAGGUUU 2709 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2202 745-763 628-646 CCUGAGUGAAGAUCACUCCUU 1207 GGAGUGAUCUUCACUCAGGUU 2710 D-2203 746-764 629-647 CUGAGUGAAGAUCACUCCAUU 1208 UGGAGUGAUCUUCACUCAGUU 2711 D-2204 747-765 630-648 UGAGUGAAGAUCACUCCAGUU 1209 CUGGAGUGAUCUUCACUCAUU 2712 D-2205 748-766 631-649 GAGUGAAGAUCACUCCAGCUU 1210 GCUGGAGUGAUCUUCACUCUU 2713 D-2206 74-92 74-92 AGCAGAGGCAACCCAUCCCUU 1211 GGGAUGGGUUGCCUCUGCUUU 2714 D-2207 749-767 632-650 AGUGAAGAUCACUCCAGCCUU 1212 GGCUGGAGUGAUCUUCACUUU 2715 D-2208 750-768 633-651 GUGAAGAUCACUCCAGCCUUU 1213 AGGCUGGAGUGAUCUUCACUU 2716 D-2209 751-769 634-652 UGAAGAUCACUCCAGCCUGUU 1214 CAGGCUGGAGUGAUCUUCAUU 2717 D-2210 752-770 635-653 GAAGAUCACUCCAGCCUGCUU 1215 GCAGGCUGGAGUGAUCUUCUU 2718 D-2211 753-771 636-654 AAGAUCACUCCAGCCUGCUUU 1216 AGCAGGCUGGAGUGAUCUUUU 2719 D-2212 754-772 637-655 AGAUCACUCCAGCCUGCUGUU 1217 CAGCAGGCUGGAGUGAUCUUU 2720 D-2213 755-773 638-656 GAUCACUCCAGCCUGCUGCUU 1218 GCAGCAGGCUGGAGUGAUCUU 2721 D-2214 756-774 639-657 AUCACUCCAGCCUGCUGCUUU 1219 AGCAGCAGGCUGGAGUGAUUU 2722 D-2215 757-775 640-658 UCACUCCAGCCUGCUGCUCUU 1220 GAGCAGCAGGCUGGAGUGAUU 2723 D-2216 758-776 641-659 CACUCCAGCCUGCUGCUCCUU 1221 GGAGCAGCAGGCUGGAGUGUU 2724 D-2217 75-93 75-93 GCAGAGGCAACCCAUCCCCUU 1222 GGGGAUGGGUUGCCUCUGCUU 2725 D-2218 759-777 642-660 ACUCCAGCCUGCUGCUCCAUU 1223 UGGAGCAGCAGGCUGGAGUUU 2726 D-2219 760-778 643-661 CUCCAGCCUGCUGCUCCACUU 1224 GUGGAGCAGCAGGCUGGAGUU TITI D-2220 761-779 644-662 UCCAGCCUGCUGCUCCACGUU 1225 CGUGGAGCAGCAGGCUGGAUU 2728 D-2221 762-780 645-663 CCAGCCUGCUGCUCCACGUUU 1226 ACGUGGAGCAGCAGGCUGGUU 2729 D-2222 763-781 646-664 CAGCCUGCUGCUCCACGUGUU 1227 CACG U G G AG CAG CAGG CU G U U 2730 D-2223 764-782 647-665 AGCCUGCUGCUCCACGUGAUU 1228 UCACGUGGAGCAGCAGGCUUU 2731 D-2224 765-783 648-666 GCCUGCUGCUCCACGUGAAUU 1229 UUCACGUGGAGCAGCAGGCUU 2732 D-2225 766-784 649-667 CCUGCUGCUCCACGUGAAGUU 1230 CUUCACGUGGAGCAGCAGGUU 2733 D-2226 767-785 650-668 CUGCUGCUCCACGUGAAGCUU 1231 GCUUCACGUGGAGCAGCAGUU 2734 D-2227 768-786 651-669 UGCUGCUCCACGUGAAGCAUU 1232 UGCUUCACGUGGAGCAGCAUU 2735 D-2228 76-94 76-94 CAGAGGCAACCCAUCCCCCUU 1233 GGGGGAUGGGUUGCCUCUGUU 2736 D-2229 769-787 652-670 GCUGCUCCACGUGAAGCAGUU 1234 CUGCUUCACGUGGAGCAGCUU 2737 D-2230 770-788 653-671 CUGCUCCACGUGAAGCAGUUU 1235 ACUGCUUCACGUGGAGCAGUU 2738 D-2231 771-789 654-672 UGCUCCACGUGAAGCAGUUUU 1236 AACUGCUUCACGUGGAGCAUU 2739 D-2232 772-790 655-673 GCUCCACGUGAAGCAGUUCUU 1237 GAACUGCUUCACGUGGAGCUU 2740 D-2233 773-791 656-674 CUCCACGUGAAGCAGUUCGUU 1238 CGAACUGCUUCACGUGGAGUU 2741 D-2234 774-792 657-675 UCCACGUGAAGCAGUUCGUUU 1239 ACGAACUGCUUCACGUGGAUU 2742 D-2235 775-793 658-676 CCACGUGAAGCAGUUCGUGUU 1240 CACGAACUGCUUCACGUGGUU 2743 D-2236 776-794 659-677 CACGUGAAGCAGUUCGUGUUU 1241 ACACGAACUGCUUCACGUGUU 2744 D-2237 777-795 660-678 ACGUGAAGCAGUUCGUGUCUU 1242 GACACGAACU GCU UCACG U U U 2745 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2238 778-796 661-679 CGUGAAGCAGUUCGUGUCUUU 1243 AGACACGAACUGCUUCACGUU 2746 D-2239 77-95 77-95 AGAGGCAACCCAUCCCCCAUU 1244 UGGGGGAUGGGUUGCCUCUUU 2747 D-2240 779-797 662-680 GUGAAGCAGUUCGUGUCUGUU 1245 CAGACACGAACUGCUUCACUU 2748 D-2241 780-798 663-681 UGAAGCAGUUCGUGUCUGAUU 1246 UCAGACACGAACUGCUUCAUU 2749 D-2242 781-799 664-682 GAAGCAGUUCGUGUCUGACUU 1247 GUCAGACACGAACUGCUUCUU 2750 D-2243 782-800 665-683 AAGCAGUUCGUGUCUGACCUU 1248 GGUCAGACACGAACUGCUUUU 2751 D-2244 783-801 666-684 AGCAGUUCGUGUCUGACCUUU 1249 AGGUCAGACACGAACUGCUUU 2752 D-2245 784-802 667-685 GCAGUUCGUGUCUGACCUGUU 1250 CAGGUCAGACACGAACUGCUU 2753 D-2246 785-803 668-686 CAGUUCGUGUCUGACCUGCUU 1251 GCAGGUCAGACACGAACUGUU 2754 D-2247 786-804 669-687 AGUUCGUGUCUGACCUGCGUU 1252 CGCAGGUCAGACACGAACUUU 2755 D-2248 787-805 670-688 GUUCGUGUCUGACCUGCGGUU 1253 CCGCAGGUCAGACACGAACUU 2756 D-2249 788-806 671-689 UUCGUGUCUGACCUGCGGAUU 1254 UCCGCAGGUCAGACACGAAUU 2757 D-2250 78-96 78-96 GAGGCAACCCAUCCCCCACUU 1255 GUGGGGGAUGGGUUGCCUCUU 2758 D-2251 789-807 672-690 UCGUGUCUGACCUGCGGAGUU 1256 CUCCGCAGGUCAGACACGAUU 2759 D-2252 790-808 673-691 CGUGUCUGACCUGCGGAGCUU 1257 GCUCCGCAGGUCAGACACGUU 2760 D-2253 791-809 674-692 GUGUCUGACCUGCGGAGCCUU 1258 GGCUCCGCAGGUCAGACACUU 2761 D-2254 792-810 675-693 UGUCUGACCUGCGGAGCCUUU 1259 AGGCUCCGCAGGUCAGACAUU 2762 D-2255 793-811 676-694 GUCUGACCUGCGGAGCCUGUU 1260 CAGGCUCCGCAGGUCAGACUU 2763 D-2256 794-812 677-695 UCUGACCUGCGGAGCCUGAUU 1261 UCAGGCUCCGCAGGUCAGAUU 2764 D-2257 795-813 678-696 CUGACCUGCGGAGCCUGAGUU 1262 CUCAGGCUCCGCAGGUCAGUU 2765 D-2258 796-814 679-697 UGACCUGCGGAGCCUGAGCUU 1263 GCUCAGGCUCCGCAGGUCAUU 2766 D-2259 797-815 680-698 GACCUGCGGAGCCUGAGCUUU 1264 AGCUCAGGCUCCGCAGGUCUU 2767 D-2260 798-816 681-699 ACCUGCGGAGCCUGAGCUGUU 1265 CAGCUCAGGCUCCGCAGGUUU 2768 D-2261 79-97 79-97 AGGCAACCCAUCCCCCACUUU 1266 AGUGGGGGAUGGGUUGCCUUU 2769 D-2262 799-817 682-700 CCUGCGGAGCCUGAGCUGUUU 1267 ACAGCUCAGGCUCCGCAGGUU 2770 D-2263 800-818 683-701 CUGCGGAGCCUGAGCUGUCUU 1268 GACAGCUCAGGCUCCGCAGUU 2771 D-2264 801-819 684-702 UGCGGAGCCUGAGCUGUCAUU 1269 UGACAGCUCAGGCUCCGCAUU Till D-2265 802-820 685-703 GCGGAGCCUGAGCUGUCAGUU 1270 CUGACAGCUCAGGCUCCGCUU 2773 D-2266 803-821 686-704 CGGAGCCUGAGCUGUCAGAUU 1271 UCUGACAGCUCAGGCUCCGUU 2774 D-2267 804-822 687-705 GGAGCCUGAGCUGUCAGAUUU 1272 AUCUGACAGCUCAGGCUCCUU 2775 D-2268 805-823 688-706 GAGCCUGAGCUGUCAGAUGUU 1273 CAUCUGACAGCUCAGGCUCUU 2776 D-2269 806-824 689-707 AGCCUGAGCUGUCAGAUGGUU 1274 CCAUCUGACAGCUCAGGCUUU mi D-2270 807-825 690-708 GCCUGAGCUGUCAGAUGGCUU 1275 GCCAUCUGACAGCUCAGGCUU rm D-2271 808-826 691-709 CCUGAGCUGUCAGAUGGCGUU 1276 CGCCAUCUGACAGCUCAGGUU rm D-2272 80-98 80-98 GGCAACCCAUCCCCCACUCUU 1277 GAGUGGGGGAUGGGUUGCCUU 2780 D-2273 809-827 692-710 CUGAGCUGUCAGAUGGCGGUU 1278 CCGCCAUCUGACAGCUCAGUU 2781 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2274 810-828 693-711 UGAGCUGUCAGAUGGCGGCUU 1279 GCCGCCAUCUGACAGCUCAUU 2782 D-2275 811-829 694-712 GAGCUGUCAGAUGGCGGCGUU 1280 CGCCGCCAUCUGACAGCUCUU 2783 D-2276 812-830 695-713 AGCUGUCAGAUGGCGGCGCUU 1281 GCGCCGCCAUCUGACAGCUUU 2784 D-2277 813-831 696-714 GCUGUCAGAUGGCGGCGCUUU 1282 AGCGCCGCCAUCUGACAGCUU 2785 D-2278 814-832 697-715 CUGUCAGAUGGCGGCGCUCUU 1283 GAGCGCCGCCAUCUGACAGUU 2786 D-2279 815-833 698-716 UGUCAGAUGGCGGCGCUCCUU 1284 GGAGCGCCGCCAUCUGACAUU 2787 D-2280 816-834 699-717 GUCAGAUGGCGGCGCUCCAUU 1285 UGGAGCGCCGCCAUCUGACUU 2788 D-2281 817-835 700-718 UCAGAUGGCGGCGCUCCAGUU 1286 CUGGAGCGCCGCCAUCUGAUU 2789 D-2282 818-836 701-719 CAGAUGGCGGCGCUCCAGGUU 1287 CCUGGAGCGCCGCCAUCUGUU 2790 D-2283 819-837 702-720 AGAUGGCGGCGCUCCAGGGUU 1288 CCCUGGAGCGCCGCCAUCUUU 2791 D-2284 81-99 81-99 GCAACCCAUCCCCCACUCCUU 1289 GGAGUGGGGGAUGGGUUGCUU 2792 D-2285 820-838 703-721 GAUGGCGGCGCUCCAGGGCUU 1290 GCCCUGGAGCGCCGCCAUCUU 2793 D-2286 82-100 82-100 CAACCCAUCCCCCACUCCCUU 1291 GGGAGUGGGGGAUGGGUUGUU 2794 D-2287 821-839 704-722 AUGGCGGCGCUCCAGGGCAUU 1292 UGCCCUGGAGCGCCGCCAUUU 2795 D-2288 822-840 705-723 UGGCGGCGCUCCAGGGCAAUU 1293 UUGCCCUGGAGCGCCGCCAUU 2796 D-2289 823-841 706-724 GGCGGCGCUCCAGGGCAAUUU 1294 AUUGCCCUGGAGCGCCGCCUU 2797 D-2290 824-842 707-725 GCGGCGCUCCAGGGCAAUGUU 1295 CAUUGCCCUGGAGCGCCGCUU 2798 D-2291 825-843 708-726 CGGCGCUCCAGGGCAAUGGUU 1296 CCAUUGCCCUGGAGCGCCGUU 2799 D-2292 8-26 8-26 GGUGCACGGAAGAGUGAGGUU 1297 CCUCACUCUUCCGUGCACCUU 2800 D-2293 826-844 709-727 GGCGCUCCAGGGCAAUGGCUU 1298 GCCAUUGCCCUGGAGCGCCUU 2801 D-2294 827-845 710-728 GCGCUCCAGGGCAAUGGCUUU 1299 AGCCAUUGCCCUGGAGCGCUU 2802 D-2295 828-846 711-729 CGCUCCAGGGCAAUGGCUCUU 1300 GAGCCAUUGCCCUGGAGCGUU 2803 D-2296 829-847 712-730 GCUCCAGGGCAAUGGCUCAUU 1301 UGAGCCAUUGCCCUGGAGCUU 2804 D-2297 830-848 713-731 CUCCAGGGCAAUGGCUCAGUU 1302 CUGAGCCAUUGCCCUGGAGUU 2805 D-2298 83-101 83-101 AACCCAUCCCCCACUCCCAUU 1303 UGGGAGUGGGGGAUGGGUUUU 2806 D-2299 831-849 714-732 UCCAGGGCAAUGGCUCAGAUU 1304 UCUGAGCCAUUGCCCUGGAUU 2807 D-2300 832-850 715-733 CCAGGGCAAUGGCUCAGAAUU 1305 UUCUGAGCCAUUGCCCUGGUU 2808 D-2301 833-851 716-734 CAGGGCAAUGGCUCAGAAAUU 1306 UUUCUGAGCCAUUGCCCUGUU 2809 D-2302 834-852 717-735 AGGGCAAUGGCUCAGAAAGUU 1307 CUUUCUGAGCCAUUGCCCUUU 2810 D-2303 835-853 718-736 GGGCAAUGGCUCAGAAAGGUU 1308 CCUUUCUGAGCCAUUGCCCUU 2811 D-2304 836-854 719-737 GGCAAUGGCUCAGAAAGGAUU 1309 UCCUUUCUGAGCCAUUGCCUU 2812 D-2305 837-855 720-738 GCAAUGGCUCAGAAAGGACUU 1310 GUCCUUUCUGAGCCAUUGCUU 2813 D-2306 838-856 721-739 CAAUGGCUCAGAAAGGACCUU 1311 GGUCCUUUCUGAGCCAUUGUU 2814 D-2307 839-857 722-740 AAUGGCUCAGAAAGGACCUUU 1312 AGGUCCUUUCUGAGCCAUUUU 2815 D-2308 840-858 723-741 AUGGCUCAGAAAGGACCUGUU 1313 CAGGUCCUUUCUGAGCCAUUU 2816 D-2309 84-102 84-102 ACCCAUCCCCCACUCCCACUU 1314 GUGGGAGUGGGGGAUGGGUUU 2817 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2310 841-859 724-742 UGGCUCAGAAAGGACCUGCUU 1315 GCAGGUCCUUUCUGAGCCAUU 2818 D-2311 842-860 725-743 GGCUCAGAAAGGACCUGCUUU 1316 AGCAGGUCCUUUCUGAGCCUU 2819 D-2312 843-861 726-744 GCUCAGAAAGGACCUGCUGUU 1317 CAGCAGGUCCUUUCUGAGCUU 2820 D-2313 844-862 727-745 CUCAGAAAGGACCUGCUGCUU 1318 GCAGCAGGUCCUUUCUGAGUU 2821 D-2314 845-863 728-746 UCAGAAAGGACCUGCUGCCUU 1319 GGCAGCAGGUCCUUUCUGAUU 2822 D-2315 846-864 729-747 CAGAAAGGACCUGCUGCCCUU 1320 GGGCAGCAGGUCCUUUCUGUU 2823 D-2316 847-865 730-748 AGAAAGGACCUGCUGCCCGUU 1321 CGGGCAGCAGGUCCUUUCUUU 2824 D-2317 848-866 731-749 GAAAGGACCUGCUGCCCGGUU 1322 CCGGGCAGCAGGUCCUUUCUU 2825 D-2318 849-867 732-750 AAAGGACCUGCUGCCCGGUUU 1323 ACCGGGCAGCAGGUCCUUUUU 2826 D-2319 850-868 733-751 AAGGACCUGCUGCCCGGUCUU 1324 GACCGGGCAGCAGGUCCUUUU 2827 D-2320 85-103 85-103 CCCAUCCCCCACUCCCACCUU 1325 GGUGGGAGUGGGGGAUGGGUU 2828 D-2321 851-869 734-752 AGGACCUGCUGCCCGGUCAUU 1326 UGACCGGGCAGCAGGUCCUUU 2829 D-2322 852-870 735-753 GGACCUGCUGCCCGGUCAAUU 1327 UUGACCGGGCAGCAGGUCCUU 2830 D-2323 853-871 736-754 GACCUGCUGCCCGGUCAACUU 1328 GUUGACCGGGCAGCAGGUCUU 2831 D-2324 854-872 737-755 ACCUGCUGCCCGGUCAACUUU 1329 AGUUGACCGGGCAGCAGGUUU 2832 D-2325 855-873 738-756 CCUGCUGCCCGGUCAACUGUU 1330 CAG U U G ACCG G GCAG CAG G U U 2833 D-2326 856-874 739-757 CUGCUGCCCGGUCAACUGGUU 1331 CCAG U U G ACCGG G CAG CAG U U 2834 D-2327 857-875 740-758 UGCUGCCCGGUCAACUGGGUU 1332 CCCAGUUGACCGGGCAGCAUU 2835 D-2328 858-876 741-759 GCUGCCCGGUCAACUGGGUUU 1333 ACCCAGUUGACCGGGCAGCUU 2836 D-2329 859-877 742-760 CUGCCCGGUCAACUGGGUGUU 1334 CACCCAGUUGACCGGGCAGUU 2837 D-2330 860-878 743-761 UGCCCGGUCAACUGGGUGGUU 1335 CCACCCAGUUGACCGGGCAUU 2838 D-2331 86-104 86-104 CCAU CCCCCACUCCCACCCU U 1336 GGGUGGGAGUGGGGGAUGGUU 2839 D-2332 861-879 744-762 GCCCGGUCAACUGGGUGGAUU 1337 UCCACCCAGUUGACCGGGCUU 2840 D-2333 862-880 745-763 CCCGGUCAACUGGGUGGAGUU 1338 CUCCACCCAGUUGACCGGGUU 2841 D-2334 863-881 746-764 CCGGUCAACUGGGUGGAGCUU 1339 GCUCCACCCAGUUGACCGGUU 2842 D-2335 864-882 747-765 CGGUCAACUGGGUGGAGCAUU 1340 UGCUCCACCCAGUUGACCGUU 2843 D-2336 865-883 748-766 GGUCAACUGGGUGGAGCACUU 1341 GUGCUCCACCCAGUUGACCUU 2844 D-2337 866-884 749-767 GUCAACUGGGUGGAGCACGUU 1342 CGUGCUCCACCCAGUUGACUU 2845 D-2338 867-885 750-768 UCAACUGGGUGGAGCACGAUU 1343 UCGUGCUCCACCCAGUUGAUU 2846 D-2339 868-886 751-769 CAACUGGGUGGAGCACGAGUU 1344 CUCGUGCUCCACCCAGUUGUU 2847 D-2340 869-887 752-770 AACUGGGUGGAGCACGAGCUU 1345 GCUCGUGCUCCACCCAGUUUU 2848 D-2341 870-888 753-771 ACUGGGUGGAGCACGAGCGUU 1346 CGCUCGUGCUCCACCCAGUUU 2849 D-2342 87-105 87-105 CAU CCCCCACUCCCACCCCU U 1347 GGGGUGGGAGUGGGGGAUGUU 2850 D-2343 871-889 754-772 CUGGGUGGAGCACGAGCGCUU 1348 GCGCUCGUGCUCCACCCAGUU 2851 D-2344 872-890 755-773 UGGGUGGAGCACGAGCGCAUU 1349 UGCGCUCGUGCUCCACCCAUU 2852 D-2345 873-891 756-774 GGGUGGAGCACGAGCGCAGUU 1350 CUGCGCUCGUGCUCCACCCUU 2853 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2346 874-892 757-775 GGUGGAGCACGAGCGCAGCUU 1351 GCUGCGCUCGUGCUCCACCUU 2854 D-2347 875-893 758-776 GUGGAGCACGAGCGCAGCUUU 1352 AGCUGCGCUCGUGCUCCACUU 2855 D-2348 876-894 759-777 UGGAGCACGAGCGCAGCUGUU 1353 CAGCUGCGCUCGUGCUCCAUU 2856 D-2349 877-895 760-778 GGAGCACGAGCGCAGCUGCUU 1354 GCAGCUGCGCUCGUGCUCCUU 2857 D-2350 878-896 761-779 GAGCACGAGCGCAGCUGCUUU 1355 AGCAGCUGCGCUCGUGCUCUU 2858 D-2351 879-897 762-780 AGCACGAGCGCAGCUGCUAUU 1356 UAGCAGCUGCGCUCGUGCUUU 2859 D-2352 880-898 763-781 GCACGAGCGCAGCUGCUACUU 1357 GUAGCAGCUGCGCUCGUGCUU 2860 D-2353 88-106 88-106 AU CCCCCACUCCCACCCCCU U 1358 GGGGGUGGGAGUGGGGGAUUU 2861 D-2354 881-899 764-782 CACGAGCGCAGCUGCUACUUU 1359 AGUAGCAGCUGCGCUCGUGUU 2862 D-2355 882-900 765-783 ACGAGCGCAGCUGCUACUGUU 1360 CAGUAGCAGCUGCGCUCGUUU 2863 D-2356 883-901 766-784 CGAGCGCAGCUGCUACUGGUU 1361 CCAGUAGCAGCUGCGCUCGUU 2864 D-2357 884-902 767-785 GAGCGCAGCUGCUACUGGUUU 1362 ACCAGUAGCAGCUGCGCUCUU 2865 D-2358 885-903 768-786 AGCGCAGCUGCUACUGGUUUU 1363 AACCAGUAGCAGCUGCGCUUU 2866 D-2359 886-904 769-787 GCGCAGCUGCUACUGGUUCUU 1364 GAACCAGUAGCAGCUGCGCUU 2867 D-2360 887-905 770-788 CGCAGCUGCUACUGGUUCUUU 1365 AGAACCAG UAGCAGCU GCG U U 2868 D-2361 888-906 771-789 GCAGCUGCUACUGGUUCUCUU 1366 GAGAACCAGUAGCAGCUGCUU 2869 D-2362 889-907 772-790 CAGCUGCUACUGGUUCUCUUU 1367 AGAGAACCAG UAGCAGCUG U U 2870 D-2363 890-908 773-791 AGCUGCUACUGGUUCUCUCUU 1368 GAGAGAACCAGUAGCAGCUUU 2871 D-2364 89-107 89-107 UCCCCCACU CCCACCCCCAU U 1369 UGGGGGUGGGAGUGGGGGAUU 2872 D-2365 891-909 774-792 GCUGCUACUGGUUCUCUCGUU 1370 CGAGAGAACCAGUAGCAGCUU 2873 D-2366 892-910 775-793 CUGCUACUGGUUCUCUCGCUU 1371 GCGAGAGAACCAGUAGCAGUU 2874 D-2367 893-911 776-794 UGCUACUGGUUCUCUCGCUUU 1372 AGCGAGAGAACCAG UAGCAU U 2875 D-2368 894-912 777-795 GCUACUGGUUCUCUCGCUCUU 1373 GAGCGAGAGAACCAGUAGCUU 2876 D-2369 895-913 778-796 CUACUGGUUCUCUCGCUCCUU 1374 GGAGCGAGAGAACCAGUAGUU 2877 D-2370 896-914 779-797 UACUGGUUCUCUCGCUCCGUU 1375 CGGAGCGAGAGAACCAGUAUU 2878 D-2371 897-915 780-798 ACUGGUUCUCUCGCUCCGGUU 1376 CCGGAGCGAGAGAACCAGUUU 2879 D-2372 898-916 781-799 CUGGUUCUCUCGCUCCGGGUU 1377 CCCGGAGCGAGAGAACCAGU U 2880 D-2373 899-917 782-800 UGGUUCUCUCGCUCCGGGAUU 1378 UCCCGGAGCGAGAGAACCAUU 2881 D-2374 900-918 783-801 GGUUCUCUCGCUCCGGGAAUU 1379 UUCCCGGAGCGAGAGAACCUU 2882 D-2375 90-108 90-108 CCCCCACUCCCACCCCCACUU 1380 GUGGGGGUGGGAGUGGGGGUU 2883 D-2376 901-919 784-802 GUUCUCUCGCUCCGGGAAGUU 1381 CUUCCCGGAGCGAGAGAACUU 2884 D-2377 902-920 785-803 UUCUCUCGCUCCGGGAAGGUU 1382 CCUUCCCGGAGCGAGAGAAUU 2885 D-2378 903-921 786-804 UCUCUCGCUCCGGGAAGGCUU 1383 GCCUUCCCGGAGCGAGAGAUU 2886 D-2379 904-922 787-805 CUCUCGCUCCGGGAAGGCCUU 1384 GGCCUUCCCGGAGCGAGAGUU 2887 D-2380 905-923 788-806 UCUCGCUCCGGGAAGGCCUUU 1385 AGGCCUUCCCGGAGCGAGAUU 2888 D-2381 906-924 789-807 CUCGCUCCGGGAAGGCCUGUU 1386 CAGGCCUUCCCGGAGCGAGUU 2889 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2382 907-925 790-808 UCGCUCCGGGAAGGCCUGGUU 1387 CCAGGCCUUCCCGGAGCGAUU 2890 D-2383 908-926 791-809 CGCUCCGGGAAGGCCUGGGUU 1388 CCCAGGCCUUCCCGGAGCGUU 2891 D-2384 909-927 792-810 GCUCCGGGAAGGCCUGGGCUU 1389 GCCCAGGCCUUCCCGGAGCUU 2892 D-2385 910-928 793-811 CUCCGGGAAGGCCUGGGCUUU 1390 AGCCCAGGCCUUCCCGGAGUU 2893 D-2386 91-109 91-109 CCCCACUCCCACCCCCACAU U 1391 UGUGGGGGUGGGAGUGGGGUU 2894 D-2387 911-929 794-812 UCCGGGAAGGCCUGGGCUGUU 1392 CAGCCCAGGCCUUCCCGGAUU 2895 D-2388 912-930 795-813 CCGGGAAGGCCUGGGCUGAUU 1393 UCAGCCCAGGCCUUCCCGGUU 2896 D-2389 913-931 796-814 CGGGAAGGCCUGGGCUGACUU 1394 GUCAGCCCAGGCCUUCCCGUU 2897 D-2390 914-932 797-815 GGGAAGGCCUGGGCUGACGUU 1395 CGUCAGCCCAGGCCUUCCCUU 2898 D-2391 915-933 798-816 GGAAGGCCUGGGCUGACGCUU 1396 GCGUCAGCCCAGGCCUUCCUU 2899 D-2392 916-934 799-817 GAAGGCCUGGGCUGACGCCUU 1397 GGCGUCAGCCCAGGCCUUCUU 2900 D-2393 917-935 800-818 AAGGCCUGGGCUGACGCCGUU 1398 CGGCGUCAGCCCAGGCCUUUU 2901 D-2394 918-936 801-819 AGGCCUGGGCUGACGCCGAUU 1399 UCGGCGUCAGCCCAGGCCUUU 2902 D-2395 919-937 802-820 GGCCUGGGCUGACGCCGACUU 1400 GUCGGCGUCAGCCCAGGCCUU 2903 D-2396 920-938 803-821 GCCUGGGCUGACGCCGACAUU 1401 UGUCGGCGUCAGCCCAGGCUU 2904 D-2397 92-110 92-110 CCCACUCCCACCCCCACACUU 1402 GUGUGGGGGUGGGAGUGGGUU 2905 D-2398 921-939 804-822 CCUGGGCUGACGCCGACAAUU 1403 UUGUCGGCGUCAGCCCAGGUU 2906 D-2399 922-940 805-823 CUGGGCUGACGCCGACAACUU 1404 GUUGUCGGCGUCAGCCCAGUU 2907 D-2400 923-941 806-824 UGGGCUGACGCCGACAACUUU 1405 AGUUGUCGGCGUCAGCCCAUU 2908 D-2401 924-942 807-825 GGGCUGACGCCGACAACUAUU 1406 UAGUUGUCGGCGUCAGCCCUU 2909 D-2402 925-943 808-826 GGCUGACGCCGACAACUACUU 1407 GUAGUUGUCGGCGUCAGCCUU 2910 D-2403 926-944 809-827 GCUGACGCCGACAACUACUUU 1408 AGUAGUUGUCGGCGUCAGCUU 2911 D-2404 9-27 9-27 GUGCACGGAAGAGUGAGGUUU 1409 ACCUCACUCUUCCGUGCACUU 2912 D-2405 927-945 810-828 CUGACGCCGACAACUACUGUU 1410 CAGUAGUUGUCGGCGUCAGUU 2913 D-2406 928-946 811-829 UGACGCCGACAACUACUGCUU 1411 GCAGUAGUUGUCGGCGUCAUU 2914 D-2407 929-947 812-830 GACGCCGACAACUACUGCCUU 1412 GGCAGUAGUUGUCGGCGUCUU 2915 D-2408 930-948 813-831 ACGCCGACAACUACUGCCGUU 1413 CGGCAGUAGUUGUCGGCGUUU 2916 D-2409 93-111 93-111 CCACUCCCACCCCCACACU U U 1414 AGUGUGGGGGUGGGAGUGGUU 2917 D-2410 931-949 814-832 CGCCGACAACUACUGCCGGUU 1415 CCGGCAGUAGUUGUCGGCGUU 2918 D-2411 932-950 815-833 GCCGACAACUACUGCCGGCUU 1416 GCCGGCAGUAGUUGUCGGCUU 2919 D-2412 933-951 816-834 CCGACAACUACUGCCGGCUUU 1417 AGCCGGCAGUAGUUGUCGGUU 2920 D-2413 934-952 817-835 CGACAACUACUGCCGGCUGUU 1418 CAGCCGGCAGUAGUUGUCGUU 2921 D-2414 935-953 818-836 GACAACUACUGCCGGCUGGUU 1419 CCAGCCGGCAGUAGUUGUCUU 2922 D-2415 936-954 819-837 ACAACUACUGCCGGCUGGAUU 1420 UCCAGCCGGCAGUAGUUGUUU 2923 D-2416 937-955 820-838 CAACUACUGCCGGCUGGAGUU 1421 CUCCAGCCGGCAGUAGUUGUU 2924 D-2417 938-956 821-839 AACUACUGCCGGCUGGAGGUU 1422 CCU CCAGCCGGCAG U AG U U U U 2925 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2418 939-957 822-840 ACUACUGCCGGCUGGAGGAUU 1423 UCCUCCAGCCGGCAGUAGUUU 2926 D-2419 940-958 823-841 CUACUGCCGGCUGGAGGACUU 1424 GUCCUCCAGCCGGCAGUAGUU 2927 D-2420 94-112 94-112 CACU CCCACCCCCACACU CU U 1425 GAGUGUGGGGGUGGGAGUGUU 2928 D-2421 941-959 824-842 UACUGCCGGCUGGAGGACGUU 1426 CGUCCUCCAGCCGGCAGUAUU 2929 D-2422 942-960 825-843 ACUGCCGGCUGGAGGACGCUU 1427 GCGUCCUCCAGCCGGCAGUUU 2930 D-2423 943-961 826-844 CUGCCGGCUGGAGGACGCGUU 1428 CGCGUCCUCCAGCCGGCAGUU 2931 D-2424 944-962 827-845 UGCCGGCUGGAGGACGCGCUU 1429 GCGCGUCCUCCAGCCGGCAUU 2932 D-2425 945-963 828-846 GCCGGCUGGAGGACGCGCAUU 1430 UGCGCGUCCUCCAGCCGGCUU 2933 D-2426 946-964 829-847 CCGGCUGGAGGACGCGCACUU 1431 GUGCGCGUCCUCCAGCCGGUU 2934 D-2427 947-965 830-848 CGGCUGGAGGACGCGCACCUU 1432 GGUGCGCGUCCUCCAGCCGUU 2935 D-2428 948-966 831-849 GGCUGGAGGACGCGCACCUUU 1433 AGGUGCGCGUCCUCCAGCCUU 2936 D-2429 949-967 832-850 GCUGGAGGACGCGCACCUGUU 1434 CAGGUGCGCGUCCUCCAGCUU 2937 D-2430 950-968 833-851 CUGGAGGACGCGCACCUGGUU 1435 CCAGGUGCGCGUCCUCCAGUU 2938 D-2431 95-113 95-113 ACU CCCACCCCCACACU CCU U 1436 GGAGUGUGGGGGUGGGAGUUU 2939 D-2432 951-969 834-852 UGGAGGACGCGCACCUGGUUU 1437 ACCAGGUGCGCGUCCUCCAUU 2940 D-2433 952-970 835-853 GGAGGACGCGCACCUGGUGUU 1438 CACCAGGUGCGCGUCCUCCUU 2941 D-2434 953-971 836-854 GAGGACGCGCACCUGGUGGUU 1439 CCACCAGGUGCGCGUCCUCUU 2942 D-2435 954-972 837-855 AGGACGCGCACCUGGUGGUUU 1440 ACCACCAGGUGCGCGUCCUUU 2943 D-2436 955-973 838-856 GGACGCGCACCUGGUGGUGUU 1441 CACCACCAGGUGCGCGUCCUU 2944 D-2437 956-974 839-857 GACGCGCACCUGGUGGUGGUU 1442 CCACCACCAGGUGCGCGUCUU 2945 D-2438 957-975 840-858 ACGCGCACCUGGUGGUGGUUU 1443 ACCACCACCAGGUGCGCGUUU 2946 D-2439 958-976 841-859 CGCGCACCUGGUGGUGGUCUU 1444 GACCACCACCAGGUGCGCGUU 2947 D-2440 959-977 842-860 GCGCACCUGGUGGUGGUCAUU 1445 UGACCACCACCAGGUGCGCUU 2948 D-2441 960-978 843-861 CGCACCUGGUGGUGGUCACUU 1446 GUGACCACCACCAGGUGCGUU 2949 D-2442 96-114 96-114 CUCCCACCCCCACACUCCCUU 1447 GGGAGUGUGGGGGUGGGAGUU 2950 D-2443 961-979 844-862 GCACCUGGUGGUGGUCACGUU 1448 CGUGACCACCACCAGGUGCUU 2951 D-2444 962-980 845-863 CACCUGGUGGUGGUCACGUUU 1449 ACG U G ACCACCACCAG G U G U U 2952 D-2445 963-981 846-864 ACCUGGUGGUGGUCACGUCUU 1450 GACGUGACCACCACCAGGUUU 2953 D-2446 964-982 847-865 CCUGGUGGUGGUCACGUCCUU 1451 GGACGUGACCACCACCAGGUU 2954 D-2447 965-983 848-866 CUGGUGGUGGUCACGUCCUUU 1452 AG G ACG U G ACCACCACCAG U U 2955 D-2448 966-984 849-867 UGGUGGUGGUCACGUCCUGUU 1453 CAG G ACG U G ACCACCACCAU U 2956 D-2449 967-985 850-868 GGUGGUGGUCACGUCCUGGUU 1454 CCAGGACGUGACCACCACCUU 2957 D-2450 968-986 851-869 GUGGUGGUCACGUCCUGGGUU 1455 CCCAGGACGUGACCACCACUU 2958 D-2451 969-987 852-870 UGGUGGUCACGUCCUGGGAUU 1456 UCCCAGGACGUGACCACCAUU 2959 D-2452 970-988 853-871 GGUGGUCACGUCCUGGGAGUU 1457 CUCCCAGGACGUGACCACCUU 2960 D-2453 97-115 97-115 UCCCACCCCCACACUCCCCUU 1458 GGGGAGUGUGGGGGUGGGAUU 2961 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQID NO: sense Antisense Sequence (5'-3') SEQID NO: antisense D-2454 971-989 854-872 GUGGUCACGUCCUGGGAGGUU 1459 CCUCCCAGGACGUGACCACUU 2962 D-2455 972-990 855-873 UGGUCACGUCCUGGGAGGAUU 1460 UCCUCCCAGGACGUGACCAUU 2963 D-2456 973-991 856-874 GGUCACGUCCUGGGAGGAGUU 1461 CUCCUCCCAGGACGUGACCUU 2964 D-2457 974-992 857-875 GUCACGUCCUGGGAGGAGCUU 1462 GCUCCUCCCAGGACGUGACUU 2965 D-2458 975-993 858-876 UCACGUCCUGGGAGGAGCAUU 1463 UGCUCCUCCCAGGACGUGAUU 2966 D-2459 976-994 859-877 CACGUCCUGGGAGGAGCAGUU 1464 CUGCUCCUCCCAGGACGUGUU 2967 D-2460 977-995 860-878 ACGUCCUGGGAGGAGCAGAUU 1465 UCUGCUCCUCCCAGGACGUUU 2968 D-2461 978-996 861-879 CGUCCUGGGAGGAGCAGAAUU 1466 UUCUGCUCCUCCCAGGACGUU 2969 D-2462 979-997 862-880 GUCCUGGGAGGAGCAGAAAUU 1467 UUUCUGCUCCUCCCAGGACUU 2970 D-2463 980-998 863-881 UCCUGGGAGGAGCAGAAAUUU 1468 AUUUCUGCUCCUCCCAGGAUU 2971 D-2464 98-116 98-116 CCCACCCCCACACUCCCCU U U 1469 AGGGGAGUGUGGGGGUGGGUU 2972 D-2465 981-999 864-882 CCUGGGAGGAGCAGAAAUUUU 1470 AAUUUCUGCUCCUCCCAGGUU 2973 D-2466 982-1000 865-883 CUGGGAGGAGCAGAAAUUUUU 1471 AAAUUUCUGCUCCUCCCAGUU 2974 D-2467 983-1001 866-884 UGGGAGGAGCAGAAAUUUGUU 1472 CAAAUUUCUGCUCCUCCCAUU 2975 D-2468 984-1002 867-885 GGGAGGAGCAGAAAUUUGUUU 1473 ACAAAUUUCUGCUCCUCCCUU 2976 D-2469 985-1003 868-886 GGAGGAGCAGAAAUUUGUCUU 1474 GACAAAUUUCUGCUCCUCCUU 2977 D-2470 986-1004 869-887 GAGGAGCAGAAAUUUGUCCUU 1475 GGACAAAUUUCUGCUCCUCUU 2978 D-2471 987-1005 870-888 AGGAGCAGAAAUUUGUCCAUU 1476 UGGACAAAUUUCUGCUCCUUU 2979 D-2472 988-1006 871-889 GGAGCAGAAAUUUGUCCAGUU 1477 CUGGACAAAUUUCUGCUCCUU 2980 D-2473 989-1007 872-890 GAGCAGAAAUUUGUCCAGCUU 1478 GCUGGACAAAUUUCUGCUCUU 2981 D-2474 990-1008 873-891 AGCAGAAAUUUGUCCAGCAUU 1479 UGCUGGACAAAUUUCUGCUUU 2982 D-2475 991-1009 874-892 GCAGAAAUUUGUCCAGCACUU 1480 GUGCUGGACAAAUUUCUGCUU 2983 D-2476 99-117 99-117 CCACCCCCACACUCCCCUAUU 1481 UAGGGGAGUGUGGGGGUGGUU 2984 D-2477 992-1010 875-893 CAGAAAUUUGUCCAGCACCUU 1482 GGUGCUGGACAAAUUUCUGUU 2985 D-2478 993-1011 876-894 AG AAAU U U G U CCAG CACCAU U 1483 UGGUGCUGGACAAAUUUCUUU 2986 D-2479 994-1012 877-895 GAAAUUUGUCCAGCACCACUU 1484 GUGGUGCUGGACAAAUUUCUU 2987 D-2480 995-1013 878-896 AAAUUUGUCCAGCACCACAUU 1485 UGUGGUGCUGGACAAAUUUUU 2988 D-2481 996-1014 879-897 AAUUUGUCCAGCACCACAUUU 1486 AUGUGGUGCUGGACAAAUUUU 2989 D-2482 997-1015 880-898 AUUUGUCCAGCACCACAUAUU 1487 UAUGUGGUGCUGGACAAAUUU 2990 D-2483 998-1016 881-899 UUUGUCCAGCACCACAUAGUU 1488 CUAUGUGGUGCUGGACAAAUU 2991 D-2484 999-1017 882-900 U U G U CCAG CACCACAUAG G U U 1489 CCUAUGUGGUGCUGGACAAUU 2992 D-2485 — 453-471 ACCAUCAGCUCAGAAAAGAUU 1490 UCUUUUCUGAGCUGAUGGUUU 2993 D-2486 — 454-472 CCAUCAGCUCAGAAAAGACUU 1491 GUCUUUUCUGAGCUGAUGGUU 2994 D-2487 — 455-473 CAUCAGCUCAGAAAAGACUUU 1492 AGUCUUUUCUGAGCUGAUGUU 2995 D-2488 — 456-474 AUCAGCUCAGAAAAGACUCUU 1493 GAGUCUUUUCUGAGCUGAUUU 2996 D-2489 — 457-475 UCAGCUCAGAAAAGACUCCUU 1494 GGAGUCUUUUCUGAGCUGAUU 2997 2024201349   29 Feb 2024 Duplex No. Target site of antisense sequence within NM_ 001671.4 Target site of antisense sequence within NM_ 001197216.2 Sense Sequence (5'-3') SEQ ID NO: sense Antisense Sequence (5'-3') SEQ ID NO: antisense D-2490 — 458-476 CAGCUCAGAAAAGACUCCCUU 1495 GGGAGUCUUUUCUGAGCUGUU 2998 D-2491 — 459-477 AGCUCAGAAAAGACUCCCAUU 1496 UGGGAGUCUUUUCUGAGCUUU 2999 D-2492 — 460-478 GCUCAGAAAAGACUCCCAGUU 1497 CUGGGAGUCUUUUCUGAGCUU 3000 D-2493 — 461-479 CUCAGAAAAGACUCCCAGCUU 1498 GCUGGGAGUCUUUUCUGAGUU 3001 D-2494 — 462-480 UCAGAAAAGACUCCCAGCUUU 1499 AGCUGGGAGUCUUUUCUGAUU 3002 D-2495 — 463-481 CAGAAAAGACUCCCAGCUGUU 1500 CAGCUGGGAGUCUUUUCUGUU 3003 D-2496 — 464-482 AGAAAAGACUCCCAGCUGCUU 1501 GCAGCUGGGAGUCUUUUCUUU 3004 D-2497 — 465-483 GAAAAGACUCCCAGCUGCAUU 1502 UGCAGCUGGGAGUCUUUUCUU 3005 D-2498 — 466-484 AAAAGACUCCCAGCUGCAGUU 1503 CUGCAGCUGGGAGUCUUUUUU 3006 D-2499 — 467-485 AAAGACUCCCAGCUGCAGGUU 1504 CCUGCAGCUGGGAGUCUUUUU 3007 D-2500 — 468-486 AAGACUCCCAGCUGCAGGAUU 1505 UCCUGCAGCUGGGAGUCUUUU 3008 D-2501 — 469-487 AGACUCCCAGCUGCAGGAGUU 1506 CUCCUGCAGCUGGGAGUCUUU 3009 D-2502 — 470-488 GACUCCCAGCUGCAGGAGGUU 1507 CCUCCUGCAGCUGGGAGUCUU 3010 Example 2. Efficacy of ASGR1 siRNA Molecules In Vitro

[0187] The siRNA molecules in Tier 1 and Tier 2 screening sets were synthesized without chemical modifications. Each siRNA molecule was comprised of a 21 nucleotide sense strand and 21 nucleotide antisense strand that hybridized to form a duplex region of 19 base pairs with a 2 nucleotide overhang at the 3' end of each strand. The efficacy of each of the siRNA molecules in reducing ASGR1 expression was assessed using a 384-well format in vitro immunoassay, which quantifies levels of ASGR1 protein on the cell surface of Hep3B or HepG2 cells.

[0188] Transfection complexes of the siRNA molecules and RNAiMax transfection reagent (Life Technologies) in EMEM media (ATCC 30-2003) were prepared in 384-well plates in accordance with manufacturer’s recommendations. Human hepatocellular carcinoma Hep3B (ATCC HB-8064) or HepG2 (ATCC HB-8065) cells in EMEM media supplemented with 10% fetal bovine serum and 1% antibiotic / antimycotic were added to each well. Cells were incubated for 4 days at 37 °C and 5% CO2. Four days after siRNA transfection, cells were fixed in formaldehyde, blocked with bovine serum albumin, and subsequently stained with an anti-ASGR1 primary antibody (Amgen clone 7E11, light and heavy chain sequences provided below (SEQ ID NOs: 3 and 4)) for either 1 hour at room temperature or overnight at 4 °C. Plates were 2024201349   29 Feb 2024 washed three times with phosphate buffered saline (PBS). Cells were then incubated in the dark for 45 minutes at room temperature with Alexa488-conjugated anti-human IgG secondary antibody and nuclear stain DRAQ5 (ThermoFisher #62251), which was included to assess cell number. Following three PBS washes, the plates were imaged on an Opera Phenix high-content screening system (PerkinElmer) using the 488 and 640 channels to measure anti-ASGRl antibody staining and nuclear staining, respectively. Data was analyzed using Columbus image analysis software and GeneData Screener software to quantify several measures of ASGR1 protein levels, cell count, and cell morphology on a per cell and per well basis.

[0189] Anti-ASGRl primary antibody light chain amino acid sequence: DIQMTQSPSSLSASVGDRVTIACRASQNIISYLNWYQQKPGKAPKFLIYTASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFAIYYCQQTYSTPLTFGGGTKVEIKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 3)

[0190] Anti-ASGRl primary antibody heavy chain amino acid sequence: QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAIIWHDGSNK YYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARDLSMGGMDVWGQGTTVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4)

[0191] Activity of each siRNA molecule was measured using a “Normalized Alexa 488 Mean Intensity” readout, which quantifies ASGR1 protein expression based on cell population analysis relative to ASGR1 expression in control cell populations. Cells transfected with non-targeting siRNA duplexes (i.e. siRNAs that do not have a 100% sequence match to any human gene sequences) were used as controls on each plate and a “central reference value” was calculated from these control cells. Specifically, the “central reference value” was the median value of the Alexa 488 intensity of the multiple wells containing cells transfected with non-targeting siRNAs. The “Normalized Alexa 488 Mean Intensity” was calculated for each well as follows. Nuclei and 2024201349   29 Feb 2024 cytoplasm were segmented using the DRAQ5 counterstain. The mean Alexa488 fluorescence intensity for each cell (i.e. the entire cellular region, including cytoplasm and nucleus) was measured. Individual cell values were averaged to produce a mean Alexa 488 intensity value for each well. This mean intensity value was then normalized to the central reference value to arrive at the “Normalized Alexa 488 Mean Intensity” value, which represents an ASGR1 expression measurement as a percent of control. Thus, negative “Normalized Alexa 488 Mean Intensity” values represent a reduced ASGR1 expression relative to control cells. Cell counts as assessed by the DRAQ5 stain were also normalized to cell counts for control cells and thus, represent a cell viability measurement as a percent of control.

[0192] The Tier 1 siRNA molecules were tested in duplicate at three different concentrations (0.3 nM, 1.25 nM, and 5 nM) in the in vitro immunoassay in both Hep3B cells and HepG2 cells. The reduction in ASGR1 cell surface expression relative to expression in cells transfected with non-targeting siRNAs in Hep3B cells for each siRNA molecule is shown in Table 2 below. Cell count measurements are also provided. For clarity, the data for the lowest concentration (0.3 nM) and the data for the HepG2 cells are not shown. The data shown in Table 2 are the results from two independent transfections of each siRNA (e.g. Run 1 and Run 2). Table 2. In vitro efficacy of Tier 1 ASGR1 siRNA molecules in immunoassay screen Run 1 Run 2 Duplex No. Cell count 5 nM Normalized Alexa 488 Mean Intensity 5nM Cell count 1.25 nM Normalized Alexa 488 Mean Intensity 1.25nM Cell count 5nM Normalized Alexa 488 Mean Intensity 5nM Cell count 1.25 nM Normalized Alexa 488 Mean Intensity 1.25nM D-1011 16.51 -51.78 0.13 -14.40 25.37 -51.83 3.76 -28.05 D-1018 -17.30 -55.17 2.29 -16.02 -34.78 -52.13 30.89 -7.73 D-1024 -29.00 -18.51 -0.82 12.30 1.97 14.82 6.60 4.61 D-1036 -46.65 10.97 -10.56 7.07 -18.48 71.68 1.10 12.95 D-1055 10.56 -13.14 -1.08 -9.93 7.75 -24.90 11.92 -7.81 D-1063 9.47 -18.69 -2.54 -11.47 -25.16 -50.11 -10.17 -18.86 D-1069 -20.87 -41.89 -4.27 3.93 -11.39 -28.60 12.28 7.84 D-1082 17.70 -48.78 -8.32 -14.13 -0.15 -55.38 -5.13 -50.19 D-1089 -35.75 -60.09 -12.25 -36.42 -25.97 -57.46 -7.24 -51.34 D-1091 -18.99 -31.14 -13.76 5.02 -27.59 -20.03 3.02 -6.61 D-1098 6.89 -54.37 -2.80 -34.02 -14.23 -59.04 -11.92 -53.04 2024201349   29 Feb 2024 Run 1 Run 2 Duplex No. Cell count 5 nM Normalized Alexa 488 Mean Intensity 5nM Cell count 1.25 nM Normalized Alexa 488 Mean Intensity 1.25nM Cell count 5nM Normalized Alexa 488 Mean Intensity 5nM Cell count 1.25 nM Normalized Alexa 488 Mean Intensity 1.25nM D-1135 10.36 -7.69 -15.39 -4.17 24.96 -24.64 3.57 -5.25 D-1147 20.97 -3.11 4.36 1.69 11.90 5.13 13.93 4.34 D-1151 -4.71 -14.13 -15.57 -17.87 -12.91 -34.11 -1.19 -14.79 D-1158 26.52 -10.17 23.24 8.03 28.20 -6.52 18.06 -2.88 D-1162 -40.01 -55.60 -22.04 -36.60 -35.29 -52.50 -14.02 -41.72 D-1165 -3.62 -54.73 -7.63 -23.22 -0.86 -51.86 15.67 -18.51 D-1166 -3.32 -41.79 -11.34 -13.26 -0.25 -14.66 -4.12 -15.13 D-1167 -53.20 -59.29 -6.34 -16.20 -34.68 -52.65 2.38 -24.06 D-1168 -31.18 -46.37 -1.51 -9.31 -4.10 -34.17 -15.22 -20.42 D-1170 -12.35 -53.90 -3.32 -42.65 -23.85 -56.63 5.59 -32.93 D-1171 3.82 -31.95 -14.62 -23.16 -12.00 -49.39 9.90 -28.40 D-1172 -45.07 -58.26 -1.94 3.83 -40.15 -56.40 -18.42 -45.04 D-1173 -25.53 -57.81 5.39 -8.67 -12.00 -58.53 -24.75 -56.05 D-1174 11.06 -32.05 3.06 -15.60 -18.38 -54.41 -13.38 -40.99 D-1175 -35.25 -47.56 -9.96 -1.38 -31.75 -44.76 -24.47 -34.12 D-1176 -21.07 -48.99 -12.46 -22.28 -55.65 -30.89 -4.67 -34.03 D-1206 -20.58 -58.56 -5.65 -42.60 -4.41 -58.69 13.47 -45.33 D-1234 0.74 -45.36 -6.51 4.14 13.42 -37.24 -0.46 -19.91 D-1235 -11.85 -55.44 -20.74 -53.47 -36.41 -59.01 -20.26 -54.37 D-1237 -20.08 -20.98 5.99 19.18 4.30 -22.26 0.55 -4.37 D-1246 18.79 -44.97 -0.22 -40.27 -18.38 -57.87 7.97 -44.91 D-1250 -6.10 -51.90 0.82 2.19 0.15 -58.42 10.08 -49.16 D-1257 -10.36 -55.00 5.39 16.17 -20.30 -53.64 -15.58 -41.86 D-1285 -15.32 -50.05 8.93 9.74 -18.08 -56.70 -12.37 -45.36 D-1286 -30.00 -55.94 -0.69 -28.77 -11.19 -48.78 -2.70 -42.37 D-1288 -26.13 -60.85 3.32 -3.82 -9.16 -56.60 8.07 -36.50 D-1289 -11.95 -48.94 -13.41 -9.24 -3.49 -53.30 -9.72 -31.07 D-1291 -21.57 -62.92 -2.37 4.10 10.28 -57.93 -5.22 -46.85 D-1293 7.88 -59.68 -4.18 -17.53 -1.47 -60.64 1.56 -48.52 D-1294 -13.93 -61.42 9.01 -8.13 4.20 -58.50 7.79 -49.89 D-1296 32.37 -35.87 -3.58 -26.73 21.72 -42.10 28.96 -8.80 D-1299 9.97 -15.14 5.99 -4.68 14.33 -12.03 -4.77 -16.17 D-1301 42.98 8.71 10.05 11.59 18.48 -7.91 1.65 0.99 D-1302 8.78 -15.98 11.08 4.83 4.61 -11.01 -0.73 -2.26 D-1303 18.39 8.99 15.05 3.34 34.38 16.39 4.95 0.93 2024201349   29 Feb 2024 Run 1 Run 2 Duplex No. Cell count 5 nM Normalized Alexa 488 Mean Intensity 5nM Cell count 1.25 nM Normalized Alexa 488 Mean Intensity 1.25nM Cell count 5nM Normalized Alexa 488 Mean Intensity 5nM Cell count 1.25 nM Normalized Alexa 488 Mean Intensity 1.25nM D-1335 -4.41 -57.42 -7.81 -12.59 -2.78 -53.97 -5.32 -38.92 D-1340 15.42 -56.65 12.63 -47.35 18.08 -56.73 11.55 -47.26 D-1342 -1.34 -55.68 1.60 -30.81 -14.13 -55.74 24.66 -34.02 D-1350 12.25 -46.29 16.43 -17.81 8.86 -45.60 11.73 -15.78 D-1364 -36.14 -58.31 -7.81 -45.74 -31.95 -57.24 -2.47 -42.87 D-1365 -45.46 -59.21 1.08 -39.04 -54.43 -55.49 -9.26 -47.65 D-1367 -2.23 -49.60 27.47 -0.24 0.35 -55.94 15.49 -40.01 D-1373 29.80 -55.97 22.64 -34.90 -9.37 -57.64 15.40 -50.30 D-1376 9.37 -54.03 4.61 -6.55 -18.48 -58.89 23.74 -40.26 D-1387 -15.62 -60.74 12.03 -24.43 -22.84 -59.13 -0.46 -55.15 D-1389 37.33 -60.30 -1.68 -58.97 -6.03 -59.85 6.51 -56.49 D-1390 -7.09 -62.69 1.94 -19.96 18.08 -60.28 11.92 -58.45 D-1397 -17.90 -62.94 10.13 -56.73 25.06 -60.77 4.12 -56.43 D-1398 -7.09 -61.91 9.27 -39.40 -6.43 -56.41 27.77 -34.30 D-1399 -33.81 -62.45 12.59 -17.06 2.08 -59.75 11.14 -50.83 D-1400 46.65 -59.41 13.50 -36.58 16.15 -59.11 11.92 -48.21 D-1403 24.74 -0.88 20.40 4.38 -19.29 -29.75 11.27 4.71 D-1405 -7.78 -10.82 8.24 -5.29 4.30 -1.20 -4.03 -5.98 D-1406 -3.92 -9.59 -1.85 -8.89 -5.01 -9.40 23.74 15.19 D-1407 18.69 -3.89 -7.29 -12.59 -4.30 -19.11 9.90 -6.78 D-1408 8.73 -49.20 -12.98 -42.77 -1.47 -53.33 12.19 -35...

Claims

What is claimed:

1. An RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a region having a sequence that is complementary to an ASGR1 mRNA sequence, and wherein said region comprises at least 15 contiguous nucleotides from an antisense sequence listed in Table 1, Table 6, or Table 8.

2. The RNAi construct of claim 1, wherein the sense strand comprises a sequence that is sufficiently complementary to the sequence of the antisense strand to form a duplex region of about 15 to about 30 base pairs in length.

3. The RNAi construct of claim 2, wherein the duplex region is about 17 to about 24 base pairs in length.

4. The RNAi construct of claim 2, wherein the duplex region is about 19 to about 21 base pairs in length.

5. The RNAi construct of any one of claims 2 to 4, wherein the sense strand and the antisense strand are each about 15 to about 30 nucleotides in length.

6. The RNAi construct of claim 5, wherein the sense strand and the antisense strand are each about 19 to about 27 nucleotides in length.

7. The RNAi construct of claim 5, wherein the sense strand and the antisense strand are each about 21 to about 25 nucleotides in length.

8. The RNAi construct of any one of claims 1 to 7, wherein the RNAi construct comprises at least one blunt end.2024201349   29 Feb 20249. The RNAi construct of any one of claims 1 to 7, wherein the RNAi construct comprises at least one nucleotide overhang of 1 to 4 unpaired nucleotides.

10. The RNAi construct of claim 9, wherein the nucleotide overhang has 2 unpaired nucleotides.

11. The RNAi construct of claim 9 or 10, wherein the RNAi construct comprises a nucleotide overhang at the 3' end of the sense strand, the 3' end of the antisense strand, or the 3' end of both the sense strand and the antisense strand.

12. The RNAi construct of any one of claims 9 to 11, wherein the nucleotide overhang comprises a 5'-UU-3' dinucleotide or a 5'-dTdT-3' dinucleotide.

13. The RNAi construct of any one of claims 1 to 12, wherein the RNAi construct comprises at least one modified nucleotide.

14. The RNAi construct of claim 13, wherein the modified nucleotide is a 2'-modified nucleotide.

15. The RNAi construct of claim 13, wherein the modified nucleotide is a 2'-fluoro modified nucleotide, a 2'-O-methyl modified nucleotide, a 2'-O-methoxyethyl modified nucleotide, a 2'-O-allyl modified nucleotide, a bicyclic nucleic acid (BNA), or combinations thereof.

16. The RNAi construct of claim 15, wherein the modified nucleotide is a 2'-O-methyl modified nucleotide, a 2'-O-methoxyethyl modified nucleotide, a 2'-fluoro modified nucleotide, or combinations thereof.

17. The RNAi construct of claim 13, wherein all of the nucleotides in the sense and antisense strands are modified nucleotides.2024201349   29 Feb 202418. The RNAi construct of claim 17, wherein the modified nucleotides are 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, or combinations thereof.

19. The RNAi construct of any one of claims 1 to 18, wherein the RNAi construct comprises at least one phosphorothioate internucleotide linkage.

20. The RNAi construct of claim 19, wherein the RNAi construct comprises two consecutive phosphorothioate intemucleotide linkages at the 3' end of the antisense strand.

21. The RNAi construct of claim 19, wherein the RNAi construct comprises two consecutive phosphorothioate intemucleotide linkages at both the 3' and 5' ends of the antisense strand and two consecutive phosphorothioate intemucleotide linkages at the 5' end of the sense strand.

22. The RNAi construct of any one of claims 1 to 21, wherein the antisense strand comprises a sequence selected from the antisense sequences listed in Table 1, Table 6, or Table 8.

23. The RNAi construct of claim 22, wherein the antisense strand comprises a sequence selected from SEQ ID NO: 1606, SEQ ID NO: 1684, SEQ ID NO: 1708, SEQ ID NO: 1714, SEQ ID NO: 1743, SEQ ID NO: 1754, SEQ ID NO: 1881, SEQ ID NO: 1897, SEQ ID NO: 2321, SEQ ID NO: 2323, SEQ ID NO: 2491, SEQ ID NO: 2508, SEQ ID NO: 2553, SEQ ID NO: 2650, SEQ ID NO: 2651, SEQ ID NO: 1946, SEQ ID NO: 2002, SEQ ID NO: 2865, SEQ ID NO: 2867, SEQ ID NO: 2869, SEQ ID NO: 2873, SEQ ID NO: 2969, SEQ ID NO: 3701, SEQ ID NO: 3702, SEQ ID NO: 3716, SEQ ID NO: 3718, SEQ ID NO: 3722, SEQ ID NO: 4618, SEQ ID NO: 4619, SEQ ID NO: 4621, SEQ ID NO: 4627, SEQ ID NO: 4630, SEQ ID NO: 4634, SEQ ID NO: 4638, or SEQ ID NO: 4639.

24. The RNAi construct of claim 22 or claim 23, wherein the sense strand comprises a sequence selected from the sense sequences listed in Table 1, Table 6, or Table 8.

25. The RNAi construct of claim 24, wherein the sense strand comprises a sequence selected from SEQ ID NO: 103, SEQ ID NO: 181, SEQ ID NO: 205, SEQ ID NO: 211, SEQ ID NO:2024201349   29 Feb 2024240, SEQ ID NO: 251, SEQ ID NO: 378, SEQ ID NO: 394, SEQ ID NO: 818, SEQ ID NO: 820, SEQ ID NO: 988, SEQ ID NO: 1005, SEQ ID NO: 1050, SEQ ID NO: 1147, SEQ ID NO: 1148, SEQ ID NO: 443, SEQ ID NO: 499, SEQ ID NO: 1362, SEQ ID NO 1364, SEQ ID NO: 1366, SEQ ID NO: 1370, SEQ ID NO: 1466, SEQ ID NO: 3050, SEQ ID NO: 3051, SEQ ID NO: 3065, SEQ ID NO: 3067, SEQ ID NO: 3071, SEQ ID NO: 4443, SEQ ID NO: 4444, SEQ ID NO: 4446, SEQ ID NO: 4452, SEQ ID NO: 4455, SEQ ID NO: 4459, SEQ ID NO: 4463, or SEQ ID NO: 4464.

26. The RNAi construct of any one of claims 22 to 25, wherein:(a) the sense strand comprises the sequence of SEQ ID NO: 181 and the antisense strand comprises the sequence of SEQ ID NO: 1684;(b) the sense strand comprises the sequence of SEQ ID NO: 205 and the antisense strand comprises the sequence of SEQ ID NO: 1708;(c) the sense strand comprises the sequence of SEQ ID NO: 211 and the antisense strand comprises the sequence of SEQ ID NO: 1714;(d) the sense strand comprises the sequence of SEQ ID NO: 240 and the antisense strand comprises the sequence of SEQ ID NO: 1743;(e) the sense strand comprises the sequence of SEQ ID NO: 820 and the antisense strand comprises the sequence of SEQ ID NO: 2323;(f) the sense strand comprises the sequence of SEQ ID NO: 1147 and the antisense strand comprises the sequence of SEQ ID NO: 2650;(g) the sense strand comprises the sequence of SEQ ID NO: 1148 and the antisense strand comprises the sequence of SEQ ID NO: 2651;(h) the sense strand comprises the sequence of SEQ ID NO: 1364 and the antisense strand comprises the sequence of SEQ ID NO: 2867;(i) the sense strand comprises the sequence of SEQ ID NO: 1366 and the antisense strand comprises the sequence of SEQ ID NO: 2869; or(j) the sense strand comprises the sequence of SEQ ID NO: 1370 and the antisense strand comprises the sequence of SEQ ID NO: 2873.2024201349   29 Feb 202427. The RNAi construct of any one of claims 1 to 26, wherein the RNAi construct is any one of the duplex compounds listed in any one of Tables 1 to 10.

28. The RNAi construct of claim 27, wherein the RNAi construct is D-1098, D-l 176, D-1200, D-1206, D-1235, D-1246, D-1373, D-1389, D-1813, D-1815, D-1983, D-2000, D-2045, D-2142, D-2143, D-1438, D-1494, D-2357, D-2359, D-2361, D-2365, D-2461, D-3036, D-3037, D-3051, D-3053, D-3057, D-3779, D-3780, D-3782, D-3788, D-3791, D-3795, D-3799, or D-3800.

29. The RNAi construct of claim 28, wherein the RNAi construct is D-1200, D-1206, D-1235, D-1815, D-2143, D-2359, D-2361, D-2365, D-2142, D-l 176, D-3779, D-3782, D-3788, D-3799, orD-3800.

30. The RNAi construct of any one of claims 1 to 29, wherein the RNAi construct reduces the expression level of ASGR1 in liver cells following incubation with the RNAi construct as compared to the ASGR1 expression level in liver cells that have been incubated with a control RNAi construct.

31. The RNAi construct of claim 30, wherein the liver cells are Hep3B cells, HepG2 cells, or primary human hepatocytes.

32. The RNAi construct of any one of claims 1 to 29, wherein the RNAi construct inhibits at least 45% of ASGR1 expression at 5 nM in Hep3B cells in vitro.

33. The RNAi construct of any one of claims 1 to 29, wherein the RNAi construct inhibits ASGR1 expression in Hep3B cells with an IC50 of less than about 10 nM.

34. The RNAi construct of any one of claims 1 to 29, wherein the RNAi construct inhibits ASGR1 expression in Hep3B cells with an IC50 of less than about 1 nM.2024201349   29 Feb 202435. The RNAi construct of any one of claims 1 to 34, wherein the RNAi construct further comprises a ligand.

36. The RNAi construct of claim 35, wherein the ligand comprises a cholesterol moiety, a vitamin, a steroid, a bile acid, a folate moiety, a fatty acid, a carbohydrate, a glycoside, or antibody or antigen-binding fragment thereof.

37. The RNAi construct of claim 35, wherein the ligand targets delivery of the RNAi construct to hepatocytes.

38. The RNAi construct of claim 37, wherein the ligand comprises a monoclonal antibody or antigen-binding fragment thereof that specifically binds to human ASGR1.

39. The RNAi construct of claim 38, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a substitution of at least one amino acid with a cysteine amino acid, and wherein the sense strand is covalently attached to the monoclonal antibody or antigenbinding fragment thereof through the side chain of the cysteine amino acid.

40. The RNAi construct of claim 35, wherein the ligand comprises galactose, galactosamine, or N-acetyl-galactosamine.

41. The RNAi construct of claim 40, wherein the ligand comprises a multivalent galactose moiety or multivalent N-acetyl-galactosamine moiety.

42. The RNAi construct of claim 41, wherein the multivalent galactose moiety or multivalent N-acetyl-galactosamine moiety is trivalent or tetravalent.

43. The RNAi construct of any one of claims 35 to 42, wherein the ligand is covalently attached to the sense strand optionally through a linker.2024201349   29 Feb 202444. The RNAi construct of claim 43, wherein the ligand is covalently attached to the 3' end or 5' end of the sense strand.

45. A pharmaceutical composition comprising the RNAi construct of any one of claims 1 to 44 and a pharmaceutically acceptable carrier, excipient, or diluent.

46. A method for reducing the expression of ASGR1 in a patient in need thereof comprising administering to the patient the RNAi construct of any one of claims 1 to 44.

47. The method of claim 46, wherein the expression level of ASGR1 in hepatocytes is reduced in the patient following administration of the RNAi construct as compared to the ASGR1 expression level in a patient not receiving the RNAi construct.

48. The method of claim 46, wherein the patient is diagnosed with or at risk for coronary artery disease.

49. The method of claim 46, wherein the patient has elevated levels of non-HDL cholesterol.

50. The method of claim 46, wherein the patient has a history of myocardial infarction.

51. A method for reducing non-HDL cholesterol in a patient in need thereof comprising administering to the patient the RNAi construct of any one of claims 1 to 44.

52. The method of claim 51, wherein the non-HDL cholesterol is LDL cholesterol.

53. A method for treating or preventing cardiovascular disease in a patient in need thereofcomprising administering to the patient the RNAi construct of any one of claims 1 to 44.

54. The method of claim 53, wherein the cardiovascular disease is coronary artery disease or myocardial infarction.2024201349   29 Feb 202455. A method for reducing the risk of myocardial infarction in a patient in need thereof comprising administering to the patient the RNAi construct of any one of claims 1 to 44.

56. The method of claim 55, wherein the patient is diagnosed with coronary artery disease.

57. The method of claim 55, wherein the patient has elevated levels of non-HDL cholesterol.

58. The method of any one of claims 46 to 57, wherein the RNAi construct is administered to the patient via a parenteral route of administration.

59. The method of claim 58, wherein the parenteral route of administration is intravenous or subcutaneous.

60. An RNAi construct of any one of claims 1 to 44 for use in a method for reducing non-HDL cholesterol in a patient in need thereof.

61. The RNAi construct of claim 60, wherein the non-HDL cholesterol is LDL cholesterol.

62. An RNAi construct of any one of claims 1 to 44 for use in a method for treating or preventing cardiovascular disease in a patient in need thereof.

63. The RNAi construct of claim 62, wherein the cardiovascular disease is coronary artery disease or myocardial infarction.

64. An RNAi construct of any one of claims 1 to 44 for use in a method for reducing the risk of myocardial infarction in a patient in need thereof.

65. The RNAi construct of claim 64, wherein the patient is diagnosed with coronary artery disease.2024201349   29 Feb 202466. The RNAi construct of claim 64, wherein the patient has elevated levels of non-HDL cholesterol.

67. Use of an RNAi construct of any one of claims 1 to 44 in the preparation of a medicament for reducing non-HDL cholesterol in a patient in need thereof.

68. The use of claim 67, wherein the non-HDL cholesterol is LDL cholesterol.

69. Use of an RNAi construct of any one of claims 1 to 44 in the preparation of amedicament for treating or preventing cardiovascular disease in a patient in need thereof.

70. The use of claim 69, wherein the cardiovascular disease is coronary artery disease or myocardial infarction.

71. Use of an RNAi construct of any one of claims 1 to 44 in the preparation of a medicament for reducing the risk of myocardial infarction in a patient in need thereof.

72. The use of claim 71, wherein the patient is diagnosed with coronary artery disease.

73. The use of claim 71, wherein the patient has elevated levels of non-HDL cholesterol.

Images